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ABSTRACT.
Myo-inositol 1,4,5-trisphosphate-induced Ca2+-release from permeabilised platelets 
was found to be stereospecific. D-InsP3 was found to be a full agonist whereas its 
enantiomer, L-wyo-inositol 1,4,5-trisphosphate was inactive. A temperature 
dependence of InsP3-induced Ca2+-release was also established. Parallel shift of the 
InsP3-dose response curve to the right were observed with increasing temperatures 
from 4°C to 37°C. This reduction in apparent efficacy was mirrored by the more 
rapid rate of InsP3 metabolism. InsP3 is metabolised faster at 37°C than at 4°C, and 
the apparent decrease in potency of InsP3 with the increase in temperature may be 
due to this increased metabolism.
With the aid of the two inositol phosphate analogues, L-myo-inositol 1,4,5- 
trisphosphorothioate and myo-inositol 1,3,5-trisphosphorothioate, we have 
confirmed the presence of different forms of the 5-phosphatase enzyme in platelets. 
InsP3 selective 5-phosphatase and an Ins(l,3,4,5)P4 selective 5-phosphatase have 
been demonstrated.
A structure-activity relationship has been established for the structural requirements 
for InsP3-induced Ca2+-mobilisation in platelets at the InsP3 receptor. It is apparent 
that the vicinal 4,5-bisphosphate is essential for activity as shown when examining 
analogues with modifications at these positions. The hydroxyls on the 2-, 3- and 6- 
positions play a less considerable role, with only the 6-hydroxyl playing a small, 
but significant role in receptor activation and Ca2+-mobilisation.
As a result of examining over 30 inositol phosphate analogues, to date, the best 
receptor antagonists uncovered are the three partial agonists scyllo-inositol 1,2,4,5- 
tetrakisphosphorothioate, L-c/wra-inositol 2,3,5-trisphosphorothioate and myo­
I I
inositol 1,4,6-trisphosphorothioate. These will provide tools in designing future 
antagonist.
Studies on the role of Ca2+-entry upon InsP3-production were investigated using the 
Ca2+-influx inhibitor SKF 96365. However, this compound was not found to be a 
pure influx inhibitor in platelets, but that it was capable of inhibiting PAF-induced 
InsP3-production, 5-HT release and Ca2+-mobilisation. It was, however, unable to 
modify InsP3- and Ins(l,3,4,5)P4-induced Ca2+-release.
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ADP-ribose adenosine diphosphate ribose
ATP adenosine 5'-trisphosphate
BAPTA 1,2-bis(2-aminophenoxy)ethane-N,N,N* jN'-tetraacetic acid.
BSA bovine serum albumin
cAMP adenosine 3':5'-cyclic monophosphate
cADP-ribose cyclic adenosine diphosphate ribose
[Ca2+]e extracellular calcium concentration
[Ca2+]i intracellular calcium concentration
CHCI3 chloroform
CPM counts per minute
DAG diacylglycerol
DMSO dimethylsulphoxide
EC50 concentration producing 50% of maximal response
EDTA ethylenediamine tetraacetic acid
EGTA ethyleneglycol-bis(B-aminoethylether)
N,N,N' ,N'-tetraacetic acid 
Fura-2 AM fura-2 acetomethoxy ester
G-protein guanine nucleotide-binding proteins
Gi G-protein associated with inhibition of AC
G, G-protein associated with activation of AC
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HPLC high pressure liquid chromatography
IC50 concentration producing 50% inhibition of response
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LT's leukotrienes
NO nitric oxide
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PKC protein kinase C
p l a 2 phospholipase A2
PLC phospholipase C
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RMCE receptor mediated calcium entry
t x a 2 thromboxane




Rabbit platelets were used to study phosphoinositide (PI) signalling. Platelets 
provide an ideal model for studying the effects of D-T/zyo-inositol 1,4,5- 
trisphosphate (InsP3) and its analogues as they do not possess a nucleus or RNA 
that will complicate and interfere with the signalling mechanism. This thesis is 
written in such a way that the introduction contains a literature review of 
research carried out until the start of this study, i.e. until 1990. The rest of the 
literature is reviewed, along with my results, in the discussion section.
1 The blood platelet.
Blood platelets circulate as smooth anucleate biconvex discs, lfim  thick and 2- 
3fim in diameter. They are formed by fragmentation of the cytoplasm of 
megakaryocytes in the bone marrow. In general, platelets are incapable of 
protein synthesis in biologically significant quantities, however newly formed 
platelets often contain ribosomes and RNA from the parent cell cytoplasm. The 
platelet count in peripheral blood is 2.5x 108/ml with a turnover of 3x 
107/ml/day. The half life of the platelet in circulation is 8- 10 days, for review 
see Siess, (1989). Although platelets contain no nucleus, they contain cellular 
organelles such as mitochondria, open canilicular systems, microtubules, dense 
tubular system and storage granules (dense granules, <*i granules and a i 
granules) (Crawford and Scrutton, 1987).
The major purpose of platelets in the circulation is participation in the 
haemostatic reaction, where they play a role in the formation of a cellular plug 
at the site of vascular damage fulfilling their primary role in arresting bleeding.
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Although most of our understanding of blood platelets concerns the role of this 
cell in haemostasis and in disorders of this process such as thrombosis, the ease 
of isolation of a homogeneous cell population, the lack of a nucleus to 
complicate cellular responses and the wide range of functions platelets possess 
has meant that they have been used extensively to study signal transduction, 
adhesion and secretion.
1.1 The basic platelet response.
Platelets are very rapidly activated and respond to a wide range of agonists upon 
cell surface receptor occupation. The platelet response can be classified into two 
categories that may be related to different functions of platelets in vivo. First, 
the reversible platelet response, including adhesion, shape change and primary 
reversible aggregation and second, the irreversible platelet response that 
comprises release reaction and secondary irreversible aggregation. These latter 
irreversible responses are involved in the haemostatic function of platelets 
reviewed in Siess, (1989).
Resting circulating platelets are discoid and have a smooth ripple surface. The 
first physiological responses upon stimulation are platelet adhesion and shape 
change. Physiological vasodilation, which leads to gaps within the endothelial 
lining or pathophysiological vascular injury resulting in the exposure of 
subendothelial tissue. Both these effects contribute to the adhesion process. 
Platelets adhere to the subendothelial material by their interaction with two 
specific macromolecule proteins, collagen and von Willebrand's factor (vWf). 
Adhesion proceeds in two distinct phases: (i) an initial contact phase in which a 
platelet is bound to the vessel wall by a small amount of membrane or through 
pseudopodia and (ii) a spreading phase in which the platelet is more intimately
3
bound to the subendothelium by a large amount of endothelium (Leytin et al.,
1984).
Following adhesion, shape change occurs. This is characterised by two distinct 
morphological features; the spheration of the platelet and the extrusion of 
pseudopods. In addition, the membrane surface becomes irregular and folded. 
All platelet stimuli except adrenaline and phorbol esters induce full platelet 
shape change. Adrenaline and phorbol esters do not raise [Ca2+]i, inducing only 
some pseudopod formation without platelet spheration (Bendtzen et al., 1983; 
Cusack and Hourani, 1982). This indicates that platelet spheration and 
pseudopod formation are separate independent events.
Subsequent to adhesion and shape change, aggregation can occur. In vitro this 
can be distinguished into two types, primary and secondary aggregation. The 
former is reversible and can occur without a release reaction and the latter is 
irreversible and associated with the release reaction. Primary reversible 
aggregation is induced by low concentrations of platelet stimuli in the presence 
of extracellular Mg2+ or Ca2+. Primary aggregation results from the exposure 
of the fibrinogen receptor and some subtle change in the glycoproteins nb and 
Dla giving rise to the formation of reversible cross-linking of platelets by 
fibrinogen molecules (Bennett and Vilaire, 1979). Secondary aggregation results 
from reinforcing these fibrinogen links by secreted thrombospondin (Leung and 
Nachman, 1982).
The final step is the release reaction (Holmsen et al., 1969; Holmsen, 1978; 
Holmsen, 1985). This occurs by the exocytotic discharge of the granule 
contents. There are at least three types of secretory granules; dense-, at- and a i  
(lysosomal) secretory granules. These three storage granules can be
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distinguished by their density and their discharge is under differential or graded 
control (Thevenod et al., 1989).
In general a lower concentration of agonist is needed to release the contents of 
the argranules than the dense granules (Holmsen, 1978), for review see Siess 
(1989).
The platelet haemostatic function must be highly regulated in order to allow the 
formation of a haemostatic plug when needed and otherwise prevent 
haemorrhage or thrombosis. The balance between antiaggregatory and 
proaggregatory signals is achieved by compounds which are able to promote or 
inhibit platelet activation. These compounds originate from an extrinsic source 
(thrombin and vWf), from activated platelets themselves [adenosine diphosphate 
(ADP), 5-HT, Ca2+, thromboxane (TXA2)] or from the vascular endothelium 
[PGI2, nitric oxide (NO)] (Siess, 1989). The release reaction has a self­
amplification effect on the response where the release of the granule contents 
such as ADP and 5-HT stimulate the activation of yet other platelets, thus 
amplifying the original stimulus.
The vascular endothelium also plays a role in haemostasis. It is capable of 
producing NO and this causes an increase in cGMP levels by acting through a 
soluble guanylate cyclase. In platelets, an increase in levels o f cGMP is anti­
aggregatory, inhibiting aggregation (Radomski e ta l., 1990; Siess, 1989). 
Furthermore PGI2, which is also released from the vascular endothelium, also 
acts to inhibit aggregation (McIntyre et al 1985) by activating adenylate cyclase 
and increasing cAMP levels (Siess, 1989).
Two major pathways have been proposed for AA liberation (see figure 1); a 























Figure 1. The biosynthetic pathway for arachidonic acid (AA) formation and its 
metabolites through the cyclo-oxygenase pathway.
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the sequential action of PLC on phosphatidylinositol lipids followed by the 
action of DAG-lipase, the former route having a greater role. Ca2+ dependent 
activation of PLA2 and subsequent eicosanoid biosynthesis is considered 
essential to promote platelet self-amplification (Siess, 1989; Lapetina et al.,
1986). TxA2 is a potent vasoconstrictor and agonist on platelets.
Its action is short lived due to its rapid metabolism to TXB2 (Hamberg et al., 
1975) PLA2 is an enzyme involved in the liberation from membrane 
phospholipids of an arachidonyl residue (AA) from membrane phospholipids 
which can be subsequently metabolized to various bioactive lipid mediators such 
as PGs, TxA2 and leukotrienes (Takayama et al., 1991). The isolation of a 
cytosolic soluble PLA2 from rabbit platelets has recently been implicated in AA 
liberation in rabbit stimulated platelets (Takayama et al., 1991).
1.2 Platelet agonists and their signalling mechanisms.
Platelets are non-electrically excitable cells (Thevenod et al., 1989). The 
absence o f a nucleus and hence nuclear receptors means that activation is 
confined to cell surface receptor activation. Thus, surface receptors have 
coupling mechanisms which allow a signal to be carried (transduced) from the 
cell surface receptor through the membrane to the cytosol, leading to the 
formation or liberation of intracellular messenger molecules. There are several 
components of signal transducing mechanisms these include; D-T/zyo-inositol 
1,4,5-trisphosphate (InsPa), Ca2+, cAMP, diacylglycerol (DAG) and protein 
tyrosine kinases (PTK's) (Berridge and Irvine, 1989; Berridge, 1986) which in 
turn act on targets inside the cell.
























Figure 2 . The signalling mechanisms of excitatory and inhibitory platelet 
agonists.
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These responses are achieved by the interaction of each of these agonists with 
specific cell surface receptors, based upon demonstration of saturable binding 
and the existence of the same specific inhibitors of both binding and platelet 
response. Thus, while there is a high degree of specificity at the level o f the 
agonist-receptor interaction, this specificity is almost lost by the appearence of 
the same final responses, (Holmsen, 1985). The specificity that remains at the 
level of response execution is of a quantitative nature. These platelet agonists 
can thus be devided into weak, intermediately strong and strong agonists 
according to how far in the response sequence they drive the platelets.
All platelet agonists trigger PIP2 hydrolysis, with the exception of adrenaline 
and collagen, see figure 2. Thus, agonists such as thrombin, PAF, TXA2, ADP, 
a-adrenergic and fi-adrenergic receptors couple G-proteins, Haslam and 
Davidson (1984ab) reviewed in Siess, (1989). Subsequently, activating PLC 
which in turn hydrolysis PIP2 to give the two second messengers DAG and 
InsP3, (Haslam and Davidson, 1984ab; Marks et ah, 1990). In permeabilised 
platelets L1SP3 has been shown to cause secretion, aggregation and protein 
phosphorylation (Lapetina et al., 1984; Brass et al., 1987) and these events 
appear to be a consequence of the ability of InsP3 to mobilise Ca2+ sequestered 
within the platelet dense tubular system (Authi and Crawford, 1985; Nishizuka, 
1986; Uemura et ah, 1990). As all platelet agonists act through PI, modulation 
of the PI signalling pathway in platelets could represent an effective way to 
modulate platelet activity.
1.3 Platelets in health and disease.
The number of circulating platelets in normal persons is maintained within a 
narrow range and the factors that regulate this count are poorly understood.
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However 60- 70% of all platelets are in the peripheral circulation and in 
dynamic equilibrium with a pool of platelets in the spleen. Extreme alterations 
in platelet number, too few as in thrombocytopenia, or too many as in 
thrombocytosis can be detrimental. High platelet numbers as in thrombocytosis 
are associated with thrombosis or patients may undergo spontaneous aggregation 
in the circulation; bleeding time may also be prolonged, especially if additional 
risk factors such as pre-existing arterial disease or prolonged immobility are 
present. On the other hand low platelet count, a side effect of aggressive 
chemotherapy or irradiation therapy, causes an inability for blood to clot and 
there is a danger of death due to excessive bleeding.
Platelets play a crucial role in haemostasis and in the pathogenesis of 
thrombosis. Their role in haemostasis is two fold: first, the formation of the 
haemostatic plug at the site of vascular injury and secondly the secretion of 
vasoactive substances leading to blood vessel contraction and recruitment of 
other platelets and substances from their granules which are involved in 
coagulation.
Diseases such as atherosclerosis rarely lead to occlusion, however the presence 
of a thrombus and the severe atherosclerotic narrowing causes occlusion of the 
vessel. 90% or more of acute transmural myocardial infarcts are associated with 
one or more segments occluded by a thrombus. This is caused by the loss or 
denudation of an area that is normally a thromboresistant endothelial layer and 
the subsequent exposure of this area to circulating platelets causing adhesion, 
aggregation, degranulation and the activation of the circulating platelets. This 
occlusion leads tissue starvation of oxygen and subsequent death in severe cases 
such as stroke.
Stress appears to be the most common cause of occlusion in vascular disease. 
During stress, circulating levels of noradrenaline and adrenaline are elevated
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and thus potentiate the risk of thrombosis. In order to reduce the long term risks 
of vascular disease, it is best to address the factors that are associated with the 
increased risk and not to use anti-thrombotic drugs when patients suffer from 
angina or have a myocardial infarction.
Hypertension, elevated blood lipids, the presence of other diseases such as 
diabetes as well as a genetic predisposition and bad living habits all increase the 
risk of thrombotic disorders.
There has been active research over the last 20 years in the search for 
compounds that depress platelet reactivity and function, and it is possible to 
divide such agents into three classes:
I. Receptor antagonists which antagonise the platelet response to specific stimuli 
by blocking the interaction of the stimulant with its receptor, eg. phentolamine 
blocks aggregation induced by catecholamines, ATP blocks platelet ADP 
receptors. However, because of the diversity of agents that can activate platelets 
and because of the self-amplification process in platelet activation, it is unlikely 
that any single type of receptor antagonist could prevent platelet thrombus 
formation when platelets in vivo are exposed simultaneously to several different 
stimuli.
n . Enzyme inhibitors which are involved in the platelet activation cascade such 
as aspirin. Aspirin irreversibly acetylates the cyclo-oxygenase enzyme hence 
blocking it and this enzyme is responsible for the production of prostaglandins 
and TxA2 from AA. Thus, inhibiting this enzyme can cause significant 
inhibition of platelet function if  the response depends completely on AA 
metabolism such as with low doses o f collagen (Roth and Majerus, 1975; 
Patrono, 1989).
l l
III. Stimulators of AC and local anaesthetics; PGI2, in platelets produced by the 
vascular endothelium, acts to stimulate AC elevating cAMP levels thus blocking 
activation. However because cAMP is a ubiquitous intracellular messenger in 
most cell, the effect of such drugs are not limited to platelets and their potential 
clinical value as antithrombotic agents is limited. Local anaesthetics are also 
non-specific, and act by stabilising cell membranes, and at low concentrations 
can inhibit secretion and aggregation.
However to date, the most significant clinical studies carried out on anti­
thrombotic agents is the finding that aspirin has a protective effect against acute 
myocardial infarction, showing a decreased incidence o f death or recurring 
myocardial infarction (Roth and Majerus, 1975; Smith and Willis, 1971). 
Aspirin has been convincingly shown to reduce the incidence of vascular 
occlusion events in a wide range of patients at risk of thrombotic complications 
(Patrono, 1989), its beneficial effects linked to the suppression of TXA2- 
dependent platelet aggregation.
Upon platelet receptor activation, InsP3 is liberated from the enzymatic cleavage 
of membrane lipids, and this in turn acts to mobilise intracellular Ca2+. Since 
platelets play a major role in many diseases such as thrombosis, the 
development of drugs that can block platelet agonists will no doubt be 
beneficial. However, so many agonists act together to elicit the platelet response 
and specific antagonists to each agent is not a practical solution. Since all 
platelet agonists possess the same signalling mechanisms, it is more reasonable 
to block platelet activation through blocking signalling. Thus, blocking the InsP3 
receptor would be a good example. If such a compound existed, then it is 
envisaged that it may have a beneficial effect in the above diseases. Platelets 
were thus used in this study.
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given that occlusive vascular disease is the major cause of death in the western 
world and the knowledge that platelets play a crucial role in this disease.
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Figure 3. The enzymatic hydrolysis of phosphatidylinositol-4,5-bisphosphate 
(PIP2) by PLC to give the second messenger molecules InsP3 and DAG.
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1.4 A historical aspect of phosphoinositide signalling.
Since the initial findings of Mabel and Lowel Hokin on the effects of 
neurotransmitters and hormones on phospholipid turnover more than three 
decades ago, studies on phosphatidylinositol (PI) metabolism have been a focus 
of attention, Michell et al., (1981), for review see Abdel-Latif, 1986. Thus, it 
was established that the polyphosphoinositide (PPI) phosphatidylinositol-4,5- 
bisphosphate (PIP2) was the one, figure 3.
1.5 DAG. InsPi and Ins(1.3.4.5VPd as second messengers.
The initial suggestion that stimulated PIP2 breakdown is involved in Ca2+ 
mobilisation (Berridge and Irvine, 1984; Berridge and Irvine, 1989) has since 
been confirmed in many cells and tissues. InsP3 induced Ca2+ mobilisation first 
reported in permeabilised pancreatic acinar cells (Streb et al., 1983) and 
successive studies confirmed that InsP3 had similar effects in many cell types 
(Berridge and Irvine, 1984; Irvine et al., 1986; Berridge and Irvine, 1989).
Analysis of the rates of receptor stimulated L1SP3 formation (Berridge, 1983; 
Downes and Wusteman, 1983; Tashjian et al., 1987; Horstman et al., 1988) 
and its subsequent complex metabolism (Berridge et al., 1988; Shears, 1989) 
further substantiate the role of L1SP3 as an intracellular messenger by 
demonstrating that it is both formed and inactivated on a time scale 
commensurate with a role in mediating receptor regulated Ca2+ signals (Merritt 
and Rink, 1987). The response of most cells to Ca2+ mobilising stimuli is 
initially relatively independent of extracellular Ca2+, but the sustained elevation 
of [Ca2+]i is absolutely dependent on extracellular Ca2+.
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The substantial literature demonstrating that these two phases of response, 
mobilisation of intracellular Ca2+ and stimulated Ca2+ entry across the plasma 
membrane are features of most cells and depend upon receptor stimulated PIP2 
hydrolysis (Putney, 1986; Putney, 1987; Putney, 1990). The link between PIP2 
hydrolysis and stimulated Ca2+ entry is not clear although most models ascribe a 
central role to InsP3 because there is reasonable agreement that empty InsP3- 
sensitive Ca2+ stores are an important control of Ca2+ entry either alone 
(Putney, 1986; Putney, 1990), or in concert with the phosphorylated product 
Ins(l,3,4,5)P4 (Irvine and Moor, 1986; Irvine and Moor, 1987; Morris et al.,
1987). This is an important idea since the triggering of Ca2+ entry is 
fundamental to the generation of the Ca2+ signals. However, the possible role of 
Ins(l,3,4,5)P4 as a second messenger remains a controversial one, and to date, a 
specific role for Ins(l,3,4,5)P4, whether it acts as a second messenger on its 
own right, synergises with InsP3 or mediated Ca2+ entry is not clear. The 
presence of an Ins(l,3,4,5)p4 receptor has become apparent and for this reason, 
Ins(l,3,4,5)P4 is perceived to play a significant role in PI signalling.
DAG is a lipophilic molecule, and on release it remains within the plane of the 
plasma membrane (Nishizuka, 1984; Nishizuka, 1986; Nishizuka, 1988). The 
amount of DAG accumulated in platelets is considerably higher than the amount 
of InsP3 produced. This consideration is important for the proposed two step 
mechanism of platelet activation (Siess, 1989), where the first step is InsP3 
formation, and Ca2+ mobilisation. These events cause platelet shape change, 
Ca2+ mobilisation primes PKC, possibly by placing the enzyme into a strategic 
position in the plasma membrane. The second step involves the activation of 
PKC by DAG leading to platelet aggregation and secretion.
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1.6 The role of Ca2+ in cell activation.
Calcium ions are key second messengers in eukaryotic cells. An absolute 
requirement for Ca2+ during muscle contraction was first observed over 100 
years ago when Ringer (1883) observed that a mixture of tap water, rather than 
distilled water, and sodium chloride was more effective in maintaining cardiac 
contractility, and he attributed this to the presence of Ca2+ ions in tap water.
In 1962, Grette first proposed a role for this ion in stimulus-secretion coupling 
in platelets (Grette, 1962). In addition, the development of the aggregometer by 
Bom (\962ab) and more significantly the of advances made in monitoring 
intracellular Ca2+ by fluorescent molecules such as quin-2 (Tsien et al. , 1982) 
has led to the undisputable role of Ca2+ in cellular signalling. Further, a key 
role for other messenger molecules is often the modulation of Ca2+ fluxes where 
the only compelling documented intracellular role o f InsP3 (a known second 
messenger molecule) is the mobilisation of this messenger ion (Berridge and 
Irvine, 1989).
The importance of Ca2+ in the transmission o f information inside living cells 
has been a subject of many reviews (Abdel-Latif, 1986; Putney, 1986; Rink and 
Merrit, 1990). Ca2+ is a regulator of many cell functions and its function is 
most recognised in excitable and secretory cells where functions such as 
contraction and secretion are controlled by this cation. In the unstimulated cell, 
the cytosolic Ca2+ concentration is *  0.1/zM, which is 104 fold lower than the 
millimolar extracellular Ca2+, and following stimulation, [Ca2+]i rises to 1- 
lQfiM. The low cytosolic [Ca2+] is maintained at this level by energy dependent 
Ca2+ transport mechanisms that either extrude Ca2+ across the plasma 
membrane or sequester Ca2+ within intracellular organelles (Gill and Cheuh,
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1985). In most cells, the cytosolic concentration of free Ca2+ ions is low * 60- 
200nM and therefore only accounts for a small fraction o f the total cellular 
calcium content (Meldolesi et al., 1990).
The mitochondria do not play a role in InsP3 induced Ca2+-mobilisation (Joseph 
et al., 1984; Thevenod et al., 1989). They are only significant if  intracellular 
Ca2+ rises over lpM  at which point mitochondrial Ca2+ uptake comes into 
action in order to limit the extent of [Ca2+]i rise (Meldolesi et al., 1990; Rink 
and Merrit, 1990). The effect of InsPs induced Ca2+ mobilisation upon receptor 
activation is not the only one. Evidence suggests that levels of Ca2+ remaining 
within such organelles appear to have important consequences for signalling and 
regulation within the cells (Putney, 1987; Takemura and Putney, 1989; Putney, 
1990).
The ER is thought to play the pivotal role in Ca2+ storage. A high affinity 
Ca2+-ATPase pump is responsible for transmembrane accumulation of high 
[Ca2+] which are maintained within the organelle and subsequent Ca2+ release 
occurs through a specific channel upon activation. Specific intracellular Ca2+ 
pump-blocking agents have recently been obtained discussed in (Rink and 
Merrit, 1990; Capiod et al., 1989), having no effect on plasma membrane ATP- 
ases. Thapsigargin (TG) and more recently 2,5-di(tert-butyl)-l,4- 
benzohydroquinone (tBuBHQ) are two such compounds which inhibit 
endoplasmic reticulum Ca2+-ATPase. They are proving to be useful tools in the 
study of intracellular Ca2+ release and storage (Rink and Merrit, 1990).
Thus, increases in intracellular Ca2+ concentration caused by agonist 
stimulation trigger a variety of responses in cells from cell differentiation and 
proliferation, secretion, metabolism and contraction. These increases are key
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signals in the platelet response, and the ability to elucidate the role o f Ca2+ in 
platelet activation and to modify Ca2+ release with the use of inositol phosphate 
analogues may provide us with useful tools to modify platelet activation. This 
can be subsequently implemented in disease states such as thrombosis and 
atherosclerosis.
1.7 InsP-< and its metabolism.
A second messenger, once released inside the cell, must be efficiently 
deactivated metabolically in order to terminate its action and return the cell to 
its basal state in preparation for a new stimulus. Additionally, metabolites of the 
second messenger may possess other physiological activities within the cell. 
These aspects have come under close scrutiny in the past few years and it has 
become apparent that the metabolism of L1SP3 to free inositol, which is then 
recycled into lipid synthesis, is of considerable complexity generating many 
inositol phosphates which are often difficult to separate. In addition, this is 
further complicated by the fact that InsP3 is not the only hydrophilic product of 
PLC induced PIP2 cleavage, PIP2 cleavage can also occur at the 2-OH of the 
phosphorus of the inositol ring, giving rise to cyclic inositol phosphate, D-myo- 
inositol-l:2cyclic,4,5- trisphosphate,
Ins(l:2 cyc,4 ,5 )P3.
Three major routes of metabolism have been identified, for review see 
(Berridge, 1987; Shears, 1989), see figures 4 and 5.
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1.7.1 Route 1.
The first route involves the action of enzyme InsP3 5-phosphatase, responsible 
for the dephosphorylation at the 5-position phosphate, this having been first 
demonstrated in erythrocytes (Downes et al., 1982). The other enzymes 
involved are the inositol polyphosphate 1-polyphosphatase and inositol 
monophosphatase, see figure 4 and 5.
The product of the action of InsP3 5-phosphatase enzyme is myo-inosiiol 1,4- 
bisphosphate [Ins(l,4)P2]. Since this has no known physiological role in the 
signalling pathway and does not mobilise Ca2+ (Berridge, 1987). Thus, the 
dephosphorylation must serve solely as an inactivating step. Hence, InsP3 5- 
phosphatase enzyme plays a vital role in terminating release of Ca2+ by InsP3. 
This enzyme is sensitive to divalent cations in that it has an absolute 
requirement for Mg2+ and is inhibited by silver, zinc and cobalt (Downes et al., 
1982; Berridge, 1987). However, this enzyme is insensitive to Li+ (Downes et 
al., 1982).
This situation is further complicated by the existence of two types of the InsP3 
5-phosphatase enzyme, a soluble type and particulate type and by the presence 
of more than one type of soluble enzyme in both brain and platelets (Majerus et 
al., 1988; Shears, 1989). The significance of the presence of enzyme subtypes 
is still unclear, for review see Shears (1989). The next step in the metabolism 
involves the enzyme inositol polyphosphate 1-polyphosphatase. This does not 
attack InsP3 or myo-inositol 1,3,4,5-tetrakisphosphate [Ins(l,3,4,5)P4], but is 
specific for Ins(l,4)p2 and /wyo-inositol 1,3,4-trisphosphate [Ins(l,3,4)P3] (see 
later) (Inhom and Majerus, 1987; Inhom and Majerus, 1988). This enzyme is 
Mg2+ dependent and Li+ sensitive and hydrolyses Ins(l,4)P2
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Figure 4 . The bifurcating signal pathway involving PIP2 breakdown to give 
InsP3 and DAG. Upon cell surface receptor occupation, a G-protein is activated 
(Gq) which binds GTP and in turn activates PLC. Both of the messengers 
produced are metabolized rapidly in order to return the cell to its resting state, 
a: InsP3 5-phosphatase, b: 1-phosphatase, c: inositol monophosphatase, d: InsP3 
3-kinase, e: 4-phosphatase, f: 3-phosphatase.
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to give myo-inositol 4-phosphate [Ins(4)P]. Ca2+ can also inhibit this enzyme 
with 40% inhibition occurring at 1/zM Ca2+ (Inhom and Majerus, 1988).
There have been two reports that Ins(l,4)P2 can be dephosphorylated to myo­
inositol 1-phosphate [Ins(l)P] via an inositol polyphosphate 4-phosphatase 
(Storey et al., 1984; Takimoto et al., 1987), however, Inhom and Majerus 
(Inhom and Majerus, 1987; Inhom and Majerus, 1988) have proposed that the 
product of the enzyme reaction was incorrectly identified as Ins(l)P, and it was 
in fact Ins(4)P. Thus, the major enzyme of metabolism is the 1-phosphatase 
(Inhom and Majerus, 1987; Inhom and Majerus, 1988). Ins(4)P is then 
dephosphorylated by a nonspecific phosphatase, inositol monophosphatase, 
which has no specificity for Ins(4)P but also acts on Ins(l)P, myo-inositol 3- 
phosphate [Ins(3)P] and myoinositol 6-phosphate [Ins(6)P]. This enzyme is 
inhibited by Li+ (Nahorski, 1990; Kennedy et al., 1990; Kendall and 
Whitworth, 1990), and the product of hydrolysis is free myoinositol, which can 
enter the lipid cycle.
1.7.2 Route 2.
Metabolism begins with the phosphorylation of InsP3 by InsP3 3-kinase (Irvine 
et al., 1988; Irvine et al., 1985; Berridge and Irvine, 1989) to give 
Ins(l,3,4,5)P4, and the physiological significance of this molecule has eluded 
most investigators. The other enzymes involved are the Ins(l,3,4,5)P4 5- 
phosphatase, the inositol polyphosphate 1-phosphatase, the inositol 
polyphosphate 4-phosphatase, the inositol polyphosphate 3-phosphatase and 
inositol monophosphatase, see figure 4. The 3-kinase enzyme is mostly soluble 
in all tissues studied, for review see (Shears, 1989), and has an absolute 
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Figure 5. The metabolism of InsP3 by the two enzymes InsP3 3-kinase and InsP3 
5-phosphatase and the subsequent breakdown of these metabolites by further 
enzymes (see text for explanation).
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from ATP to the 3-position of InsP3. There is evidence that an increase in Ca2+ 
stimulates this enzyme in many tissues in a calmodulin-dependent manner. 
Thus, transient receptor-mediated elevations in cytosolic Ca2+ can increase the 
rate of Ins(l,3 ,4 ,5 )P4 formation and this may have significant functions (see 
later).
Ins(l,3 ,4 ,5 )P4 is subsequently metabolized by the Ins(l,3 ,4 ,5 )P4 5-phosphatase 
enzyme, which may be similar to InsP3 5-phosphatase. In brain this enzyme 
attacks both InsP3 and Ins(l,3 ,4 ,5 )P4, however, generally different forms will 
attack InsP3 or Ins(l,3 ,4 ,5 )P4 preferentially. The soluble type I 5-phosphatase 
enzyme and the particulate type have higher affinity for L1SP3 over 
Ins(l,3 ,4 ,5 )P4, thus Ins(l,3 ,4 ,5 )P4 may act as a competitive inhibitor, on the 
other hand type II soluble enzyme has poor affinity for Ins(l,3 ,4 ,5 )P4. What the 
significance o f this is or how important the inhibition is in vivo is difficult to 
gauge and until these enzymes are fully purified an interrelationship between 
tissue and enzyme will then become clear.
The product of 5-phosphatase hydrolysis is Ins(l,3 ,4 )P3, which can either be 
phosphorylated by a 6 -kinase to give myo-inositol 1,3,4,6-tetrakisphosphate 
[Ins(l,3 ,4 ,6 )P4] (Balia et al., 1987; Shears et al., 1987; Stephens et al., 1990; 
King et al., 1990) (see later), or dephosphorylated by two enzymes, the inositol 
polyphosphate 1-phosphatase, a Mg2+ dependent enzyme, to give myo-inositol 
3,4-bisphosphate [Ins(3 ,4 )P2] (Inhom et al., 1987).
The second route is via an inositol polyphosphate 4-phosphatase that gives rise 
to myo-inositol 1,3-bisphosphate [Ins(l,3 )p2], a Mg2+ dependent enzyme that is 
not inhibited by I i + (Bansal et al., 1987; Bansal et al., 1990). Further
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metabolism by specific enzymes leads to the monophosphates and subsequently 
to inositol, see figure 4 and 5.
1.7.3 Route 3.
Recently, reports have indicated the presence of Ins(l,3,4,5)P4 3-phosphatase 
activity (Hoer et al., 1988; Doughney et al., 1988; Cullen et al., 1989) which 
leads to the reformation of InsP3 (Shears, 1989). The role of this novel enzyme 
could therefore be in maintaining InsP3 levels and the significance o f this is not 
determined. It has been suggested that the substrate for this 3-phosphatase is 
/wyo-inositol 1,3,4,5,6-pentakisphosphate [Ins(l,3,4,5,6)P5], in preference to 
L1SP3. Thus, its actions on L1SP3 only become apparent when this inhibitory 
effect is removed.
Ins(l,3,4,5)P4 has also been implicated in the production of In s(l,3 ,4 ,5 ,6)Ps by 
a novel 6-kinase although other evidence has suggested that Ins(l,3,4,5,6)Ps is 
produced by the action of a 3-kinase on myo-inositol 1,4,5,6-tetrakisphosphate 
[Ins(l,4,5,6)P4] (Stephens et al., 1988ab) see later section on higher inositol 
phosphates) (Stephens et al., 1990; Stephens and Downes, 1990).
1.8 Platelet lipids and the PI cycle.
The outer membrane lipid composition of human platelets is phosphatidylcholine 
(PC) 23%, phosphatidylethanolamine (PE) 11%, phosphatidylserine (PS) 4.5% 
and PI 5-7%. PPI make up a minor percentage of membrane lipids, 
phosphatidylinositol 4-phosphate (PIP) and PIP2 accounting for 15 »12%  of 
total polyphosphoinositol lipids, reviewed in Siess, (1989) (Mauco et al., 1984; 
Billah and Lapetina, 1982).
24
Ptd lns(3)P -  Ptd lns(3,4)P2 v x Ptd lns(3,4,5)P.
PI 3-kinse
Ptd Ins
PI 3-kinse PI 3-kinse
PI 4-kinase PIP 5-kinase
V- Inositol










Figure 6. Membrane inositol phospholipids phosphorylation. The classical 
pathway involving the phosphorylation of the 4-OH and the 5-OH by the two 
enzymes, PI 4-kinase and PI(4)P 5-kinase, is shown in the lower half of the 
diagram. Each of these lipids can serve as substrates for the PI 3-kinase giving 
rise to the novel 3-phosphorylated inositol lipids (shown in the upper half of the 
diagram).
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The PPI's are synthesized by the sequential phosphorylation of PI by the 
enzymes PI 4-kinase and PI(4)P 5-kinase, both are membrane bound (Kaulen 
and Gross, 1976). PI and PPI exist in both resting and stimulated platelets in 
metabolically homogeneous pools. After platelet stimulation with agonists such 
as thrombin, ADP or AA, a rapid decrease in PIP2 is observed and after 5 
seconds of agonist addition a total of 20- 50% loss of total mass is observed 
due to PLC activation (Siess, 1989). This loss is transient and 10 seconds after, 
levels return to normal (Agranoff et al., 1983; Billah and Lapetina, 1982). 
Levels of PI do not decrease after platelet stimulation, in fact they are found to 
increase after a lag time of 30 seconds from platelet stimulation (Billah and 
Lapetina, 1982) due to resynthesis and flux.
Two types of enzymes have been established in the synthesis o f inositol lipids, 
type I kinase [with intrinsic tyrosine kinase activity (Takenawa et al., 1990; 
Auger et al., 1989)], leading to the phosphorylation at the novel-3 positions, 
and type n  kinase being the classical kinase involved in PIP and PIP2 
production and phosphorylation at the 4-and 5- positions (Sultan et al., 1990; 
Auger et al., 1989; Cunningham et al., 1990; Takenawa et cd., 1990; Whitman 
et al., 1988), see figure 6.
PI turnover in platelets was first noted by Firkin and Williams, who 
demonstrated that 32P-labelled phosphate was incorporated into PA, PI and PPI. 
In addition, recently, the novel lipid phosphatidylinositol 3-phosphate [PI(3)P] 
and phosphatidylinositol 3,4-bisphosphate [PI(3,4)P2] have been shown to 
accumulate upon thrombin stimulation (Sultan et al., 1990; Cunningham et al., 
1990). However a role for these lipids in platelets is still unclear, but a 
suggested role for these 3-phosphorylated lipids in other cells has been as
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second messengers in regulating cell growth and differentiation, for review see 
Berridge (1990).
1.9 InsP-t metabolizing enzymes in platelets.
1.9.1 InsPo and Ins(1.3.4.51Pd 5-Phosphatase.
As in most other cells, platelets metabolize InsP3 by two enzymes, a 
dephosphorylation and inactivation by a 5-phosphatase, and phosphorylation 
through a 3-kinase (Daniel et al., 1987). Two forms o f 5-phosphatase enzyme 
are thought to exist. Initial data suggests that the 5-phosphatase is mainly 
cytosolic (Connolly et al., 1985), however, recent evidence suggests a 
particulate enzyme (Vedia et al., 1988). There are multiple isoforms of the 
inositol polyphosphate-5-phosphatase enzyme distributed between the soluble 
and particulate fractions and these act on three substrates, InsP3 , Ins(l,3,4,5)p4 
and Ins(l:2cyc,4,5)P3.
In human platelets, two forms of the cytosolic 5-phosphatase have been isolated 
(Connolly et al., 1985; Mitchell et al., 1989). Type I enzyme has a molecular 
weight of 45kDa and requires Mg2+. It has greater activity against 
Ins(l,3,4,5)P4 as a substrate at low substrate concentration, and consistent with 
this is that low concentrations of Ins(l,3,4,5)P4 (1/*M) inhibit InsP3 or 
Ins(l:2cyc,4,5)P3 breakdown. This implies that cellular levels of InsP3 
metabolites may be sustained under conditions where Ins(l,3,4,5)P4 is formed. 
Type I enzyme is also phosphorylated by PKC (Connolly et al., 1986) and this 
is associated with an increase in enzyme activity, thus PKC activation tends to 
reduce levels o f InsP3, terminating signalling.
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The type II enzyme has a molecular weight of 75kDa and hydrolyses the same 
substrates as type I (Mitchell et al., 1989). However, it has a lower affinity for 
both InsP3 and Ins(l,3,4,5)P4 and is not phosphorylated by PKC. It requires 
Mg2+ for activity, and unlike the type I enzyme, metabolites of L1SP3 do not 
inhibit enzyme activity. Further studies have shown that a membrane bound, 
particulate enzyme is also present in platelets, and approximately 40% of InsPs 
5-phosphatase activity is membrane-bound (Vedia et al., 1988), with a 
molecular weight of 49kDa (Connolly et al., 1985). The existence of 3 types of 
5-phosphatase enzyme confounds the simple interpretation of the role o f this 
enzyme in controlling inositol phosphate fluxes and in turn Ca2+ signalling. 
Approximately twice as much type n  enzyme is present in platelets as the type 
I, and since type I enzyme has lower affinity for Ins(l,3,4,5)P4 than type n, it 
appears that cellular levels of Ins(l,3,4,5)P4 may influence which of the 
phosphatases hydrolyse L1SP3.
____________________________________ Km__________________
Enzyme type_____________ InsP?_______ Ins(1.3.4.5iP^
Soluble: Type I 7.5/zM 0.5/xM
:Type II 24/xM 7.5jiM
membrane bound 100/xM
Table 1. The two types of 5-phosphatase enzymes in platelets and their affinities 
for InsP3 and Ins(l,3,4,5)P4.
This is further complicated by the fact that type I enzyme is phosphorylated and 
activated by PKC. Thus type I enzyme hydrolyses L1SP3 >  Ins(l,3,4,5)P4.
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Therefore, at low substrate concentration Ins(l,3 ,4 ,5 )P4 is hydrolysed rapidly 
and competitively inhibits InsP3 hydrolysis, and at high substrate concentration 
InsP3 is metabolized at a greater rate. For a summary see Table 1.
1.9.2 InsP  ^3-Kinase.
The 3-kinase enzyme responsible for the 3-phosphorylation of L1SP3 (InsP3 3- 
kinase), is a Ca2+/calmodulin dependent enzyme as for other cell types (Biden 
et al., 1987; Daniel et al., 1987; Daniel et al., 1988).
In stimulated platelets, Ins(l,3,4)P3 is the major metabolite and not Ins(l,4)P2 
as found in other cells (Daniel et al., 1988), and since this route of metabolism 
consumes ATP, one can envisage that the metabolites o f this pathway may play 
an important role in platelet function. However, as for as Ca2+ mobilisation 
goes, Ins(l,3,4)P3 has been shown to be very poor at releasing Ca2+, if  at all 
(Irvine et al., 1986) and its direct function in platelets or any other cell type has 
not yet been defined. Further, King et al., (1990) have recently found that 
thrombin-stimulation of permeabilised platelets causes the accumulation o f a 
novel inositol tetrakisphosphate by the action of a 6-kinase enzyme. The 
metabolite was identified as Ins(l,3,4,6)P4. However, this accumulation is 
minor in comparison with its precursor Ins(l,3,4)P3, and it is thought to play 
only a minor part (King et al., 1990).
InsP3 3-kinase is a substrate for PKC (King and Rittenhouse, 1989), and thus 
receptor occupation will phosphorylate this enzyme increasing its activity, thus 
removing InsP3 from the cytosol and its Ca2+ mobilising actions. However, Lin 
et al., (1990) have proposed that PKC inhibits the 3-kinase enzyme, based upon 
studies using PKC activators and inhibitors.
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InsP3 3-kinase consists of two polypeptides, 53 and 36 kDa molecular weight, 
and the majority of activity is associated with the 36kDa component. It is not 
known if these two different polypeptides are distinct enzymes (Takazawa et a l., 
1989) or if they share a precursor-product relationship (Lee et al., 1990).
In platelets, Ins(l:2cyc,4,5)P3 is formed upon thrombin stimulation (Weber and 
Johnson, 1986; Ishii et al., 1986). This inositol phosphate is capable of 
mobilising Ca2+ (Wilson et al., 1985) in platelets with a similar potency to 
InsP3, however little interest in this compound as a second messenger has been 
maintained due to its low ability to release Ca2+ in other cell systems.
1.10 Lithium (Li+) as an inhibitor of inositol trisphosphate metabolism.
Lithium is an uncompetitive inhibitor of the 1- phosphatase and inositol 
monophosphatase (Inhom and Majerus, 1987; Drummond, 1987; Inhom and 
Majerus, 1988), see figure 4. Li+ is uniquely effective in the therapy and 
prophylaxis of manic depression. In the last few years there has been growing 
evidence that the actions of Li+ in affective disorders is related to its ability to 
interfere with PI signalling (Batty and Nahorski, 1985), for review see 
(Nahorski et al., 1990). It has been argued that Li+ may act by reducing the 
supply o f inositol for the resynthesis of Pi's that are used to generate second 
messengers.
However, until alternative inhibitors of inositol monophosphatase or inositol 
uptake are shown to be as efficacious as Li+ clinically, the therapeutic actions 
o f Li+ can not be ascribed to these cellular actions. On a positive note however, 
the stimulus-dependent effects of Li+ on PI signalling at concentrations within
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the therapeutic range highlight the potential of targeting drugs at an intracellular 
second messenger signalling system.
1.11 InsP  ^receptor.
It has been known for some years now that the ability of InsP3 to open a Ca2+ 
channel in the membrane associated with the endoplasmic reticulum or 
specialised calciosome depends critically on the positional distribution of the 
phosphate groups on the inositol ring (Potter, 1990be). It is reasonable to 
assume therefore, that InsP3 interacts with a specific receptor linked directly or 
indirectly to this Ca2+ channel.
The initial identification of specific InsP3 binding proteins was achieved using 
radioligand binding assays and these utilised membranes from peripheral tissues 
such as neutrophils, hepatocytes and adrenal gland microsomal membranes 
(Baukal et a l ,  1985; Spat et al., 1986), however, due to the low abundance o f 
InsP3 receptors in these tissues, subsequent studies turned to the CNS where 
pH]InsP3 binding in the cerebellum was detected over 100 times greater than in 
most peripheral tissue (Worley et a l ,  1981ab; Willcocks et a l ,  1987; Worely 
et a l , 1989).
The native molecular weight of the InsP3 binding protein is about 1 million 
daltons as assessed by gel filtration studies (Supattapone et a l ,  1988). 
However, the purified receptor protein is a single 260 kDa (Supattapone et a l ,
1988) band when analysed on SDS-PAGE, suggesting a tetrameric structure. 
Upon receptor isolation, most o f the biochemical and pharmacological 
properties of the InsP3-binding protein remain unaltered, with one exception: 











Figure 7 . The structure of the I11SP3 receptor. It consists o f a large 
transmembrane protein with eight hydrophobic domains at the carboxy 
terminus; a large hydrophilic domain that contains the regulatory sites for 
phosphorylation and the ligand binding domain at the amino terminus (Mignery 
and Sudhof, 1990).
32
is unaffected by Ca2+ even at concentrations 10000 fold higher than those that 
inhibit binding in crude membranes (Supattapone et al., 1988), and this 
property can be reconstituted by the addition of detergent extracted membranes 
to the purified membrane receptor (Danoff et al., 1988) and the ability of Ca2+ 
to inhibit InsP3 binding has been proposed to be mediated through a separate 
protein called "calmedin" (Danoff et al., 1988).
InsP3 activates Ca2+ release, cooperatively, through the direct binding to a 
ligand activated Ca2+-channel, thus allowing Ca2+ mobilisation (Debs et al., 
1988; Meyer et al., 1990; Meyer and Stryer, 1990) by the release of Ca2+ from 
intracellular non-mitochodrial pools (Streb et al., 1983). The site of action has 
been an area of some controversy in recent years and the initial suggestion that 
the InsP3-sensitive Ca2+-pool is part o f the endoplasmic reticulum (ER) has 
recently been questioned, although the bulk of the evidence points to this fact 
(Streb et al., 1983; Streb et al., 1984; Putney, 1990). The proposal that a novel 
calsequestrin-containing organelle referred to as "calciosome" is the L1SP3 
sensitive-Ca2+ pool (Volpe et al., 1988; Meldolesi et a l ,  1990). However, as 
yet there does not seem to be any overwhelming evidence for a clearly 
identifiable and discrete Ca2+ storage organelle.
1.12 Regulation of the InsP  ^receptor.
The InsP3 receptor and the actions of L1SP3 are highly regulated by a variety of 
agents including Ca2+, pH, PKA and ATP (Worley et al., 1987ab; Willcocks et 
a l ,  1987; Joseph e ta l., 1989).
Ca2+ was found to be a potent inhibitor of pH]InsP3 binding with an IC50 of 
300nM suggesting that Ca2+ released by InsP3 may act as a negative feedback 
mechanism inhibiting further Ca2+
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C y t o s o l








S t i m u l a t i o n I n h i b i t i o n
Figure 8 . Multiple effects of Ca2+ on the InsP3 receptor. Cytosolic Ca2+ can 
exert both an stimulatory and an inhibitory effect on InsP3-induced Ca2+- 
mobilisation. The inhibitory effects mediated by a membrane calmedin, whereas 
the stimulatory modes o f action are not yet known.
34
release (Joseph et al., 1989; Zao and Mullam, 1990; Berridge, 1990; Petersen 
and Wakui, 1990). Calcium has also been shown to have a biphasic regulation 
on the action of InsP3 (lion, 1990), see figure 8 .
The receptor can be phosphorylated by protein kinase A (PKA) (Weeks et al., 
1984; Walaas et al., 1986). This results in a decrease in the potency in InsP3 for 
releasing Ca2+ (Supattapone et al., 1988) by phosphorylating the Ca2+-ATPase. 
Adenine nucleotides can also directly allosterically regulate the InsP3-activated 
Ca2+ channels. This allosteric regulation is selective for ATP with other adenine 
nucleotides being less potent and guanine nucleotides being ineffective (Ferris et 
al., 1990).
1.13 InspT receptor subtypes and receptor heterogeneity.
InsP3 binding sites have been described in many tissues. Variations have been 
reported in the affinity values of these binding proteins to InsP3, eg. in the rat 
cerebellum a reported affinity, Kd= 40nM (Worley et al., \9%lab) compared 
with Kd 5nM in bovine adrenal cortex (Baukal et al., 1985). In addition, 
conflicting reports of InsP3 binding affinities within a single tissue have come to 
light, eg. in the liver, Nunn & Taylor (1990) show a Kd of 5.5nM, whereas 
Guillemette et al (1988) show a Kd of 1.7nM and Mauger et al find two binding 
affinities Kd of 2.23 and 8 8 nM (Mauger et al., 1989). Similar discrepancies 
have been found in other tissues, and Varney et al., (1990) have suggested that 
although these discrepancies within the affinities of L1SP3 to receptors in 
different tissues are present, no consistent pattern is present to suggest receptor 
subtypes.
This confusion regarding the discrepancies within receptor affinities could be 
simply solved by the discovery of a high affinity receptor antagonist. Heparin, a
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sulphated polysaccharide, binds with relatively high affinity, <2/zM to the 
InsP3 receptor, thus antagonising the actions of L1SP3 and has been used widely 
as an antagonist (Ghosh et a l ,  1986; Cullen et al., 1988; Tones et al., 1989). 
However, it should be noted that heparin has other actions within the cell; it has 
been found to inhibit the 3-kinase enzyme (Takazawa et al., 1989), to stimulate 
L-type Ca2+ channels (Knaus et al., 1990), to uncouple receptors from their G- 
proteins including those that stimulate InsP3 formation (Mousli et al., 1990) and 
to inhibit InsP3 3-kinase and Ins(l,3 ,4 ,5 )P4 binding sites. These other effects 
severely limit the ability to utilise heparin as an InsP3 receptor antagonist. A 
second compound, decavanadate, has been found to inhibit InsP3-induced Ca2+- 
mobilisation (Fohr et al., 1989), however this also interacts with Ins(l,3,4,5)P4 
binding and the enzymes associated with InsP3 metabolism. Thus to date of 
starting this study, no specific InsP3-receptor antagonists were available.
A recent report indicates that InsP3 receptors in the liver can exist in two states, 
a high and low affinity states, regulated by cytosolic Ca2+ (Mauger et al., 1989; 
Pietri et al., 1990). The role of Ca2+ is clearest in the cerebellum where 
increases in [Ca2+]i that occur upon stimulation (0.1- 1/xM) decrease the affinity 
of the InsP3 receptor and the sensitivity of Ca2+ mobilisation to InsP3 (Worley 
et a l ,  \9Zlab\ Joseph et al., 1989). This occurs in the absence of ATP at 4°C  
thus does not require protein phosphorylation (Supattapone et al., 1988). The 
same is observed in other tissues, eg. uterine smooth muscle (Varney et al., 
1990), neuroblastoma cells (Chueh and Gill, 1986). However, other tissues such 
as blood platelets (Brass and Joseph, 1985), the adrenal cortex (Varney et al., 
1990) and the vas deferens (Mourey et a l ,  1990) increases in cytosolic [Ca2+]» 
have very little effect on L1SP3 binding to its receptor.
These different sensitivities, to Ca2+, have been explained by the differential 
distribution of calmedin, a large neutral membrane protein, which confers Ca2+
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sensitivity upon purified receptors (Danoff et al., 1988), see earlier). However, 
the situation is not this simple, because whereas calmedin is an integral 
membrane protein, Ca2+ sensitivity in a variety of peripheral tissue is 
irreversibly lost after exposure to low [Ca2+], suggesting that the Ca2+-binding 
protein in these tissues may only be loosely associated with the membrane (Zhao 
and Muallem, 1990).
In platelets, InsP3-stimulated Ca2+-mobilisation has been demonstrated (Brass 
and Joseph, 1985; Adunyah and Dean, 1986) by a ligand binding reaction and 
InsP3-binding proteins have been demonstrated (Hansson et al., 1990). Further 
little work has been done on this receptor in this tissue regarding cloning and 
receptor expression. Ligand binding has been shown to increase with an increase 
in pH, and at high pH two binding sites have been distinguished, one being of 
low ligand affinity and the second showing high affinity. These data suggest the 
presence of either more than one receptor subtype or of negative cooperativity. 
However, binding data alone cannot distinguish between these two possibilities.
Since the InsP3 receptor has been cloned, a significant homology between itself 
and the ryanodine receptor found in skeletal muscle has been demonstrated (Fill 
and Coronado, 1988; Kwan and Putney, 1990; Shah and Part, 1988). The 
significance of these similarities will only be revealed with future investigations 
in this area.
1.14 Modified inositol phosphates.
Recognition that D-myoinositol 1,4,5-trisphosphate is a second messenger has 
stimulated renewed interest in the chemistry of inositol phosphates within the 
last decade. The major structural requirements for InsP3-stimulated Ca2+-
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mobilisation are the presence of the 4,5 vicinal phosphates with the additional 
phosphate at the 1- or 2- positions which increases the affinity (Berridge and 
Irvine, 1984; Potter, 1990abc). L-myo-inositol 1,4,5-trisphosphate (L-InsP3>, 
the enantiomer of the naturally occurring molecule, is inactive (Strupish et al., 
1988; Taylor et al., 1989). It is important to emphasise that to the date of 
beginning this study, although inositol phosphates and their analogues available 
differ widely in their affinities for the InsP3-receptor and their ability to 
mobilise Ca2+, all the compounds tested appear to be full agonists.
The contributions of the ring hydroxyl groups have been investigated, Henne et 
al. (1988) have studied 1-position modifications, where the phosphate moiety 
was substituted with bulky ester groups resulting in minimal loss o f biological 
activity. Modifications at the 2-position also cause little or no loss in activity 
(Hirata e ta l., 1989; Hirata eta l., 1990).
Compound E£so
InsP3 0 .13±  0.01/xM
6-deoxy-Ins(l,4,5)P3 6/xM
jcy//o-Ins(2)F(l,4,5)P3 0 .77±  0.08/xM
Ins(2,2)F2(l,4 ,5)P 3 0.41 ±  O.OSfiM
Table 2 . The effect of modifying ring hydroxyls on InsP3 induced-Ca2+ 
mobilisation. Modification at the 6-OH exemplified by 6-deoxy-Ins(l,4,5)P3 
shows a significant loss in activity as indicated by the EC50, whereas 
modifications at the 2-OH show little if  any loss in Ca2+ mobilising activity.
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Removal o f the 2-OH or its replacement by a fluorine atom show little effect. 2- 
deoxy-ttryo-inositol-1,4,5-trisphosphate [Ins(2)deoxy(l,4,5)P3] is 2.5 less 
potent, DL-2,2-difluoro-2-deoxy-/7ryo-inositol 1,4,5-trisphosphate
[Ins(2,2)F2(l,4,5)P3] is 1.6 fold less potent, and DL-2-deoxy-2-fluoro-5cy//o- 
inositol 1,4,5-trisphosphate [jcy//oIns(2)F(l,4,5)P3] is 3 fold less potent than 
InsP3 (Hirata et al., 1989; Safrany et al., 1990), see Table 2.
All these results lead us to assume that the 2-OH cannot be making a major 
contribution to ligand receptor binding and subsequent activation, otherwise 
these major alterations in 2-OH functional groups will have had a significant 
effect on binding and activation.
These data (from Table 3) should be compared with modifications at the 6-OH 
where D-6-deoxy-/nyo-inositol 1,4,5-trisphosphate [6-deoxy-Ins(l,4,5)P3] has 
an EC50 of 6/xM (Safrany et al., 1990) and DL-6-methoxy-/wyo-inositol 1,4,5- 
trisphosphate [6-methoxy-Ins(l,4,5)P3] has an EC50 of 65jiM (Polokoff et al., 
1988). Such losses in activity indicate that the 6-OH is important for receptor 
binding and activation. The 6-OH is a neighbour to both 1- and 5-phosphate 
groups and removal of this group may effect the conformation of these adjacent 
phosphates, thus making it weaker, as seen above.
3-Deoxy-tfzyo-inositol 1,4,5-trisphosphate [3-deoxy-Ins(l,4,5)P3] has also been 
synthesized and it appears to be a full agonist in releasing 45Ca from NIH 3T3 
cells. Although an EC50 is not yet available, maintenance of activity appears to 
be probable (Seewald et a l ,  1990), leading to the perhaps surprising conclusion 
that the 3-OH is not essential for InsP3 receptor binding and Ca2+ mobilisation. 
No data are available concerning the conformation of InsP3 bound to its 
receptor. While the three phosphates will most likely make the major
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contribution to binding energy with the receptor, the three hydroxyls at the 2-, 
3- and 6- positions may act as either hydrogen bond donors to the receptor 
protein or hydrogen bond acceptors from the protein, and from the above 
modifications it can be seen that both the 6-OH and the 3-OH are important in 
activity. In addition, multiple deletions of the hydroxyl groups can lead to a 
substantial loss of Ca2+-mobilising activity as demonstrated by DL-1,2,4- 
cyclohexane-3,5,6-trisphosphate (loss of «  130 fold activity for the racemic 
mixture) (Polokoff et al., 1988).
Phosphorothioate analogues, mya-inositol 1,4,5-trisphorothioate [Ins(l,4,5)PS3] 
and myo-inositol 5-phosphorothioate 1,4-bisphosphate |Ins(5)PS(l,4)P2] have 
both been synthesized. Ins(l,4,5)PS3 being metabolically stable and 
Ins(5)PS(l,4)P2 being still closer to InsP3 in structure. Both of these analogues 
are potent mobilizers of Ca2+ (Taylor et al., 1988; Taylor et al., 1989) and 
resistant to the 5-phosphatase enzyme (Willcocks et a l ,  1988; Csatb and 
Czametzki, 1988; Taylor et al., 1989). However, Ins(5)PS(l,4)P2 is a substrate 
for the 3-kinase whereas Ins(l,4,5)PS3 is not, suggesting that the 4-phosphate 
may interfere sterically or electronically with the 3-OH, thus inhibiting substrate 
binding.
Ins(l,4,5)PS3 is therefore a persistent activator of the InsP3 receptor being 
resistant to metabolic enzymes. As a consequence of this Ins(l,4,5)PS3 has been 
used to demonstrate the synergy between InsP3 and Ins(l,3,4,5)P4 Irvine et al. 
(1988), where in lacrimal acinar cells (Morris et al., 1987) Ins(l,3,4,5)P4 was 
essential in conjunction with InsP3 in maintaining a Ca2+-dependent K+ current, 
dependent upon extracellular Ca2+, Ins(l,4,5)PS3 alone gave rise to a single 
transient response typical of InsP3, but together with Ins(l,3,4,5)P4 it evoked 
the same sustained response, confirming that the transient response with InsP3 
was not due to rapid metabolism and that Ins(l,3,4,5)P4 was not producing its
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effect by protecting L1SP3 against metabolism by the 5-phosphatase (Changya et 
al.t 1989).
Inositol phosphorothioates have found applications in studies of the 
polyphosphoinositide signalling pathway, discussed in Potter et ah (1990abc). 
Thus, chemical modified inositol phosphates and their phosphorothioate 
analogues are proving to be valuable pharmacological tools in helping to unravel 
the PI signalling pathway. However the greatest benefit will be gained when a 
specific small molecule antagonist is identified and to this end many laboratories 
are working. This will greatly enhance our knowledge of this complex signal 
transduction pathway, for review see Potter (1990abc).
1.15 Permeabilisation methods.
The hydrophilic nature of inositol phosphates and their analogues renders these 
compounds impermeable to intact cell membranes. Direct access to the 
intracellular space is however necessary if  these compounds are to interact with 
an intracellular receptor. Thus the cell membrane needs to become permeable 
and this can be achieved by one of many ways:
1.15.1 Electrical.
When a suspension of cells is exposed to a high electric field, their membranes 
become permeable to solutes (Knight and Baker, 1982; Baker and Knight, 1978; 
Knight and Scrutton, 1980). It is thought that the voltage develops across the 
membrane and causes the membrane to breakdown and become permeable. The 
magnitude of the potential difference across the cell membrane will therefore 
depend upon the intensity of the field and the cell radius and will vary with cell 
size. Thus an electric field applied across cells will cause a breakdown of the
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plasma membranes of a homogeneous cell population and will not affect the 
functional integrity of smaller intracellular organelles. Platelets are very small 
cells with a diameter of 1- 3/xm and therefore require a relatively large field 
strength to permeabilise the cell membrane (Knight et al., 1984; Knight and 
Scrutton, 1980; Hughes and Crawford, 1990; Knight et al., 1988).
1.15.2 Chemical.
Various chemical agents have been used to provide access into the intracellular 
compartment of the cell. These include :
a-toxin (Seeger et al., 1984; Thealestam, 1983; McGee et al., 1983); ATP4- 
(Cockcroft and Gomperts, \919ab\ Cockcroft and Gomperts, 1980; Gomperts et 
al., 1983); Detergents, eg. saponin and digitonin (Lapetina et al., 1984). 
Saponin was used extensively in this study, and it exerts its action by interacting 
with the plasma membrane cholesterol, dissolving it, rendering the cells 
permeable. The use of detergents has been extensive in studying InsP3- 
stimulated Ca2+-mobilisation in many cell types including platelets (Brass and 
Joseph, 1985; Bjorck et al., 1986; Diamond and Henrich, 1987).
1.16 Ca2+ detection.
Ca2+ plays a pivotal role platelet functions. Changes in cytosolic Ca2+ 
concentrations are important for shape change, aggregation and secretory 
responses, as shown in figure 9.
Free Cytosolic Ca2+ is low, being » lOOnM (Rink et al., 1982) and this is 
10000 fold less than the concentration of free Ca2+ in the plasma (ImM). 












Figure 9 . Ca2+ pools and Ca2+ transport systems in platelets. ER, endoplasmic 
reticulum; Mito, mitochondrion; PM, plasma membrane.
cytosolic [Ca2+]f will cause platelet activation, mechanisms in resting platelets 
exist that limit Ca2+ influx from the plasma and actively remove Ca2+ from the 
cytosol. Ca2+ released into the cytosol, in stimulated platelets, can originate 
from either the extracellular plasma via Ca2+ channels or from its mobilisation 
from one or more intracellular pools.
Various methods exist to measure Ca2+ fluxes, pools and intracellular 
concentrations in stimulated and resting cells. The direct measurement of 
[Ca2+]i was made possible by the synthesis and subsequent development o f 
Ca2+-fluorescent indicators.
Indicators o f free Ca2+ ions which can be loaded into cells in a non-disruptive 
manner initiated a revolution in the studies of intracellular Ca2+ homoeostasis. 
The first o f these indicators was quin-2 (Tsien, 1988), the structure of which is 
based on EGTA, and it selectively binds Ca2+. Subsequently, fura-2 and indo-1 
(Grynkiewicz et al., 1985), a second generation of indicators, became available. 
Quin-2 is not cell permeable, unlike its ester derivative, and the second 
generation of indicators (Tsien, 1988). Thus the acetomethoxy ester derivatives 
of quin-2, fura-2 and indo-1 are able to cross cell membranes and once inside 
the cell, cytosolic esterases cleave the ester groups trapping the indicator in the 
cell cytosol. Fura-2 is the choice of fluorescent indicator in this study because 
cell loading requires incubations of 30 minute at 37 °C making simple to use in 
addition to the advantages over quin-2 (see below).
These new indicators have several advantages over quin-2 as indicated by 
Grynkiewicz et al., (1985):
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I. Higher efficiency of fluorescence and increased brightness, reducing the 
required loading levels thus reducing any buffering of Ca2+ transients that is 
observed with quin-2.
n . Better selectivity for Ca2+ ions over other divalent cations.
HI. Ca2+ binding to fura-2 and indo-1 alters the wavelength of excitation and 
emission which enables the use of ratio fluorescence at two wavelengths giving 
more accurate [Ca2+]i readings.
IV. Less autofluorescence due to longer wavelength.
V. Lower affinities for Ca2+, which gives a wider window for [Ca2+]i 
measurements.
Tsien and coworkers have since developed a new group of fluorescent indicators 
based on rhodamine and fluorescein chromaphores (Tsien et al., 1982; Minta et 
al., 1989), fluo-3 is one such dye. It has visible excitation and emission 
wavelength which are more convenient for fluorescent microscopy and flow 
cytometry than the UV required by the previous indicators. However, one 
disadvantage is that upon Ca2+ binding it increases in fluorescence without an 
accompanied increase in wavelength as seen with fura-2 and indo-1, making it 
unsuitable for ratio fluorescence. The free acids of these dyes are also used to 
measure [Ca2+]„ but because they are unable to cross membranes, they need to 
be used in a permeabilised cell preparation or in a cell homogenate preparation, 
and fiira-2 free acid has been used extensively in this study.
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45Ca2+ accumulation in platelets has been studied to identify the organelle 
responsible for Ca2+ sequestration (Brass, 1984). Within the platelet, both the 
dense tubular system and the mitochondrion can act as Ca2+ storage organelles 
(LePeuch et al., 1983) see earlier, and sequestering is most likely to occur 
within the dense tubular system (Menashi et al., 1981).
Platelet membrane fractions have demonstrated Ca2+ accumulation in the 
presence of ATP. Subsequently, a Ca2+-dependent ATP-ase was found to be 
localised in the dense tubular system (Menashi et al., 1981). Hence 45Ca2+ is 
taken up via the Ca2+-dependent ATP-ase pump into the dense tubular system. 
In addition, further studies show that two distinct Ca2+ pumps are associated 
with the plasma and intracellular human platelet membranes indicating the 
possible involvement of both Ca2+-ATPases in the regulation of intracellular 
[Ca2+] (Enyedi et al., 1986; Enouf et al., 1987). Many studies have been 
carried out using 45Ca2+ as a probe for Ca2+-mobilisation in InsP3-stimulated 
platelets (Brass and Joseph, 1985; Authi and Crawford, 1985) and in the present 
study, 45Ca measurements are undertaken to assess the mobilisation abilities of 
inositol phosphate analogues.
The discovery of ion selective membranes for their later use in ion selective 
electrodes has meant the ability to be able to directly measure Ca2+ release in a 
cell suspension is available. Ion selective electrodes have been widely used to 
study Ca2+ transport and mobilisation in cells (Yamazaki et al., 1979; Streb et 
al., 1983). The ion selective electrode is based on a liquid membrane of 
calcium-bis[di(decyl)phosphate] sensor dissolved in dioctylphenylphosphonate 
and this was an important milestone in Ca2+-ion determination (Craggs et al., 
1979). Subsequent modifications and advances within membrane technology has
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lead to the design of mini-electrodes and improved sensors based on a neutral 
carrier system (Ammann et al., 1975; Kopp et al., 1990).
1.17 Functional responses of platelets.
Dense granule release and aggregation are both Ca2+ dependent functional 
responses. Aggregation is dependent on both Ca2+ and Mg2+ for the binding of 
fibrinogen to its receptor (see earlier). Thus, aggregation and Ca2+ mobilisation 
should be parallel independent processes. However, to date no studies have been 
carried out to study the effect o f InsP3-stimulated aggregation and whether this 
mimicks Ca2+-mobilisation is not certain. Aggregation is detected using an 
optical aggregometer (Bom, 1962ab). A limitation on the use of this 
aggregometer is that it does not distinguish between primary and secondary 
aggregation.
Platelets release their granule contents upon stimulation. Granule release can 
occur either via a weak agonist such as ADP or adrenaline, dependent on the 
presence of extracellular Ca2+ and Mg2+, which causes initial platelet 
aggregation, AA release and the consecutive formation of TxA2 and PGs that 
stimulate secretion, or release can occur independently of extracellular Ca2+ 
with strong agonists such as PAF, thrombin and collagen (Siess, 1989).
In permeabilised platelets, InsP3 has been shown to induce dense granule release 
in a dose dependent manner (Brass and Joseph, 1985; Brass et al., 1987), and 
dense granule release as a measure of platelet function using permeabilised 
platelets has been assessed in this study.
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L 18 AIMS.
Ca2+-mobilisation is a common feature of the majority of platelet agonists 
examined to date. As InsP3-induced Ca2+-mobilisation is the only well 
characterised system for receptor-operated calcium-mobilisation in platelets, 
antagonism o f the Ins?3  receptor in platelets is a worthwhile therapeutic goal. 
Therefore the aims of this thesis are:
1. To study Ca2+-mobilisation induced by I11SP3 and its analogues in order 
to develop structure/activity relationships of inositol phosphates. 
InsP3-stimulated Ca2+-mobilisation in permeabilised platelets has been studied in 
many tissues, but little work has been carried out in platelets. The availability of 
many novel inositol phosphate analogues has made it possible to investigate the 
Ca2+-mobilising abilities of these compounds and thus to establish 
structure/activity relationships.
2 . T o  i d e n t i f y  p o t e n t ia l  L1SP3 r e c e p t o r  a n t a g o n is t s .
The availability of a specific InsP3-receptor antagonist would contribute greatly 
to the understanding of the PI signalling pathway and in this study, we have 
investigated potential antagonistic activity expressed by the inositol phosphate 
analogues.
3.  T o  in v e s t ig a t e  t h e  m e t a b o l i s m  o f  In sP 3  i n  p la t e le t s  a n d  t h e  e n z y m e s  
in v o lv e d  i n  t h e  m e t a b o l i s m ,  n a m e ly  ln s P 3  5-p h o s p h a t a s e  a n d  In s P 3  3-  
k in a s e .
InsP3 is metabolized by a series of complex steps to give active and inactive 
metabolites. The two main enzymes involved in InsP3 breakdown are the 5-
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phosphatase and the 3-kinase enzymes. In addition, the effect of temperature on 
InsP3 metabolism was studied at 4°C, 20°C and 37°C.
4 . T o  d e t e r m in e  t h e  e f f e c t s  o f  in o s i t o l  p h o s p h a t e  a n a lo g o u s  o n  I11SP3- 
m e t a b o l i s in g  e n z y m e s ,  n a m e ly  I11SP3 5-p h o s p h a t a s e  a n d  I11SP3 3- k in a s e ,
To examine the effect of metabolic enzyme inhibitors on InsP3 metabolism. To 
establish the possibility of the presence of isozymes and to assess the 
significance o f one metabolic route over the other.
5.  T o  e s t a b l i s h  t h e  f u n c t io n a l  e f f e c t s  o f  In sP 3  a n d  a n a lo g u e s  o n  
p e r m e a b i l i s e d  p la t e le t s  i n  t e r m s  o f  C a 2+ r e le a s e ,  a g g r e g a t io n  a n d  d e n s e  
g r a n u le  r e le a s e .
Elevation of [Ca2+]i is known to trigger both aggregation and secretion in 
platelets. In this study we have attempted to show these effects with the possible 
aim of elucidating an inhibitor to platelet function.
6.  T o  e x a m in e  t h e  r e la t io n s h ip  b e t w e e n  t h e  in h ib i t io n  o f  C a 2+ in f lu x  a n d  
L1SP3 g e n e r a t io n ,  d e n s e  g r a n u le  r e le a s e ,  C a 2+ m o b i l i s a t io n  a n d  I11SP3- 
s t im u la t e d  C a 2+ - m o b i l i s a t io n .
Ca2+ influx is thought to play an important role in the Ca2+-response induced 
by InsP3, by refilling the intracellular pools. In this study, the Ca2+-influx 
inhibitor, SKF 93635, was used to elucidate the role of influx in PAF- 









Bovine serum albumin (BSA) fraction v, protease free; Adenosine 5- 
trisphosphate (ATP, disodium salt); ethylenediamine-tetraacetic acid (EDTA); 
ethyleneglycol-bis(b-aminoethylether)N,N,N',N'-tetraacetic acid (EGTA); 
saponin; heparin, H-3393 and low molecular weight 3000 (H-5271); 
oligomycin; leupeptin; hepes (acid); mops; quin-2 (free acid) were all purchased 
from Sigma chemical company, Poole, Dorset, UK.
Calcium chloride (AnalaR); digitonin (AnalaR); D-glucose (AnalaR); 
magnesium chloride hexahydrate (AnalaR); sodium dihydrogen orthophosphate; 
sodium hydroxide; potassium hydroxide; sodium succinate (AnalaR); tri-sodium 
citrate (AnalaR); ammonium sodium orthophosphate; Dow Coming silicone oils 
556 and 550 were all purchased from BDH ltd, Avon, UK.
Ionomycin (free acid); Ins(l)P (potassium salt) and Ins(l,3,4,6)P4 (ammonium 
salt), were purchased from Calbiochem Company, Novobiochem, UK Ltd. 
Ins(l,4,5)P3 (potassium salt), and Ins(l,3,4,5)P4 (potassium salt) were 
purchased from The University of Rhode Island Foundation, Kingstone, RI, 
USA. Nitrocellulose filter discs and GF-B filter strips for the Brandell cell 
harvester were purchased from Whatman laboratory sales, Maidstone, Kent, 
UK. Chelex 100 chelating ion exchange resin was obtained from Bio-Rad, 
U.S.A; a-toxin was obtained from from Gibco BRL, Middlesex, UK.
Ammonium hydrogen orthophosphate (AnalR); MeOH (HPLC grade); 
tetrahydrofuran (THF) (HPLC grade) and diacylglycerol (DAG) were obtained
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from Fisons, FSA laboratory supplies, Loughborough, UK. Fura-2 
acetomethoxy ester (fura-2 AM) and Fura-2 free acid, calcium calibration kit 
and l,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), were 
purchased from Molecular Probes, Eugene, Oregon, USA. Platelet activating 
factor (PAF) was from Bachem Bioscience Inc. Bubendorf, Switzerland. 
Hypnorm was purchased from Janssen Pharmaceuticals Ltd., Oxon, UK.
SKF 96365 was a gift from Dr C.Poll, Bayer, Slough, UK. All the inositol 
phosphate analogues tested were provided by Prof. B.V.L.Potter.
2.1.2 Radiochemicals.
D-myo-pH]-inositol 1,4,5-trisphosphate, pH]InsP3, potassium salt 
(44/iCi/mmol; 10/xCi/ml); Calcium[45Ca] Chloride, 45Ca, (2mCi/ml); [14C]5- 
hydroxytryptamine creatine sulphate [14C]5-HT, (54mC/mmol;50/xCi/ml) and 
P2P]gamma-Adenosine 5-trisphosphate, p2P]gamma-ATP, (3Ci/mmol) were 
obtained from Amersham International, Aylesbury, Bucks, UK.
52
2.1.3 Buffers.








The above were dissolved in 950 mis of Milli-Q water and the pH adjusted to
7.4 with NaOH and the volume made up to 1 litre. Prior to use, 5.5mM glucose 
(lOOmg/lOOmls) and 0.25% BSA (250mg/100mls)were added and the mixture 
stirred gently avoiding any frothing.








KH2P 04 2.0mM 2.72g
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The above, when dissolved in 1 litre of Milli-Q water, gave a 5x stock which 
was stored as 50 ml aliquots in plastic containers at -20°C. Prior to use, 10 mis 
of the stock 5x concentrate was brought to a total volume of 50 mis with Milli- 
Q water giving the working ICB. 5mM ATP was added and the pH adjusted to 
6.9 with 20%w/v KOH (since ATP rapidly decomposes under acidic aqueous 
solutions, (Dawson and Clarke, 1972) and oligomycin 5fil o f 5mg/ml stock was 
also added, and the [Ca2+]f was adjusted.











This buffer was prepared daily as some of the reagents break down on storage. 
The above were dissolved in Milli-Q water, the pH was adjusted to 7.1 and the 
final buffer was stored in a plastic container. This buffer is referred to as buffer 
A in the text.
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EGTA 2mM 20ml of 200mM
This buffer was prepared daily, as required, by dissolving the reagents in Milli­
es water and adjusting the pH to 7.3. This buffer is referred to as buffer B in the 
text.











These constituents were dissolved in Milli-Q water and the pH was adjusted to 
7.0. The buffer was prepared daily as some constituents decompose upon 
storage. This buffer is referred to as buffer C in the text.







The above were dissolved in Milli-Q water and the pH adjusted to 7.2. This 
buffer was prepared daily to avoid the breakdown of any of the constituents. 
This buffer is referred to as buffer D in the text.
2.1.4 Drugs and solutions.
l-0-Octadecvl-2-acetvl-sn-%lvcero-3-phosphocholine (PAF1.
A 10-2M stock solution was dissolved in chloroform:methanol (4:1, v/v) and 
stored at -20°C. Sub-aliquots (10/d) were removed, dried under nitrogen and 
made up to 1ml in PBS containing 2.5mg/ml BSA to give a final concentration 
of HHM PAF. This was stored as 40/d aliquoted at -20°C.
Prostacyclin (PGIVL
PGI2 was a gift from Dr.B.J.R.Whittle, Wellcome laboratories, Beckenham, 
Kent, lmg/ml stock solutions were prepared by dissolving the solid in 0.5M
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Tris/HCl buffer (pH 10.5) and 40/*g/40/ri aliquots were stored at -20°C. Prior 
to use, an aliquot was thawed and diluted to 1 ml in 0 .0 1M Tris/HCl buffer (pH 
10.5) and stored on ice.
Ionomvcin.
A stock solution of 5mM in dry DMSO was prepared and stored at 4°C. 
Diacvlglycerol (DAG1.
ImM stock solution in CHCI3 was prepared, aliquots of 10/xl were dried down 
and stored at -20°C.
Digitonin.
Stock solution of ImM in 70% ethanol was kept at 4°C.
Ins(1.4.51Pi and analogues.
All analogues were provided as the triethylam monium salts freeze dried solids at 
0.25- 1.0 /xmoles. Stock solutions of ImM in Milli-Q water were kept at -20°C 
and subsequent dilutions were carried out with ICB.
Fura-2 AM & Fura-2 free acid.
A 3x 10-3M solution of Fura-2 AM was prepared by dissolving in dry DMSO 
and stored at -20°C. A ImM Stock solutions of Fura-2 free acid were prepared 
by dissolving in Milli-Q water and sub-aliquots o f 20/zl were stored at -20°C 
wrapped in aluminium foil.
Oligomvcin.
5mg/ml solutions in ethanol were prepared and stored at -20°C.
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All other agonists and reagents were prepared daily as required.
Decavanadate.
The species o f vanadate present in aqueous solution is strongly dependent upon 
the pH of that solution and the concentration of vanadate present. At pH 7.2, 
vanadate (1.25mmol/l) exists as 50% tetramer, 30% monomer, 10% dimer and 
10% other species. At pH 3.75, only decavanadate exists, (Fohr et al., 1989). 
0.5M  Stock solutions of monovanadate were prepared by dissolving sodium 
ortho-vanadate (4.6g) in 50ml of 1M KOH. Solutions of KC1 (150mmol/l; 
2.2g/250ml) and 20mmol/l mops (1.155g/250ml) were prepared in the same 
flask and the pH adjusted to 7.2. Decavanadate (5mmol/l) was prepared by the 
addition o f 1ml of monovanadate to 99ml of KCl/Mops mixture and the pH 
titrated to 3.75 giving a distinctive yellow colour of the decavanadate in solution 
and prior to use the pH was titrated back to 7.2, (Fohr et al., 1989). 
Decavanadate shows characteristic UV absorbance, and using a UV 
spectrophotometer it appears as a broad peak between 350 and 400nm.
Ca2+sponge.
Commercially available chelating resin (Chelex 100) does not sufficiently lower 
metal ion contamination from solutions of Ca2+ indicator dyes, (Meyer et al., 
1990). As a result a heptadentate DTPA-based resin was prepared.
DTPA anhydride (12g, 33.6mmol) was suspended in a mixture o f 100ml dry 
distiled DMSO and 400 ml glacial acetic acid. Dry aminoethyl Bio-Gel P-2 
(16g) was then added and the mixture stirred and refluxed for 4 hours at 131°C. 
The resulting resin was filtered and washed twice with DMSO, twice with 0 .1M 
NaOH, twice with 0.1M HC1 and finally with 100 ml Milli-Q water, (Meyer et 




New Zealand white female rabbits 3.5- 4.5kg were used. Rabbits were sedated 
with an intramuscular injection of 0.25ml/kg Hypnorm (0.32mg fentyl 
citrate/ml and lOmg fluanisone/ml). After 30 minutes, 38ml o f blood was 
collected into plastic tubes, from the ear artery, into 3.2% trisodium citrate 
(9:1, v/v) using a 19 gauge needle. This was followed by gentle inversion of the 
tubes.
2.2.2 Preparation of washed platelets.
Washed rabbit platelets were prepared according to the method for human 
platelets described by Poll et al (1986). This method is a modification of the 
original one described by Blackwell et al (1982). The collected blood was 
centrifuged at 185g for 10 minutes which gave rise to two layers. The platelet 
rich plasma (PRP) is the top layer and this was retained, discarding the lower 
red blood cell layer. To the PRP, PGI2 (300ng/ml) was added and mixed by 
gentle inversion, the PRP was then centrifuged at 1250g for 15 minutes to give 
a platelet pellet. After removing the plasma, the pellet was resuspended in HBT 
and lOOng/ml PGI2 was added to the suspension. The platelet suspension was 
centrifuged once again at 1250g for 15 minutes giving a washed platelet pellet.
The platelet suspension, after the final wash was left for 60- 90 minutes to allow 
the elevated cAMP levels (due to PGI2 addition) to return to normal and full 
platelet function to return.
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2.2.3 Preparation of permeabilised platelets.
2.2.3.1 Determination of the free ICa2+l of ICB.
2ml aliquots of ICB were placed in a cuvette, 1/tM fura-2 free acid was added 
and the calcium concentration of the buffer was determined fluorometrically. 
Maximal and minimal fluorescence, (Fmax and Fmin), were determined and these 
values used in the equation in the later section 2.2.6. This gives the free Ca2+ 
concentration [Ca2+]f. Fmax was obtained by the addition of lOmM Ca2+, this 
excess Ca2+ binds to the free fura in the cell suspension thus giving a maximal 
fluorescence. The pH of the suspension was then rendered alkaline with 60- 
80/xl of 2M NaOH and 100- 200/d of 50mM EGTA was added to reduce the 
[Ca2+]f producing a drop in fluorescence to a minimum. Further additions of 
50mM EGTA should not produce a further drop in fluorescence. However, if  a 
drop is observed, then sufficient EGTA has not been used and a further aliquote 
should be added. The changes in fluorescence were recorded and used to give 
actual Ca2+ concentrations in nM (see later section 2.2.6).
EGTA (40- 100/d) of lOmM was added to the above working buffer, giving a 
buffered ICB. A 2ml aliquot of this buffered ICB was placed in a clean cuvette 
with 1/iM fura-2 free acid and its [Ca2+]f was determined. If the free 
concentration exceeded 200nM, then a further small addition of EGTA (5- 10/d 
of lOmM) was necessary to the working ICB. The aim of this procedure was to 
reduce the calcium concentration in ICB to mimic intracellular calcium 
concentrations, thus, concentrations of 100- 150nM [Ca2+]f were essential. 
Batches of stock ICB were found to require similar amounts of EGTA to reduce 
[Ca2+]f to between 100- 150nM suggesting that the major contaminating source 
of Ca2+ was the ICB's constituent salts.
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Whenever ICB is used it refers to a buffer whose Ca2+ content has been 
buffered to between 100- 150nM, unless otherwise stated.
2.2.3.2 Permeabilisation techniques.
2.2.3.2.1 Chemical.
Platelets were washed as described in sections 2.2.2. The suspension was 
centrifuged at 1250g for 15 minutes and the resulting pellet was resuspended in 
ICB. The suspension was centrifuged once again and the pellet resuspended to 
5mis in ICB and allowed to equilibrate at room temperature for 20- 30 minutes. 
Saponin 40/zg/ml (40^1 of 5mg/ml stock) was added and the platelets were 
mixed for 1 minute and pelleted a final time using the above conditions, and 
resuspended in ICB to give a corrected final cell count of 109 platelets/ml. The 
permeabilised platelets were then left to recover for 60 minutes prior to use.
When permeabilising using a-toxin, a similar procedure is followed as above. 
Platelets were washed as described in section 2.2.2, and the suspension was 
pelleted as above. The pellet was resuspended in buffer A and centrifuged as 
above. The resulting pellet was resuspended in the same buffer and a-toxin (100 
U/107cells) was added to the cell suspension and left in contact for 10 minutes. 
The suspension was then centrifuged and the final pellet resuspended in the high 
K+ buffer to a corrected cell count of 109 cells/ml, after which the cells were 
left to recover for 60 minutes. The cells were then ready for use.
61
2.2.3.2.2 Electrical.
Platelets were washed as described in section 2.2.2, and were pelleted once 
more. The resulting pellet was resuspended in ICB and centrifuged, at 1250g, as 
above. The pellet was resuspended in ICB at a concentration of 5x 109 cells/ml. 
500/d aliquots were placed in the chamber of the electroporator, already 
containing a marker such as 1/xM lucifer yellow or 500cpm pH]InsP3, 
exposed to a number of cycles of high voltage discharge (5- 15 cycles at 2- 
5kV), after permeabilisation all the aliquots were pooled and the cell count 
corrected to 109 platelets/ml. The cells were then ready for use.
2.2.4  Resealing of electropermeabilised platelets.
Platelets were washed as in section 2.2.2, electroporated as above and the 
aliquots combined. The platelet suspension was then removed and kept at 37°C. 
At predetermined time points, 0, 30 and 60 minutes, aliquots o f 500/xl were 
removed to test for resealing and incorporation of lucifer yellow or pH]InsP3 
into the platelets by UV spectrophotometry or liquid scintillation.
2.2.4.1 To test for resealing of electropermeabilised platelets.
Platelets were washed as in section 2.2.2, loaded with [14C]5-HT, washed a 
further once in HBT and twice in ICB and resuspended to 5x 109cell/ml. 500/xl 
aliquots were then porated as above, pooled together and kept at 37°C. At 
predetermined time points, 0, 30 and 60 minutes, 100/xl aliquots were removed 
and challenged with ImM Ca2+ and [14C]5-HT release was determined (see later 
section 2.2.7).
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2.2.5 Preparation of platelet membranes.
2.2.5.1 Preparation of crude platelet membranes.
Platelets were isolated and washed twice in HBT as in section 2.2.2 and then 
two times in ICB. Prior to disruption the platelets were centrifuged at 1250g for 
15 minutes and resuspended to 109 cell/ml in ICB containing 10/xM leupeptin 
and 10/zM pepstatin. The platelet suspension was then rapidly freeze-thawed 
three times by placing in liquid nitrogen and subsequently at 37°C. The 
resulting suspension was centrifuged at 25 OOOg for 60 minutes, and the pellet 
resuspended in ICB containing 10/xM leupeptin. The protein concentration of 
the platelet membrane suspension was determined using the Bio-rad Protein 
assay (see 2.2.11).
2 .2.5.2 Preparation of a pure platelet membrane.
Platelets were isolated and washed as in section 2.2.2, the platelet pellet was 
suspended in buffer C to a small volume of 5mls. 1ml aliquots were kept on ice 
and sonicated for 5x 10 seconds. Subsequently, the sonicated aliquotes were 
pooled together to give the platelet homogenate. The platelet homogenate was 
centrifuged at 2000g for 30 minutes and the resulting supernatant was kept aside 
while the pellet was resuspended in buffer C and resonicated as above. The 
resulting sonicated suspension was centrifuged at 3OOOg for 30 minutes and the 
supernatant combined with that of the first sedimentation giving a complete 
homogenate of platelet membranes. The complete homogenate was then 
centrifuged at 60 000 for 60 minutes, the resulting pellet was resuspended in 1 
ml of buffer C and the protein content determined. The suspension was
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subsequently diluted in the storage buffer (buffer D), according to the final 
protein concentration required, and stored as 500/xl aliquots at -70°C.
2.2.6  Ca2+ measurements in permeabilised platelets.
2.2.6.1 45Ca2+ release assay from permeabilised platelets.
2.2.6.1.1 4SCa2+ uptake and the investigation of permeabilisation.
Washed platelets were prepared as described as in section 2.2.2 and were 
permeabilised with 20/xg/ml, 4fig/ml and 80/tg/ml saponin. 15/*Ci 45Ca (100/xl 
of 1 in 10 dilution of stock) was added and uptake into the cells was determined 
by removing duplicate 100/d aliquots, into separate tubes, at timed intervals of 
0, 10, 30, 60, 90, 120, 150 and 180 minutes. 45Ca uptake was terminated by the 
addition of 250/xl of silicon oil mixture (55%: 45% of fluid 556 and fluid 550), 
to each tube and the cells were centrifuged through the silicon oil (16 OOOg, 5 
minutes), resulting in the separation of the aqueous and oil phases and giving 
rise to a pellet which contains the unreleased 45Ca. After centrifugation, the 
aqueous layer was removed and the tubes inverted, for 20 minutes, to allow the 
oil to run from the tube, leaving the platelet pellet at the bottom of the tube, 
lm l o f optiphase scintillent was then added to each tube, and the amount of 45Ca 
determined by liquid scintillation.
This initial method of centrifuging the platelets through silicon oil proved to be 
problematic. The platelets were not pelleting in the conventional manner but 
smearing all over the tube. Subsequently, making it difficult to separate the 
aqueous layer from the oil layer and not resulting in an intact pellet at the 
bottom of the tube (possibly due to the adhesive nature of stimulated platelets). 
The density of the oil was modified to a lower density to allow the easier
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movement of cells through the oil, and to a higher density to allow the more 
uniform movement with a longer time for centrifugation. However, in both 
cases complete pellet separation proved to be difficult. Thus, an alternative 
method was employed to achieve seperation of the stimulated platelets from 
their bathing medium. This was achieved using a cell harvester with GF-B filter 
strips. The platelet suspension was filtered through these strips, and the 
stimulated platelets with their associated radioactivity would remain on the filter 
strips. The rest of the unassociated radioactivity going to waste. The amount of 
45Ca associated with the stimulated platelets was subsequently determined by 
liquid scintillation.
2 .2.6.1.2 Calculation for InsPi- or analogue-induced 45Ca release.
% 45Ca release induced by InsP3 or analogue Th- IP
Tb- I
Where:
Tb is the cpm loaded into permeabilised, untreated platelets (100/xl; 109 
cells/ml); IP is the cpm remaining in permeabilised platelets (100/xl; 109 
cells/ml) after challenging with InsP3 or analogue (lOnM -100/xM) for 3 
minutes; I is the cpm remaining in permeabilised platelets (100/xl; 109 cells/ml) 
after ionomycin treatment (30/xM).
% Ionomycin-induced 45Ca release Th-1
Tb
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Where Tb is the cpm loaded into permeabilised, untreated platelets (100/xl; 109 
cells/ml); I is the cpm remaining in permeabilised platelets (100/xl; 109 cells/ml) 
after ionomycin treatment (30/xM)
2.2.6.2.3 4SCa2+ release from permeabilised platelets.
Platelets were isolated, washed and permeabilised as in section 2.2.3 , 
resuspended in ICB and loaded with 15/xCi 45Ca and left for 60- 90 minutes (as 
above). After this time platelets (100/xl; 109 cells/ml) were in contact with 3/xM 
InsP3, for 0, 5, 15, 30, 45, 60, 180, 300 and 600 seconds, at 4°, 20°C and 
37°C and the cell associated 45Ca, for the time course, determined by rapid 
filtration as above. 100% release was determined by 30/xM ionomycin and all 
results were expressed as a percentage of ionophore-releasable 45Ca, see above.
2.2.6.1.4 Optimum cell number.
Washed platelets were prepared as in section 2.2.2, and were resuspended to a 
cell count o f 108, 2x 108 and 109 platelets/ml in ICB. The platelets were then 
permeabilised with 40/xg/ml saponin and incubated with 15/xCi 45Ca (see section 
2.2.3) for 60- 90 minutes. 100/xl aliquotes o f the permeabilised platelets were 
then stimulated with 3/xM InsP3 for 3 minutes, and the associated radiolabel 
isolated by rapid filtration. The percentage uptake, and release of 4SCa by the 
cells by the agonist were determined as above.
2.2.6.1.5 Platelet integrity upon saponin treatment.
Platelets were isolated and washed as in section 2.2.2, loaded with [14C]5-HT 
(see section 2.2.7) and washed a further two times in HBT, twice in ICB and
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resuspended to 109 cells/ml in ICB, as in section 2.2.2. Platelets were then 
permeabilised with varying saponin concentrations of 5, 10, 20, 40 and 80/xg/ml 
saponin for 1 minute, and [14C]5-HT release, by the permeabilised platelets, 
was determined as in section 2.2.7.
2.2 .6 .1 .6  Analogue-induced 4SCa-release.
Platelets were washed and permeabilised as in section 2.2.3, resuspended in ICB 
at 109 cells/ml, and loaded with 15/xCi 45Ca and left for 60- 90 minutes (as 
above). After this time platelets (100/xl; 109cells/ml) were challenged with a 
dose range of the analogue (lOnM- 100/xM) for 3 minutes at 4° C or 20°C, to 
give a dose response curve. The cell associated 45Ca radiolabel was isolated by 
rapid filtration, and determined by liqiud scintillation. An InsP3 dose response 
curve (lOnM- 30/xM) was also constructed daily in order to assess platelet 
responsiveness. 100% release was determined by 30/xM ionomycin and all 
results were expressed as a percentage of ionophore-releasable 45Ca, see above.
2.2 .6 .1 .7  Testing for antagonistic activity.
Platelets were washed and permeabilised as in section 2.2.3, resuspended in ICB 
at 109cells/ml and loaded with 15/xCi 45Ca for 60- 90 minutes (as above). After 
this time platelets (100/xl; 109 cells/ml) were challenged with mixtures of 
analogue (lOnM- 100/xM) and InsP3 (300nM at 4°C and 3/xM at 20°C) for 3 
minutes at 4° C or 20°C to give a dose response curve. 45Ca release was 
terminated after 3 minutes by rapid filtration and 45Ca determined by liquid 
scintillation. An InsP3 dose response curve (lOnM- 30/xM) was also constructed 
daily in order to assess platelet responsiveness. 100% release was determined
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by 30/xM ionomycin and all results were expressed as a percentage of 
ionophore-releasable 45Ca, see above.
2.2.6.2 Fluorometric measurements.
2.2.6.2.1 Platelet preparation.
Platelets were isolated and washed as described in section 2.2.2. The platelets 
were resuspended in ICB to a corrected cell number of 5x 109cell/ml and left to 
recover for 45 minutes. Platelets were permeabilised with either saponin 
(40/xg/ml for 1 minute) or electrically (5- 15 cycles at 5kV) (see section 2.2.3) 
and resuspended to 109 cells/ml. 2mls aliquots of these permeabilised platelets 
were placed in a quartz cuvette and 1/xM fura-2 free acid added. The Ca2+ 
signal was calibrated, by obtaining the Fn** and F^n (see section 2.2.3.1), and 
the basal Ca2+ concentration of the permeabilised platelet suspension in the 
cuvette was buffered to between 100- 200nM. The changes in fluorescence, 
upon agonist addition, were recorded using a PTi fluorometer (excitation 340 
and 380 nM, emission 510nM; 4nm slit width) fitted with a thermostated 
cuvette compartment and a stirring attachment.
2 .2.6.2.2 Calibration of the fluorescence.
This was carried out prior to the experiment by measuring the maximal 
fluorescence (Fmax) and the minimum fluorescence (Fmm). Fmax was obtained 
by the addition of lOmM Ca2+. This excess Ca2+ binds to the free fura in the 
cell suspension thus giving a maximal fluorescence. The pH of the suspension 
was then rendered alkaline with 60- 80/xl of 2M NaOH and 100- 200/xl of 
50mM EGTA was added to reduce the [Ca2+]f producing a drop in fluorescence
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to a minimum. Free Ca2+ measurements using fluorescent indicators rely on the 
change in fluorescent properties following Ca2+ binding to report the degree of 
Ca2+ saturation of the indicator. At equilibrium, this is related to the free 
[Ca2+] according to the mass action equation
Kd =  fXl x fCa2+T 
[CaX]
which gives;
[Ca2+] =  Ka x fCaXl 
[X]
where;
X is the fluorescent indicator which binds Ca2+; Kd is the dissociation constant 
of the fluorescent indicator
Using the fluorescent dye Fura-2 AM, two wavelengths can be used to carry out 
[Ca2+]i measurements and obtain signals which are proportional to Ca2+- bound 
and Ca2+- free indicator. The ratio of fluorescence at the two wavelengths is 
directly related to the ratio of the two forms of dye and therefore can be used to 
calculate [Ca2+]i. The equation which relates measured Ca2+- bound/ Ca2+-free 
fluorescence ratio (R) to [Ca2+]i is similar to that o f the single-wavelength 
equation;
[Ca2+]i= Kd x R-Rmin x So 
Rmax“R Sb2
where;
Rmtx is the fluorescence ratio under saturating Ca2+; Rmm is the fluorescence 
ratio under free Ca2+ conditions; So/Sbi is the ratio o f fluorescence values of
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Ca2+- bound/ Ca2+- free indicator measured at the wavelength used to monitor 
the Ca2+ free concentration.
The main advantage of dual wavelength indicators such as Fura-2 AM is that the 
absolute concentration of the indicator within the cell is not vital as a ratio of 
bound/ free indicator is used, thus equivalent loading of cells between days is 
not essential (Grynkiewicz et al.t 1985).
2.2.6.2.3 Modifications on the original technique.
Intact washed platelets were suspended in different buffers prior to 
permeabilisation. ICB (buffered Ca2+ to 100- 150nM and unbuffered), HBT, 
Buffers A and B were used. In addition, preloading with fura-2 AM, 
permeabilisation of platelets in the cuvette and electroporation of cells were 
investigated.
2.2.7 Assessment of permeabilised platelet function. r14C15-HT release assay.
5-HT is accumulated into platelet dense granules by several mechanisms, against 
a concentration gradient (Pletscher, 1986). This phenomenon is utilized in this 
assay and upon incubating platelets with [14C]5-HT, accumulation into the dense 
granule is achieved. Upon activation, dense granules release their contents 
which includes the radiolabel.
2.2.7.1 Platelet preparation.
Platelets were isolated and washed as described in section 2.2.2. The pellet was 
subsequently resuspended to a cell number of 8x 108cells/ml and incubated with
7 0
200nCi/ml [14C]5-HT at 37°C for 30 minutes. This was followed by washing 
the platelets twice in HBT to remove any extracellular [14C]5-HT and twice in 
ICB (or high K+ buffer A; depending on the experiment). The washed platelets 
were permeabilised either, electrically (5- 15 cycles at 5kV) or with saponin 
(40/xg/ml for 1 minute) (see results). 500/zl aliquots of the permeabilised 
platelets were transferred to Eppendorf tubes and stimulated with the 
appropriate agent for 10 minutes at 37°C. Release was terminated by removing 
500/d aliquots into ice-cold Eppendorfs containing 40/xl of lOOmM EGTA. The 
samples were centrifuged at 12 OOOg for 5 minutes and two 200/d aliquots of 
the supematent were removed into 4 mis of liquid scintillent and the amount of 
[14C]5-HT was determined by liquid scintillation.
Percentage release from platelets was then calculated using the following 
equation (Holmsen & Dangelmaier, 1989):
% [14C]5-HT release =  Ts-Bo x 100
Tc-Bo
where,
Tc is counts per minute (cpm) in the same volume of untreated, uncentrifuged 
platelets; Ts is the cpm obtained after centrifugation of stimulated platelets; Bo 
is the cpm due to the extracellular [14C]5-HT in untreated, centrifuged platelets.
2 .2.7.2 Electroporated cells:
Platelets were isolated and washed in HBT (as in section 2.2.2) and loaded with 
200nCi [14C]5-HT, as above. The washed platelets were then washed twice in 
HBT, to remove any excess [14C]5-HT, and twice in ICB, finally resuspended 
to 109 cells/ml in ICB and left for one hour to recover. 1ml aliquots of the intact 
platelets were transferred to the perspex chamber of the electroporator and a
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current was passed over the cells for 5-10 seconds at varying intensities and 
number of cycles (5- 15 cycles at 2- 5kV). The treated platelets were then 
removed from the perspex chamber, and [14C]5-HT release assay was carried 
out on 100^1 aliquots of the permeabilised cells (as above).
2.2.7.3 Saponin permeabilised cells.
Platelets were isolated washed in HBT (as in section 2.2.2), loaded with 200nCi 
[14C]5-HT, as above. The platelets were then washed two times in HBT and 
finally resuspended in HBT to 4x 109 cells/ml. The platelets were then left for 
an hour to rest and prior to use diluted 1 in 3 with High K+ buffer, (Brass and 
Joseph, 1985). 500/xl aliquots were transferred into eppendorf tubes, treated 
with saponin, 5/ig/ml- 80/ig/ml to ascertain the effect o f saponin on platelet 5- 
HT content (see results). Subsequently, permeabilised platelets were treated 
with an agonist and the [14C]5-HT release ability of each agonist was evaluated 
(as above).
2.2.8 Ca2+ measurements in platelet membranes.
2.2.8.1 45Ca2+ release assay in platelet membranes.
2.2.8.1.1 45Ca2+ uptake in platelet membranes.
Platelet membranes, crude or pure were prepared as in section 2.2.5 and were 
used in these experiments. Platelet membranes were loaded with 15/xCi 45Ca and 
uptake into the membranes cells was determined by removing duplicate 100/xl 
aliquots at 0, 10, 15, 30, 60, 120 and 180 minutes. The amount of membrane 
associated 45Ca determined by rapid filtration o f the suspension on a Brandell
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harvester using GF-B filter strips. The radioactivity was then determined by 
liquid scintillation and the time-course of 45Ca uptake was determined.
2.2.8.1.2 45Ca2+ release from platelet membranes.
Platelet membranes (crude or pure) were prepared as in section 2.2.5 and 
loaded with 15/xCi 45Ca for 90- 120 minutes. 100/xl aliquots of these membranes 
were incubated with a dose range of InsP3 (lOnM- 30/xM) for 3 minutes and 
45Ca release was terminated by rapid filtration as above. 100% release was 
determined by 30/xM ionomycin and all InsP3 induced 45Ca release was 
expressed as a percentage of ionophore-releasable 45Ca (see section 2.2.6.1).
2.2.8.1.3 The effect of heparin on InsP  ^ induced 45Ca release.
Platelet membrane preparations, crude or pure were prepared as above and 
loaded with 15/xCi 45Ca for 90- 120 minutes. 100/xl aliquots of these membranes 
were incubated with a dose range of heparin (lOOng/ml- 100/xg/ml) for 3 and 5 
minutes, followed by 10/xM InsP3 for 3 minutes. 45Ca release was terminated by 
rapid filtration, and the amount of 45Ca release determined by liquid 
scintillation, using the equations in section 2.2.6.1.
2.2.8.2 Fluorometric measurements from platelet membranes.
2 .2 .8 .2 .I. Calibration of the fluorescence.
The Ca2+ content of ICB was determined as in section 2.2.3 and adjusted to 
100- 200nM Ca2+. Platelet membranes were prepared as in section 2.2.5. The 
membrane suspension was then centrifuged at 25 000 rpm for 30 minutes and 
the protein concentration of the membrane suspension was determined. The
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resulting pellet was then resuspended, in ICB, at varying protein concentrations 
o f O.lmg/ml, 0.3mg/ml and 0.95mg/ml. 2mls o f membranes were then 
transferred to a quartz cuvette and placed in the thermostated compartment of 
the fluorometer and stirred. 1/iM fura-2 free acid was then added and the 
fluorescence signal was calibrated using excess Ca2+ ( »  lOmM), to give the 
maximal signal, and excess EGTA (100- 200/zl o f 50mM) with alkali (60- 80/d 
of 2mM) to give the minimum fluorescence. The changes in fluorescence were 
recorded on a PTi fluorometer as before and the actual [Ca2+] was thus 
calculated according to the equation of Grynkiewicz et al (1985).
2 .2 .8 .2 .2 Ca2+ measurements in platelet membranes.
Platelet membranes were prepared as in sections 2.2.5. Platelet membranes 
were centrifuged at 25 000 rpm for 30 minutes and the protein concentration of 
the membrane suspension was determined. The resulting pellet was then 
resuspended, in ICB, at a protein concentration of 0.95mg/ml. 2mls of 
membranes were then transferred to a quartz cuvette and placed in the 
thermostated compartment of the fluorometer and stirred. 1/xM fiira-2 free acid 
was then added and the fluorescence signal was calibrated. Agonists were then 
added to subsequent 2ml aliquotes of membranes in the cuvette, and changes in 
Ca2+ were recorded over time on a PTi fluorometer.
2.2.9 Methods in the study of mvo-inositol 1.4.5-trisphosphate metabolism.
2.2.9.1 PHIInsP-i metabolism.
Platelets were washed and permeabilised, with 40/ig/ml saponin, as in section
2.2.3 and were left to recover for 60 minutes. After 60 minutes recovery time, 
50nCi pH]-InsP3 was added to 100/xl aliquots of permeabilised platelets and
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metabolism was allowed to proceed. Metabolism was terminated after 0, 1, 3 
and 10 minutes by the addition of 500/xl of ice cold chloroform/ methanol (1:1) 
with added 1 % HC1, 200/d chloroform, 200/d chloroform/ methanol (2:1) and 
100/xl water, (Ward et al., 1992). The samples were then centrifuged at 
1400rpm for 5 minutes and the aqueous layer retained. The organic layer was 
re-extracted with a further 500/xl chloroform/ methanol (1:1) with 1% HC1, 
100/xl chloroform and 100/xl water. The sample was centrifuged as above and 
the aqueous layers combined. The combined aqueous samples were then 
neutralized to pH 7.5 using 200/xl ImM Hepes, 10M KOH ( «  100- 200/xl) and 
10/xl universal indicator (to check pH), dried down using a speed vac and finally 
reconstituted to 200/xl with Milli-Q water. 100/xl aliquots were either injected on 
the HPLC, or stored at -20°C for later analysis on an HPLC.










A is Milli-Q water; B is phosphate buffer.
Ammonium hydrogen orthophosphate buffer (1.25M) was prepared by 
dissolving 165 grams in 800 mis Milli-Q water. The pH was then adjusted to
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3.8 using orthophosphoric acid and the final volume made to 1 ltr, (Ward et a l ,  
1992).
2.2.9 .1 .2 The effect of InsPi metabolic enzyme inhibitors on PHl-InsPi 
metabolism.
Platelets were washed and permeabilised, with 40/ig/ml saponin, as in section
2.2.3 and left to recover for 60 minutes. 100/d Aliquots o f the permeabilised 
platelets were preincubated with a dose range (0, 3, 10 and 30/xM) of the agent 
[Ins(l,3,5)PS3, L-Ins(l,4,5)PS3] or vehicle for 5 minutes, then followed by the 
addition of 50nCi pH]-InsP3. Metabolism was allowed to proceed and 
terminated after 0, 1, 3 and 10 minutes as above, and the inositol phosphates 
extracted as above and injected onto an HPLC separation column.
2.2.9.2 Methods to incorporate P2Plgamma-ATP into mvo-inositol 1.3.4.5- 
tetrakisphosphate.
2.2.9.2.1 P2Pl-incorporation into Ins(1.3.4.51P*.
Platelets were washed and permeabilised, with 40/xg/ml saponin, as in section
2.2.3 and left to recover for 60 minutes. 100/d Aliquots o f the permeabilised 
platelets were then incubated with 1/iCi p2P]gamma-ATP for 1,3,5 and 10 
minutes and incorporation was terminated by quenching with 500/zl ice cold 
chloroform/ methanol (1:1) with 1% HC1, 200/d chloroform/ methanol (2:1), 
200/d chloroform and 200/d water. The samples were centrifuged at 1400 rpm 
for 5 min, the aqueous layer retained and the organic layer re-extracted with 
500/d chloroform/ methanol (1:1) with 1% HC1 (as above). The samples were 
then centrifuged as above and the aqueous layers combined and neutralised to
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pH 7.5 using 10/xl universal indicator, ImM Hepes and 10M KOH. The 
samples were then treated as above.
2.2.9.2.2 The effect of InsPi metabolic enzyme inhibitors on P2P1 gamma-ATP 
incorporation.
Platelets were washed and permeabilised, with 40/ig/ml saponin as in section
2.2.3 and left to recover for 60 minutes. 100/tl aliqoutes of the permeabilised 
platelets were pretreated with a dose range (3- 30/iM) of the analogue 
[Ins(l,3,5)PS3 or L-Ins(l,4,5)PS3 or vehicle] for 5 minutes then 1/xCi 
P2P]gamma-ATP was added and incorporation o f p2P]gamma-ATP was 
terminated at 1,3,5 and 10 minutes (as above) and the inositol phosphates 
extracted, see earlier.
2.2.10 Studies on whole platelets.
2.2.10.1 Fluorometric Ca2+ measurements.
2.2.10.1.1 Platelet preparation.
Platelets were isolated and washed and prepared as in section 2.2.2. The platelet 
pellet was resuspended to a corrected cell count of 8x 108cell/ml and incubated 
with 2.5juM Fura-2 AM for 30 minutes at 37°C. The cell suspension was 
washed twice in HBT, with the addition of lOOnM PGI2, to remove any excess 
fura-2. Finally, the platelet count was adjusted to 2x 10* platelets/ml, in HBT, 
and they were left to recover for 60- 90 minutes.
2ml aliquots of platelet suspension was placed in a thermostatted cuvette (at 
37°C) fitted with a stirrer. The Ca2+/fura 2 fluorescence was calibrated as
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described above (Grynkiewicz et al.t 1985). The changes in [Ca2+]i were 
recorded using a PTi fluorometer; excitation 340 & 380, emission 510nM, 4nm 
slit width.
2.2.10.1.2 Calibration of the fluorescence.
Calibration of the Ca2+-Fura fluorescence was carried out as described by 
Grynkiewicz et al (1985). Prior to carrying out an experiment, fluorescence was 
calibrated by measuring the maximal fluorescence (Fm«) obtained by lysing 
platelets with 50/zM digitonin in the presence of ImM Ca2+. This causes cell 
lysis, releasing intracellular fura-2, which comes into contact with excess 
calcium and binds to it giving a maximal fluorescence. The minimum 
fluorescence was obtained by rendering the platelet lysate alkali ^  8.5, with «  
80/ri of 2M NaOH and chelating the calcium with excess EGTA (100- 200/d of 
50mM), causing a drop of fluorescence to a minimum. [Ca2+]f was then 
determined using the equation in section 2.2.6.2.
2.2.10.2 Dense granule release.
Platelets were isolated and washed as described in section 2.2.3. The platelet 
pellet was resuspended to 8x 108cells/ml and incubated with 200nCi [l4C]5-HT 
for 30 minutes at 37°C. Platelets were washed twice, with the addition of PGI2, 
to remove any extracellular 5-HT and the cell count adjusted to 2x 108 
platelets/ml and left to recoverfor 60- 90 minutes. 500/cl aliquots of the platelet 
suspension were transferred into eppendorf tubes and stimulated with a dose 
range (lOnM- 30/zM) of the appropriate agonist and the assay was carried out as 
in section 2.2.7.
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2.2.10.3 Agonist-induced InsPi production from intact platelets.
2.2.10.3.1. Sample preparation.
Platelets were isolated and washed as described in section 2.2.3. The platelets 
were washed a further 2 times in HBT and the final cell count adjusted to 
109cell/ml. The platelets were then left to recover for 60- 90 minutes. Aliquots 
of 500/zl were placed in aggregometer cuvettes and the platelets were stimulated 
with 300nM PAF, with continuous stirring at 37°C. Activation was terminated 
after 5 seconds with the addition of 100/xl ice cold 20% perchloric acid. 
Proteins were allowed to sediment on ice for 20 minutes, followed by 
centrifugation at 2000g for 15 minutes at 4°C. The supematents were retained 
and titrated to pH 7.5 with 1.5M KOH containing 60mM Hepes buffer and 5/tl 
of universal indicator. Any precipitate KCIO4 was removed by sedimentation at 
2000g for 15 minutes and the supematent retained for assay.
2.2.10.3.2 Preparation of InsPi standards for pHlInsP? binding assay.
A series of eight working pH]InsP3 standards were prepared ranging from 0.19- 
25pmol/100/xl, by a serial dilution of the 25pmol standard, from an Amersham 
assay kit, into Milli-Q water. In order to minimise loss of phosphates, 
plasticware was used throughout the assay, also acidic conditions can hydrolyse 




The samples and standards, from above, were assayed for InsP3 using the D- 
myo-inositol-l,4,5-trisphosphate assay system from Amersham. Provided in this 
kit are; binding protein, assay buffer, tracer and standard.
The reagents in table 3 below were added together in eppendorf tubes, ensuring 
that the binding protein was the last to be added. The tubes were then vortexed 
and incubated for 15 minutes on ice, followed by centrifugation at 2000g for 10 
minutes at 4°C giving a pellet which contained the bound pH]InsP3. 100/xl 
aliquots of Milli-Q water and 4 mis of scintillent cocktail were added to each 
tube, and the radioactivity per sample determined by a fi-scintillation counter.
_______________________________ Volume in fxl_______________________
____________ Tc_________ NSB_________Bo_________ Std__________ Spl
Buffer 50 50 50 50 50
H20  100 50 -
Standard - 50 50
Sample 50
Tracer 50 50 50 50 50
Binding prot - 50 50 50 50
Tc is the total counts in cpm; NSB is the nonspecific binding; Bo is the zero 
standard; STD is the standard; Spl is the sample. The amount of InsP produced 
per sample was calculated according to the assay kit, and in all calculations the 
cpm for NSB has been subtracted from all other counts.
Table 3. Showing the reagents required for pH]InsP3 assay.
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2.2.11 Protein assay.
The Bio-rad protein assay was used to determine the protein content of platelet 
preparations. The Bio-rad assay is a dye binding assay based on the differential 
colour changes of a dye in response to various concentrations o f protein, 
utilising the absorbance maximum of the acidic solution of coomassie brilliant 
blue G-250 (used in the assay) which shifts from 465nm to 595 nm when 
binding to a protein occurs, (Bradford, 1976). Thus, this assay was used as the 
absorbance o f the dye-protein complex is more stable it is much easier to carry 
out, requiring only one reagent and a short incubation time and finally, it is free 
from most of the interferences which limit the application of the other assays.
2.2.11.1 Sample preparation.
Samples of platelets were washed twice in BSA free HBT and resuspended to 
the appropriate cell number of 108, 3x 108 or 109 cells/ml. The suspensions 
were then exposed to a rapid freeze thawing process for maximum cell 
disruption by immersion in liquid nitrogen and defrosting at 37°C in a water 
bath. Duplicate 100/xl aliquots were assayed against a standard curve.
NOTE
The number o f times each experiment was performed is given in the respective 
figure legends, and where possible, the data are given as the mean ±  SE. When 




3.1 45Ca-mobilisation by InsPi and analogues to develop structure/activity 
relationships and to aid identification of an InsP  ^receptor antagonist.
3.1.1 Optimising 4SCa release assay conditions.
3.1.1.1 The effect of saponin on platelet integrity.
In order to investigate the effect of saponin on platelets, platelets were loaded 
with [14C]5-HT, suspended in ICB buffer having [Ca2+]f of 100-200nM and 
treated with a dose range of saponin, for set time intervals after which time 
[14C]5-HT release was determined (figure 10).
It was found that the low concentrations of saponin (5, 10 and 20/zg/ml) had an 
insignificant effect on platelet [14C]5-HT loss over the 10 minute incubation 
time period (figure 10). 40/zg/ml saponin was a little more disruptive where 
incubations of 5 minutes caused 35% of dense granule contents to be released 
reaching a maximum of 45% release at 10 minutes. Worse still was 80/xg/ml 
saponin where 40% release occurred after incubations o f 1 minute, which 
increased with time reaching a maximum of 65% after 10 minute incubations.
A concentration is required that will permeabilise the cells but have no adverse 
effect on the platelet structure, intracellular stores and platelet function, thus a 
concentration of 20/xg/ml, 40/xg/ml and 80/xg/ml were used for further 
investigation.
3.1.1.2 Optimal saponin concentration for ^Ca loading.
Platelets were permeabilised with 20/xg/ml, 40/xg/ml and 80/xg/ml saponin for 1 
minute and 45Ca uptake determined at set time points over a period of 3 hours. 
With all the saponin concentrations tested, 45Ca loading reached a plateau after 
60 minutes and remained at this level for the following 2 hours (figure 11). 
However 20/xg/ml saponin only resulted in a maximal of
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Figure 10. The effect of saponin on dense granule integrity. Platelets were 
loaded with [14C]5-HT and treated with various saponin concentrations, 5 (•), 10 
(4 , 20 ($ , 40 ^  and 80^g/ml ®  for 1, 3, 5 and 10 minutes and degranulation 
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Figure 11. Optimal saponin concentration for 45Ca uptake and time course. 
Platelets were permeabilised with 20 (•), 40 (1) and 80/zg/ml (A) saponin for 1 
minute and 45Ca uptake into permeabilised platelets was determined over a 
period of 3 hours. Each point is mean ±  SE of three determinations.
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20% loading compared with 40% when using 40/*g/ml saponin and 50% when 
using 80/xg/ml saponin. Therefore 20/xg/ml, saponin although mild on platelets 
in terms of its integrity, produces low loading. Platelets treated with 80/xg/ml 
saponin load only 10% better than those treated with 40/xg/ml saponin, and 
when the other effects of saponin are taken into account (see a above for 5-HT 
data) it was concluded that 40^g/ml saponin was the dose of saponin to use.
3.1.1.3 Time course of 3^M InsP^-induced ^Ca release.
Platelets loaded with 45Ca were incubated with 3fiM InsP3 for different times (0- 
10 minutes) at 4°C, 20°C and 37°C and 45Ca release was determined by rapid 
filtration of the cell suspension. At 37°C, InsP3 release is maximal after 5 
seconds and rapidly decreases to zero at 5 minutes, figure 12, at 20°C, InsP3 
release shows a different profile with maximal release occurring at 45 seconds 
reaching a plateau of 45% release after 60 seconds which gently decreases to 
35% at 10 minutes. At 4°C, a peak of InsP3-induced 45Ca release is reached at 5 
seconds, reaching a plateau of 62% release after 60 seconds and slowly 
decreasing to 57% at 10 minutes. For subsequent experiments, InsP3-induced 
release was terminated at 3 minutes by rapid filtration.
3.1.1.4 Optimal cell number for ^Ca release assay.
Platelets resuspended to 108, 2x 108 and 109 platelets/ml were permeabilised 
with 40/xg/ml saponin for 1 minute, loaded with 45Ca for 60 minutes and 
stimulated with 3/zM L1SP3 at 20°C for 3 minutes, figure 13. All the platelet 
preparations loaded 45Ca to the same extent (40- 45%), however with 
108cells/ml 3/xM InsP3 released only 3% of the loaded 45Ca, 2x 108cells/ml 
released 7% but 109cells/ml released 37% of the loaded 45Ca. It therefore 
appears that the greater the concentration of the cells the better the response. 
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Figure 12. Time course of InsP3-induced 45Ca-release at 4°C (•), 20°C (A) and 
37°C (A). Permeabilised platelets were loaded with 45Ca, stimulated with 3/xM 
L1SP3 for 5, 15, 30, 45, 60, 180, 300 and 600 seconds. 45Ca release at each of 
these time points and at the three temperatures was determined in order to 
ascertain the optimal contact time between InsP3 and the permeabilised platelets. 
Each point is mean ±  SE of three determinations.
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Figure 13. Optimal cell number required for 45Ca release assay. Platelets were 
permeabilised and resuspended to 108, 2 x l0 8 and 109 cells/ml, loaded with 45Ca 
and subsequently challenged with 3juM InsP3 for 3 minutes. 45Ca uptake (open 
bars) and subsequent release 
filtration. Each point is mean
by InsP3 (closed bars) were determined by rapid 
±  SE of three determinations.
3x 10
cel l  n u m b e r
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Permeabilised platelets exhibit ATP-dependent sequestration of 45Ca. Ionomycin 
(30/xM) release 90±  3% (n=10) of sequestered 45Ca, suggesting that the Ca2+ 
was intravesicular.
3.1.2 Inositol phosphate analogues and 45Ca release.
3.1.2.1 InsP  ^and its enantiomer L-/?rvo-inositol 1.4.5-trisphosphate (L-InsPA
At 20°C, InsP3 shows full activity releasing 80 ±4% of loaded 45Ca, however 
L-InsP3 did not release 45Ca thus having no activity, see figure 14. InsP3 is the 
naturally occurring active compound that binds to the InsP3-receptor. However, 
L-InsP3 does not have the ability to bind the receptor or binds only very weakly, 
thus rendering it unable to release Ca2+, see appendix for structures (n=6, 
mean ±SE). Thus InsP3-induced Ca2+-release from permeabilised platelets was 
found to be stereospecific.




Afyo-inositol-6-deoxy 1,4,5-trisphosphate [6-deoxy-Ins(l,4,5)P3], its 
phosphorothioate analogue, myo-inositol-6-deoxy 1,4,5-trisphosphorothioate [6- 









0.001 0.010 0.100 1.000 10.000 100.000
Conc.OuM)
Figure 14. The dose response curves for 45Ca-release from permeabilised rabbit 
platelets by D-InsP3 (•) and its enantiomer L-L1SP3 (a ) at 20°C. Saponin 
permeabilised platelets were loaded with 45Ca in the presence of mitochondrial 
uptake inhibitors, incubated with InsP3 or analogue for 3 minutes and the cell 
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Figure 15. Dose response curves to InsP3 (•), 6-deoxy-Ins(l,4,5)P3 and its 
phosphorothioate analogue, 6-deoxy-Ins(l,4,5)PS3 ($. for their ability to release 
45Ca from permeabilised rabbit platelets. Saponin permeabilised platelets were 
loaded with 45Ca in the presence of mitochondrial uptake inhibitors, incubated 
with InsP3 or analogue for 3 minutes at 20 °C and release was determined by 
rapid filtration. Each point is mean ±  SE of three determinations.
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deoxy-2,3-cyclohexylidene 1,4,5-trisphosphate [6-deoxy-2,3-cyclohex(l,4,5)P3] 
and /nyo-inositol-6-deoxy-2,3-cyclohexylidene 1,4,5-trisphosphorothioate [6- 
deoxy-2,3-cyclohex(l,4,5)PS3] were tested for their 45Ca-release ability.
6-deoxy-Ins(l,4,5)P3 is capable of releasing small amounts of 45Ca showing 
40±  2% release at 30/xM, see figure 15, thus having an EC50 of >  30/xM. In 
comparison, its phosphorothioate analogue, 6-deoxy-Ins(l,4,5)PS3, releases a 
maximum of 8 ±  1% 45Ca at 30/xM therefore it can be said to be a vey weak 
agonist. (n=3, mean ±  SE)
Compound EC™ at 20°C
L1SP3 1.14± 0.09/xM
6-deoxy-Ins(l ,4,5)P3 ^  30/xM
6-deoxy-Ins(l ,4,5)PS3 ^ 30
The synthetic precursors of these two compounds follow the same pattern with 
the parent phosphate 6-deoxy-2,3-cyclohex-Ins(l,4,5)P3 releasing 9 ±  1.4% at 
30/xM and its phosphorothioate analogue 6-deoxy-2,3-cyclohex-Ins(l,4,5)PS3 
releasing 3 ±  1.5% at 30/xM, thus these two compounds are also very weak 
agonists, considering their Ca2+ release abilities, (n=3, mean± SE), see figure
16.
Removal of the 6-OH of InsP3 as shown in 6-deoxy-Ins(l,4,5)P3 leads to a 
substantial loss in activity (ECso of >  30/xM) and the substitution of the 
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Figure 16. Dose response curves to InsP3 ( • ) ,  6-deoxy-2,3-cyclohex- 
Ins(l,4,5)P3 (a ) and its phosphorothioate analogue, 6-deoxy-2,3-cyclohex- 
Ins(l,4,5)PS3 (A), for their ability to release 45Ca from permeabilised rabbit 
platelets. Saponin permeabilised platelets were loaded with 45Ca in the presence 
of mitochondrial uptake inhibitors, incubated with InsP3 or analogue for 3 
minutes at 20°C and release was determined by rapid filtration. Each point is 
mean ±  SE of three determinations.
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Compound EC™ at 20°C
InsP3 1.14+ 0.09/xM
6-deoxy-2,3-cyclohex-Ins( 1,4,5)P3 IV U> s
6-deoxy-2,3-cyclohex-Ins(l,4,5)PS3 >  30
6-deoxy-2,3-cyclohex-Ins(l,4,5)PS3 with EC50 of 30/xM. The synthetic 
precursors of these two analogues show no activity, and this is possibly due to 
the bulky cyclohexylidene group on positions 2- and 3- preventing receptor 
binding. Further, these compounds did not modify 3/xM InsP3-induced 45Ca- 
release, making them inactive analogues and not possessing antagonistic 
activity.
3.1.2.3 2-positional modification.
Afyo-inositol 2,2-difluoro 1,4,5-trisphosphate [Ins(2,2)F2(l,4,5)P3] was tested 
for its 45Ca release ability in comparison to InsP3.
The maximal 45Ca release induced by Ins(2,2)F2(l,4,5)P3 (83±  2.1%) was the 
same as that for L1SP3, this analogue having an EC50 of 0 .63±  0.09/xM 
compared to the EC50 of InsP3 of 1.14+ 0.1/xM (n=3, mean +  SE), see figure
17.
Ins(2,2)F2(l,4,5)P3 appears two to be two fold more potent then InsP3 at 
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Figure 17. The dose response curves to InsP3 (•) and Ins(2,2)F2(l,4,5)P3 (ft) for 
their ability to release 45Ca from permeabilised rabbit platelets. Saponin 
permeabilised platelets were loaded with 45Ca in the presence of mitochondrial 
uptake inhibitors, incubated with InsP3 and Ins(2,2)F2(l,4,5)p3 for 3 minutes at 
20°C and release was determined by rapid filtration. Each point is mean ±  SE 
of three determinations.
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Compound EC™ at 20°C
InsP3 1.14+ OAfxM
Ins(2,2)F2(l,4,5)P3 0.63± 0.09/xM
retention of 45Ca release activity after modification at the 2-position indicates 
the minor role played by this 2-OH in Ca2+ mobilisation.
3.1.2.4 Phosphorothioate analogues of InsP .^
A/yo-inositol 1,4,5-trisphosphorothioate [Ins(l,4 ,5 )PS3], wzyo-inositol-1- 
phosphate 4,5-bisphosphorothioate [Ins(l)P(4 ,5 )PS2] and D/L-myo-inositol-1- 
phosphorothioate 4,5-bisphosphate [D/L-Ins(l)PS(4 ,5 )P2] were tested for their 
45Ca-release ability.
InsP3 and all the above analogues were equally efficacious in their ability to 
release sequestered 45Ca (figure 18, n=3, mean ±  SE). However at 20°C, 
Ins(l)PS(4 ,5 )P2 was a more potent stimulus with an EC50 of 0 .65+ 0 . 1/xM (for 
the racemic mixture D/L-Ins(l)PS(4 ,5 )P2 the EC50 was 1.3+ 0 . 1/iM), 
Ins(l,4 ,5 )PS3 was the next potent with an EC50 of 0 .8 +  0 .1  followed by 
Ins(l)P(4 ,5 )PS2 with an EC50 of 0 .85+ 0.09jiM, see figure 18.
At 20°C, L1SP3 is the least potent with an EC50 of 0.97 ±  0.11/xM (n=3), this 
could be due to the fact that the phosphorothioate functional groups are resistant 
to metabolism. Thus, it is possible that these phosphorothioate analogues are in 
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Figure 18. The effect of substituting one or more phosphate groups with 
phosphorothioates on the InsP3 molecule in terms of their ability to release 45Ca 
from permeabilised rabbit platelets. Saponin permeabilised platelets were loaded 
with 45Ca in the presence of mitochondrial uptake inhibitors, incubated with 
InsP3 (•), Ins(l)P(4,5)PS2 (I), Ins(l)PS(4,5)P2 m  or Ins(l,4,5)PS3 (A) for 3 
minutes at 20°C and release was determined by rapid filtration. Each point is 
mean ±  SE of three determinations.
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Compound EC«n at 20°C
InsP3 0.97+ 0.11/xM
Ins(l,4,5)PS3 0 .8+  0.1/xM
Ins(l)P(4,5)PS2 0.85 +  0.09/xM
D/L-Ins( 1)PS (4,5)P2 1.3± 0.1/xM
[Ins(l)PS(4,5)P2] 0.65± 0.1/xM]
of receptor occupation and activation. In contrast, InsP3 is metabolised more 
rapidly at 20°C. Thus, is not present for long periods of time in the vicinity of 
the receptor and is unable to mobilise as much Ca2+ (see page 120).
3.1.2.5 Positional phosphate modifications of InsP .^
D/L-Myo-inositol 1,3,4-trisphosphate [Ins(l,3,4)P3], myoinositol 1,3,5- 
trisphosphorothioate [Ins(l,3,5)PS3] and L-myo-inositol 1,4,5- 
trisphosphorothioate [L-Ins(l,4,5)PS3] were tested for their Ca2+-mobilisation 
ability.
D/L-Ins(l,3,4)P3 releases 45Ca weakly giving 62+ 5% at 30/xM, having an 
ECso ^  10/xM (n=3, mean +  SE). However, this analogue is considered as a 
full agonist as the dose response curve dose not plateau but maintains an upward 
trend. Ins(l,3,5)PS3 was ineffective in releasing sequestered 45Ca with 30/xM 
releasing 12± 1.2% at 4°C. L-Ins(l,4,5)PS3, the enantiomer of Ins(l,4,5)PS3 
(see section 3.1.2.4) was partly effective in releasing 45Ca with 100/xM 
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Figure 19. The 45Ca release ability of some positionally modified InsP3 (•) 
analogues D/L-Ins(l,3,4)P3 (♦), Ins(l,3,5)PS3 (A) and L-Ins(l,4,5)PS3 (▲). 
Saponin permeabilised platelets were loaded with 45Ca in the presence of 
mitochondrial uptake inhibitors, incubated with InsP3 or analogue for 3 minutes 
at 20°C and release was determined by rapid filtration. Each point is mean ±  
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Figure 20. The effect of the metabolic enzyme inhibitors, L-Ins(l,4,5)PS3 and 
Ins(l,3,5)PS3, on InsP3 -stimulated 45Ca-release at (a) 4°C and (b) 37°C. 
Saponin permeabilised platelets were loaded with 45Ca in the presence o f 
mitochondrial uptake inhibitors and co-incubated with a dose range o f the 
analogue (open bars) or vehicle (closed bars) at 4°C (v/4) or 37°C (v/37) and 
InsP3 (lOOnM at 4°C and 30/nM at 37°C) for 3 minutes, v/20 is control at 
20°C, and release was determined by rapid filtration. Each point is mean ± SE 
of three determinations.
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see figure 19. This analogue is a full agonist, although this may be due to the 
potentially small presence of contaminating D-isomer in this compound.





In addition, D/L-Ins(l,3,4)P3 did not inhibit InsP3-induced 45Ca-release at 4°C 
or 20°C thus showing no antagonistic effects. In contrast to this, Ins(l,3,5)PS3 
and L-Ins(l,4,5)PS3 did potentiate 3/xM InsP3-induced 45Ca-release at 37°C but 
had no effect on lOOnM InsP3-induced 45Ca release at 4°C, indicating that these 
compounds affect the metabolism of InsP3, see figure 20.
This is supported by later data (see section on metabolism) where these two 
compounds were found to be InsP3 5-phosphatase inhibitors.
3.1.2.6 Miscellaneous inositol phosphate analogues.
Scy/fo-inositol 1,2,4-trisphosphate [scy//fl-Ins(l,2,4)P3], myo-inositol-4- 
methylene carboxylate 3,5-bisphosphate [Ins(4)CO(3,5)P2] and /nya-inositol-l- 
phosphate 4,5-pyrophosphate [Ins(l)P(4,5)pyrophosphate] were examined for 
their Ca2+-release ability in comparison to L1SP3.
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Figure 21. The dose response curve to InsP3 (•) and 5cy//oTns(l,2,4)P3 (a) for 
their ability to release 45Ca from permeabilised platelets. Saponin permeabilised 
platelets were loaded with 45Ca in the presence of mitochondrial uptake 
inhibitors, incubated with a InsP3 or analogue for 3 minutes at 20°C and release 
was determined by rapid filtration. Each point is mean ±  SE of three 
determinations.
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in releasing sequestered 45Ca at 20°C, giving a maximal release of 78±  3% 
with an EC50 of 0 .94+ 0.07/tM (n=3, mean ±  SE).
Compound EC™ at 20°C
InsP3 1.1± 0.1/iM
scy//0-Ins(l,2,4)P3 0.94± 0.07jiM
Ins(4)CO(3,5)P2 and Ins(l)P(4,5)pyrophosphate did not have the capacity to 
release 45Ca, furthermore neither analogue inhibited InsP3-induced 45Ca release 
at 20°C. Ins(4)CO(3,5)P2 does not possess a phosphate group on the 1-position, 
in addition, it has a phosphate on the 3-position and a bulky methylene 
carboxylate on the 4-position rather than a phosphate group, all of these factors 
could contribute to the lack of activity. As for Ins(l)P(4,5)pyrophosphate, the 
correct positions are occupied but the 4,5-vicinal phosphates which are deemed 
essential for activity are coupled together to form a pyrophosphate system, 
which in principle could mimic the conformation adopted by InsP3 in chelating a 
metal ion at the 4,5-bisphosphate.
3.1.2.7 Afvo-inositol 1.3.4.5-tetrakisphosphate.
[Ins(l,3,4,5)P4] and a phosphorothioate analogue, /wyo-inositol-3- 
phosphorothioate 1,4,5-trisphosphate [Ins(3) PS(1,4,5)P3] were tested for their 
Ca2+-release ability.
Ins(l,3,4,5)P4 is a naturally occurring metabolite of InsP3 and releases 45Ca 
with a lower potency than InsP3,
1 03
giving 54±  2% 45Ca release at 30/xM and an EC50 of ^10/xM (n=3, mean± 
SE). This implies that Ca2+ release upon InsP3-stimulation can be attributed in 
the main to InsP3 with Ins(l,3,4,5)P4 playing a very minor role, see figure 22.
Ins(3)PS(l,4,5)P3, a phosphorothioate analogue of Ins(l,3,4,5)P4, initially 
synthesised as an inhibitor of InsP3 3-kinase, is also weak in releasing 45Ca, 
giving 51 ±  1% release at 30/xM and an EC50 of ^  10/xM (n=3, mean ±  SE). 
The 45Ca release profiles of the two compounds are different in that although 
low doses of Ins(l,3,4,5)P4 do not release 45Ca, at 3/xM and up to 30/xM a rapid 
elevation is observed in % release (figure 22). In contrast, Ins(3)PS(l,4,5)P3 is 
weak at releasing 45Ca and only slowly rises to reach 51 ±  1%, close to that of 
Ins(l,3,4,5)P4.
3.1.2.8 Inositol tetrakisphosphate analogues.
ATyo-inositol 1,2,4,5-tetrakisphosphate [Ins(l,2,4,5)P4] and its synthetic 
precursor wyo-inositol-3,6-dibenzoyl 1,2,4,5-tetrakisphosphate
[Ins(3,6)Bz2(l,2,4,5)P4] were examined for their Ca2+-release ability in 
comparison to L1SP3.
Ins(l,2,4,5)P4 is a full agonist, as potent as L1SP3 in releasing 45Ca,
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Figure 22. The dose response curve to InsP3 (•) , its natural metabolite 
Ins(l,3 ,4 ,5 )P4 (A) and its phosphorothioate analogue Ins(3 )PS(l,4 ,5 )P3 (A) for 
their ability to release 45Ca from permeabilised platelets. Saponin permeabilised 
platelets were loaded with 45Ca in the presence of mitochondrial uptake 
inhibitors, incubated with a L1SP3 or analogue for 3 minutes at 20°C and release 
was determined by rapid filtration. Each point is mean ±  SE of three 
determinations.
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giving maximal release of 72±  5% at 30/xM with an EC50 of 0.53±  0.04/xM 
(n=3, mean ±  SE), this is in contrast to Ins(l,3,4,5)P4 which is weak at 
releasing 45Ca, see figure 23.




Ins(3,6)Bz2(l,2,4,5)P4 >  30/xM
Ins(3,6)Bz2(l,2,4,5)P4, the synthetic precursor of Ins(l,2,4,5)P4 was 
completely inactive in releasing 45Ca. This could be due to steric hindrance 
caused by the presence of the large benzoyl groups on the 3- and 6-positions, 
however more likely is the occupation of the 6-OH which is known to be 
essential for activity (see later).
3.1.2.9 Inositol tetrakisphosphate analogues.
Afyo-inositol 1,3,4,6-tetrakisphosphate [Ins (1,3,4,6)P4] and its 
phosphorothioate analogue, myoinositol 1,3,4,6-tetrakisphosphate 
[Ins(l,3,4,6)PS4] were examined for their Ca2+-release ability in comparison to 
InsP3.
Ins(l,3,4,6)P4 releases sequestered 45Ca from permeabilised platelets with a 
lower potency then InsP3, releasing 58±  3% Ca2+ at 30/xM in comparison to 
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Figure 23. The dose response curve to InsP3 (•), Ins(l,3,4,5)P4 W and some 
Ins(l,3,4,5)P4 analogues, Ins(l,2,4,5)P4 (A) and Ins(3,6)BZ2(l,2,4,5)P4 ^  for 
their ability to release 45Ca from permeabilised platelets. Saponin permeabilised 
platelets were loaded with 45Ca in the presence of mitochondrial uptake 
inhibitors, incubated with a InsP3 or analogue for 3 minutes at 20°C and release 
was determined by rapid filtration. Each point is mean ±  SE of three 
determinations.
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analogue Ins(l,3 ,4 ,6 )PS4, is weaker than its parent phosphate and 100/xM 
releases 49+4%  Ca2+, see figure 24.
3.1.3 Partial agonists.
3.1.3.1 5 cy//0 -inositol 1,2,4,5-tetrakisphosphate |>cy//0 -Ins(l,2 ,4 ,5 )P4] and its 
phosphorothioate analogue jcy/fo-inositol 1,2,4,5-tetrakisphorothioate [scyllo- 
Ins(l,2 ,4 ,5 )PS4] were examined for their Ca2+-release ability in comparison to 
InsP3.
5 cy//o-Ins(l,2 ,4 ,5 )P4 is a full agonist releasing 85% of the sequestered 45Ca and 
appearing to be more efficacious than InsP3 having an ECso of 0.1 ±  0.05/xM in 
comparison to L1SP3 which gives a maximal release of 79% and an EC50 of 
1.14± 0.19/xM, see figure 25 (n=3, mean ±  SE).
The phosphorothioate analogue 5cy//o-Ins(l,2,4,5)PS4 exhibited a low intrinsic 
activity, releasing a maximal of 61.7± 11% of the total 45Ca, having only 78% 
of the intrinsic activity or efficacy of InsP3. This indicates that this analogue,
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Figure 24. The dose response curve to InsP3 (•) and some naturally occurring 
inositol phosphates Ins(l,3 ,4 ,6)P4 (▲) and its phosphorothioate analogue 
Ins(l,3 ,4 ,6 )PS4 (A) for their ability to release 45Ca from permeabilised platelets. 
Saponin permeabilised platelets were loaded with 45Ca in the presence of 
mitochondrial uptake inhibitors, incubated with a L1SP3 or analogue for 3 
minutes at 4°C and release was determined by rapid filtration. Each point is 
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Figure 25. The dose response curve to InsP3 (•), Jcy//o-Ins(l,2,4,5)P4 (4) and 
its phosphorothioate analogue jcy//o-Ins(l,2,4,5)PS4 (A) for their ability to 
release 45Ca from permeabilised platelets. Saponin permeabilised platelets were 
loaded with 45Ca in the presence of mitochondrial uptake inhibitors, incubated 
with a InsP3 or analogue for 3 minutes at 20 °C and release was determined by 
rapid filtration. Each point is mean ±  SE of three determinations.
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0.1 ±  0.05/zm 
;> 30/xM
5cy//o-Ins(l,2,4,5)PS4, is a partial agonist. However, 5cy//o-Ins(l,2,4,5)PS4 did 
not inhibit InsP3-induced 45Ca-release at 20°C.
3.1.3.2 L-c/z/ro-inositol 2,3,5-trisphosphate [L-c/zz>o-Ins(2,3,5)P3] and its 
phosphorothioate analogue L-c/z/ro-inositol 2,3,5-trisphosphorothioate [L-chiro- 
Ins(2,3,5)PS3] were examined for their Ca2+-release ability in comparison to 
L1SP3.
L-chiro-Ins(2,3,5)P3 is a full agonist releasing 82% of the loaded 45Ca and 
having an EC50 of 1.9± 0.1/iM compared to InsP3 [EC50 of 1.04±  0.08/tM and 
a maximal release of 80%, see figure 26 (n=3, mean ±  SE)].
Compound EC™ at 20°C
InsP3 1.04± 0.08/xM
L-c/n>o-Ins(2,3,5)P3 1.9± 0.1/xM
L-c/u>(?-Ins(2,3,5)PS3 ^  30/xM
L-c/w>0-Ins(2,3,5)PS3, a phosphorothioate analogue, displayed low intrinsic 
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Figure 26. The dose response curve to InsP3 (•), L-c/zzro-Ins(2,3,5)P3 (a) and 
its phosphorothioate analogue L-c/zz'ro-Ins(2,3,5)PS3 (A) for their ability to 
release 45Ca from permeabilised platelets. Saponin permeabilised platelets were 
loaded with 45Ca in the presence of mitochondrial uptake inhibitors, incubated 
with a InsP3 or analogue for 3 minutes at 20 °C and release was determined by 
rapid filtration. Each point is mean ±  SE of three determinations.
112
of the activity of InsP3 and hence is a partial agonist. Further, L-chiro- 
Ins(2,3,5)PS3 did not produce an inhibition of InsP3-induced 45Ca-release.
3.1.3.3 Afyo-inositol 1,4,6-trisphosphate [Ins (1,4,6)P3] and its 
phosphorothioate analogue myo-inositol 1,4,6-trisphosphorothioate 
[Ins(l,4,6)PS3] were examined for their Ca2+-release ability in comparison to 
InsP3.
Ins(l,4,6)P3 is a weak full agonist giving a maximal release of 75% at 30/xM, 
with an EC50 of 2.07±  0.08/zM compared to L1SP3 which has an EC50 of 0.18 ±  
0.04/xM and a maximal release of 82%, see figure 27 (n=3, mean ±  SE).
Compound EC™ at 4°C
InsP3 0.18± 0.04/xM
Ins(l,4,6)P3 2.07±  0.08/xM
Ins(l,4,6)PS3 ^  30/xM
Upon phosphate modification to a phosphorothioate to give Ins(l,4,6)PS3, a 
substantial loss in activity was observed. Ins(l,4,6)PS3 gives a maximal 45Ca 
release of 21.1% ±  0.4%, having 25% of the intrinsic activity of InsP3, thus is 
a partial agonist.
In contrast to two partial agonists above, L-c/w>o-Ins(2,3,5)PS3 scyllo- 
Ins(l,2,4,5)PS4 tested for inhibitory effects on InSP3-induced 45Ca-release, 
Ins(l,4,6)PS3 produces a dose dependent inhibition of 300nM InsP3-induced 
45Ca release, such that 100/xM
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Figure 27. The dose response curve to InsP3 (•), Ins(l,4,6)P3 (▲) and its 
phosphorothioate analogue Ins(l,4,6)PS3 (A) for their ability to release 45Ca 
from permeabilised platelets. Saponin permeabilised platelets were loaded with 
45Ca in the presence of mitochondrial uptake inhibitors, incubated with a InsP3 
or analogue for 3 minutes at 4°C and release was determined by rapid filtration. 
Each point is mean ±  SE of three determinations.
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Figure 28. The dose response curve to InsP3 (•) and Ins(l,4,6)PS3 (a) for their 
ability to release 45Ca from permeabilised platelets and the effect of 
Ins(l,4,6)PS3 on InsP3-induced 45Ca release (A). Saponin permeabilised platelets 
were loaded with 45Ca in the presence of mitochondrial uptake inhibitors, 
inhibition of InsP3-induced 45Ca release was observed upon co-incubations of 
Ins(l,4,6)PS3 (300nM- 100/xM) with 300nM InsP3 at 4°C in a dose dependent 
manner such that lOO^ iM Ins(l,4,6)PS3 produced «  50% inhibition. Each point 
is mean ±  SE of three determinations.
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Ins(l,4,6)PS3 produced approximately 50% inhibition, see figure 28.
3.1.4 Inhibitors of InsPi-induced 4SCa-release.
3.1.4.1 The effect of heparin on InsP^-induced 45Ca-release.
Heparin (lOOng/ml- 100^g/ml) did not induce 45Ca-release from permeabilised 
platelets loaded with 45Ca, in addition, heparin (lOOng/ml- 100/xg/ml) incubated 
with permeabilised platelets for 5, 10 and 30 minutes did not induce inhibition 
of 3/zM InsP3 induced 45Ca-release at 20°C, see figure 29. Further, heparin of 
lower molecular weight (3000) did not cause any inhibition of InsP3-induced 
Ca2+ mobilisation.
3.1.4.2 The effect of Decavanadate on InsP^-induced 45Ca-release.
Decavanadate inhibits 3/iM InsP3-induced 45Ca-release at 20°C, with an IC50 of 
7.82±  0.4fiM (n=3, mean ±  SE), see figure 30. Sodium orthovanadate, the 
precursor of decavanadate was inactive, having no impact on InsP3-induced 
Ca2+-mobilisation.
3.1.4.3 The effect of Benzene 1.2.4-trisphosphate on InsPi-induced 45Ca- 
release.
Benzene 1,2,4-trisphosphate (1- 500/xM) did not produce an inhibition of 3/xM 
InsP3 induced 45Ca-release at 20°C, in addition, benzene 1,2,4-trisphosphate (1- 
100/xM) did not produce the inhibition of 300nM InsP3 induced 45Ca-release at 
4°C, see figure 31.
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Figure 29. The effect of heparin on InsP3-induced 45Ca release. Saponin 
permeabilised platelets were loaded with 45Ca in the presence o f mitochondrial 
uptake inhibitors, co-incubations of vehicle (closed bars), or heparin, 300nM- 


















Figure 30. The inhibition of 3/xM InsP3-induced 45Ca-release at 20°C by a dose 
range of decavanadate. Saponin permeabilised platelets were loaded with 45Ca in 
the presence of mitochondrial uptake inhibitors, were incubated with 
decavanadate (0.1- 30/xM) for 3 minutes and subsequently challenged with 3/xM 
InsP3 for 3 minutes. Each point is mean ±  SE of three determinations.
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Figure 31. The effect of benzene trisphosphate on InsP3 -induced 45Ca release. 
Saponin permeabilised platelets were loaded with 45Ca in the presence o f 
mitochondrial uptake inhibitors, co-incubations o f vehicle (closed bars), or 
benzene trisphosphate, 300nM- 500/xM (open bars) with 300nM InsP3 at 4°C. 
Each point is mean ±  SE of three determinations.
1 1 9
3.1.5 The effect of temperature on InsP^-induced Ca2+ release.
Dose response curves for InsP3-induced 45Ca release determined at 4°C, 20°C 
and 37 °C show a shift of the response to the right with increasing temperature. 
At 4°C, a full dose-response curve is observed with an EC50 of 0 .18±  0.1/xM 
(n=6, mean ±  SE), but this is reduced at 20°C having an EC50 of 1.14+  
0.2/xM (n=6, mean ±  SE), and by 37°C the lower concentrations tested 
(lOnM- 1/xM) release no Ca2+, and the remaining curve is very shallow (EC50 





3.1.6 The effect of temperature on scvllo-lns( 1.2.4.5)P<i-induced 45Ca release.
^cy//o-Ins( 1,2,4,5)P4 dose response curves at 4°C and 20°C are identical, 
giving maximal release of 90±  3% 45Ca with an EC50 of 0.1 ±  0.05/xM (n=3, 
mean ±  SE) whereas at 37°C, the EC50 is reduced to 5.1 ±  0.2/xM with 30/xM 








Figure 32. The effect of temperature on InsP3-induced 45Ca release. Saponin 
permeabilised platelets were loaded with 45Ca in the presence of mitochondrial 
uptake inhibitors and challenged with InsP3 for 3 minutes at 4°C (•), 20°C (a) 
and 37 °C and release was determined by rapid filtration. Each point is mean 
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Figure 33. The effect of temperature on Jcy//o-Ins(l,2,4,5)P4-induced 45Ca 
release. Saponin permeabilised platelets were loaded with 45Ca in the presence 
of mitochondrial uptake inhibitors and challenged with jcy//o-Ins(l,2,4,5)P4 for 
3 minutes at 4°C (•), 20°C (4) and 37°C (fi) and release was determined by rapid 
filtration. Each point is mean ±  SE of three determinations.
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Temperature EC<;n
4°C 0 .1±  0.05/xM
20°C 0.1 ±  0.05/xM
37°C 5 .1±  0.2/xM
3.1.7 45Ca release by non-inositol phosphate compounds.
3.1.7.1 45Ca-release ability of cyclic ADP-ribose fcADPR). the endogenous 
activator of the ryanodine receptor.
cADPR (lOOnM- 3/zM) did not elicit 45Ca-release in permeabilised platelets at 
20°C. In addition, ADP-ribose (ADPR), is also ineffective in mobilising Ca2+.
3.1.7.2 45Ca-release by the direct activation of protein kinase C by phorbol 
esters and diacylglvcerol (DAGV
Phorbol myristate acetate, PMA, (1- 300nM) and DAG (3- 300nM) did not 
mobilise 45Ca at 4°C or 20°C, in addition, both PMA and DAG did not 
attenuate or enhance 300nM or 3/xM InsP3-induced 45Ca release at 4°C and 
20 °C respectively.
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3.2 PHlInsP  ^ metabolism by the 5-phosphatase and the 3-kinase enzvmes at 
4°C. 20°C and 37°C. and the effect of inositol phosphate analogues on InsP? 
metabolism.
3.2.1 Investigation of PHlInsPi metabolism in permeabilised platelets at 4°C. 
20°C and 37°C.
pH]InsP3 metabolism by the two enzymes, the 5-phosphatase and the 3-kinase 
was examined, as shown in section 3.1.5, InsP3-induced 45Ca release changes 
with temperature, InsP3 being more potent in releasing 45Ca at 4°C than at 
37°C. The EC50 of InsP3-induced 45Ca release can be seen on page 12017.
This loss in potency is attributed to metabolism. In order to confirm this 
hypothesis, InsP3 metabolism at the three temperatures, 4°C, 20°C and 37°C 
was investigated.
The rate of pH]InsP3 metabolism was found to be temperature dependent and 
the order of the rate of metabolism was 37°C> >  20°C > 4°C, figures 34, 35 
and 36.
At 4°C, InsP3 metabolism is very slow and by 3 minutes, over 70% of InsP3 
remains, at 10 minutes the major metabolite present being Ins(l,4)P2 and 
overall very little Ins(l,3,4,5)P4 is produced ( «  5%), see figure 34.
At 20°C a very different profile can be seen. By 1 minute, a substantial amount 
of metabolism has occurred, giving rise to Ins(l,4)P2 and Ins(l,3,4,5)P4*, 
Ins(l,3,4)P3 is produced from Ins(l,3,4,5)P4 at 3 minutes and the major 
metabolite at this time is Ins(l,4)P2. At 10 minutes little InsP3 remains, the 










Figure 34. HPLC separation o f pH]InsP3 metabolites at 4°C. 100/zl Platelets 
were challenged with pH]InsP3 at 4°C and metabolism was terminated at 0, 1, 
3 and 10 minutes. The phosphates were then extracted and separated on an 
anion exchange column, (a) pH]InsP3 standard; (b) 1 min.; (c) 3 min.; (d) 10 
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Figure 35. HPLC separation of [3H]InsP3 metabolites at 20°C. 100/d samples 
of platelets were challenged with pH]InsP3 at 20°C and metabolism was 
terminated at 0, 1, 3 and 10 minutes. The phosphates were then extracted and 
separated on an anion exchange column, (a) pH]InsP3 standard; (b) 1 min.; (c) 











Figure 36. HPLC separation of pH]InsP3 metabolites at 37°C. 100/xl samples 
of platelets were challenged with pH]InsP3 at 37 °C and metabolism was 
terminated at 0, 1, 3 and 10 minutes. The phosphates were then extracted and 
separated on an anion exchange column, (a) pH]InsP3 standard; (b) 1 min.; (c) 
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Figure 37. The effect of temperature 4°C (A), 20°C (•) and 37°C on (a) loss 
of pH]InsP3*, (b) InsP2 accumulation; (c) Ins(l,3,4,5)P4 accumulation (d) 
Ins(l,3,4)P3 accumulation, and (e) InsPi accumulation. Each point is mean ±  
SE of three determinations.
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However at 37°C pH]InsP3 is metabolised very rapidly with only 20% 
pH]InsP3 remaining at 1 minute, the major metabolite at this time being 
Ins(l,4)P2, a peak corresponding to Ins(l,3,4)P3 is present but it only 
constitutes 10% of the total counts, and at 10 minutes InsPi is the only 
metabolite left. Thus metabolism at the three temperatures follows very different 
metabolic patterns and at 4° and 37°C very little Ins(l,3,4,5)P4 and hence little 
Ins(l,3,4)P3 is produced.
Thus for any subsequent metabolism studies, platelets were maintained at 20°C 
as this shows the greatest range of metabolites over the 10 minute span.
3.2.2 The effect of inositol phosphate analogues on pHjlnsP? metabolism.
Two inositol phosphate analogues, L-Ins(l,4,5)PS3 and Ins(l,3,5)PS3 have been 
shown in a preliminary fashion to have an effect on the metabolism of pH]nsP3, 
see figure 20. This inhibitory activity that was investigated in this study. InsP3 
metabolism is complex and proceeds via two enzymes a 5-phosphatase and a 3- 
kinase. These two compounds can be used as tools to elucidate the significance 
of enzyme inhibition and the possibility of isozymes.
An inhibition of InsP3 metabolism by both L-Ins(l,4,5)PS3 and Ins(l,3,5)PS3 
was observed, being maximal at 10 minutes, see figures 38, 39 and 40. The 
effect of each analogue on inositol phosphate metabolism and production is 
shown in figure 41 and 42. From figure 41 it can be seen that L-Ins(l,4,5)PS3 
produces a dose dependent conservation of InsP3 (compared to control), thus 
inhibiting InsP3 metabolism; it produces a reduction in Ins(l,4)P2 production 


















Figure 38. HPLC separation of pH]InsP3 metabolites at 10 minutes in the 
presence o f 3/xM L-Ins(l,4,5)PS3 and Ins(l,3,5)PS3. Platelets were incubated 
with analogue for 5 minutes and challenged with pH]InsP3 , see methods, (a) 
pH]InsP3 standard; (b) control InsP3 metabolism ; (c) L-Ins(l,4,5)PS3; (d) 

















Figure 39. HPLC separation of [3H]InsP3 metabolites at 10 minutes in the 
presence o f 10/iM L-Ins(l,4,5)PS3 and Ins(l,3,5)PS3. Platelets were incubated 
with analogue for 5 minutes and challenged with pH]InsP3 , see methods, (a) 
pH]InsP3 standard; (b) control InsP3 metabolism ; (c) L-Ins(l,4,5)PS3*, (d) 
















Figure 40. HPLC separation of pH]InsP3 metabolites at 10 minutes in the 
presence o f 30/zM L-Ins(l,4,5)PS3 and Ins(l,3,5)PS3. Platelets were incubated 
with analogue for 5 minutes and challenged with pH]InsP3 , see methods, (a) 
pH]InsP3 standard; (b) control InsP3 metabolism; (c) L-Ins(l,4,5)PS3; (d) 
Ins(l,3,5)PS3. Traces are representative o f three separate experiments.
1 3 2
enzyme. L-Ins(l,4,5)PS3 also causes a dose dependent reduction in the amount 
of Ins(l,3,4,5)P4 produced (compared to control) via the 3-kinase enzyme, but 
causes an inhibition of Ins(l,3,4)P3 production (from Ins(l,3,4,5)P4) compared 
to control. With L-Ins(l,4,5)PS3 both levels of Ins(l,4)P2 and InsP(l,3,4)P3 are 
reduced, and from this a clear picture emerges, where the inhibition of the 5- 
phosphatase enzyme is observed. Thus L-Ins(l,4,5)PS3 is acting as a 5- 
phosphatase inhibitor.
However regarding the effect of L-Ins(l,4,5)PS3 on the 3-kinase enzyme, a 
definite effect is not apparent. Although an inhibition of Ins(l,3,4,5)P4 
production is observed, the levels are above that of the control, with the highest 
dose of 30^M L-Ins(l,3,5)PS3 reducing levels to control levels.
Ins(l,3,5)PS3 causes a dose dependent inhibition of InsP3 metabolism, figure 
42, with 30^M bringing levels of InsP3 to the same levels of the control. It also 
produces a reduction in the amount of Ins(l,4)P2 produced (compared to 
control), thus, inhibiting the 5-phosphatase enzyme. Ins(l,3,5)PS3 causes an 
elevation in Ins(l,3,4,5)P4 levels (above control), and a reduction in the amount 
of Ins(l,3,4)P3 produced (compared to control), 30/*M Ins(I,3,5)PS3 causes 
levels of Ins(l,3,4)P3 to be reduced to the same level as control.
3.2.3 Metabolism of P2Pl-Ins(1.3.4.5)P4.
3.2.3.1 P2P1 incorporation into Insfl.3.4.5^P^.
In order to investigate the effect of the two enzyme inhibitors L-Ins(l,4,5)PS3 
and Ins(l,3,5)PS3 on the 3-kinase enzyme specifically, p2P]-ATP loaded 
platelets were used. After 10 minutes of incubation of the permeabilised 


































Figure 41. The effect of vehicle (•) or L-Ins(l,4,5)PS3, 3/xM lOfiM and 
30/xM (A) on (a) pH]InsP3; (b) InsP2 accumulation; (c) Ins(l,3,4,5)P4 
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Figure 42. The effect of vehicle (•) or Ins(l,3,5)PS3 3/xM 10/zM (A) and
30(jlM  (^) on (a) pH]InsP3; (b) InsP2 accumulation; (c) Ins(l,3,4,5)P4 
accumulation and (d) Ins(l,3,4)p3 accumulation. Each point is mean ±  SE of 
three determinations.
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sign of p2P]-Ins(l,3,4,5)P4 was detected. The traces obtained showed a clutter 
of undefinable peaks, representing p2P]-ATP, between the retention times of t=  
0- 60 minutes. InsP3 appears in our system at 55- 57 minutes and Ins(l,3,4,5)P4 
appears at 62- 65 minutes. These areas were covered by the messy p2P]-ATP 
peaks and it was not possible to establish the peak for p 2P]-Ins(l,3,4,5)P4 from 
amongst them. In addition, because of the large amounts of p2P]-ATP needed 
to carry out this experiment, it was not possible to reduce p2P]-ATP which 
would in turn help resolve the peaks of interest. Furthermore, it was possible 
that the amount of intrinsic InsP3 available may not be enough to be detected 
after phosphorylation by p2P]-ATP and to this end exogenous 30/xM InsP3 was 
added at the same time of p2P]-ATP was added, again p2P]-Ins(l,3,4,5)P3 was 
not detected.
3.2.3.2 The effect of inositol phosphate analogues on P2Pl-incorporation_into 
Ins(1.3,4.5)P3.
In order to push metabolism via the 3-kinase pathway and increase the 
possibility of p2P]-ATP induced phosphorylation of InsP3, 5 minute pre­
incubations of the permeabilised platelet with 30/xM of the known 5-phosphatase 
inhibitors, L-Ins(l,4,5)PS3 or 30/zM Ins(l,3,5)PS3 (see scheme) was 
investigated.
3-kinase
InsP3 +  p2P]-ATP * p2P]-Ins(l,3,4,5)P4 +  ADP
Scheme 1. p2P]-incorporation into Ins(l,3,4,5)P4 upon InsP3 phosphorylation. 
Upon phosphate sample analysis on the HPLC, a peak for p2P]-Ins(l,3,4,5)P4 
was not present, indicating that p2P]-ATP phosphorylation of InsP3 had not
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occurred via the 3-kinase enzyme and that p2P]-incorporation into InsP3 to 
produce p2P]-Ins(l,3,4,5)P4 had not occurred.
3.3 Platelet functional responses. Dense granule release induced by InsP-< in 
permeabilised platelets.
3.3.1 InsPi induced Dense granule release in permeabilised platelets.
3.3.1.1 Saponin permeabilisation of platelets suspended in ICB.
Upon saponin permeabilisation of platelets resuspended in ICB with [Ca2+]f 
100- 200nM (with 5/xg/ml, 10/xg/ml and 20^g/ml saponin), the amount of 
[l4C]5-HT loss upon permeabilisation was found to be dose dependent and time 
dependent, with the low concentration of 5/zg/ml saponin causing no 
degranulation upon stimulation with ImM Ca2+, thus having no 
permeabilisation effect, 10/xg/ml saponin showing 20% 5-HT release at 10 
minute permeabilisation upon Ca2+ treatment and 20jtg/ml showing 
considerable degranulation with ImM Ca2+ at 5 minutes and above. The 
platelets do not degranulate with saponin treatment unless the highest 
concentration is used, 20^g/ml, for 10 minutes (see figure 43). Hence 20/ig/ml 
saponin causes suffucient permeabilisation at the longer time incubations of 5 
and 10 minutes. However, at 10 minutes, substantial loss of 5-HT occurs with 
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Figure 43. The effect of saponin permeabilisation, 10/xg/ml (a) and 20/xg/ml (b) 
on vehicle- (open bars) and on ImM Ca2+- (closed bars) induced [14C]5-HT 
release. Platelets permeabilised with saponin 10/xg/ml and 20/xg/ml for 3, 5 and 
10 minutes, challenged with vehicle or ImM Ca2+ for 3 min. and [14C]5-HT 
release determined. Each point is the mean ±  SE of 3 determinations.
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3.3.1.2 The effect of a dose range of Ca2+ on 20fxg/ml saponin permeabilised 
platelets (5 minute incubations').
In order to establish that the above response to Ca2+ is a real response and not 
an anomaly a dose response effect to Ca2+ was investigated.
A dose dependent rise in [14C]5-HT was observed (see figure 44) upon 
challenging platelets permeabilised with 20/ig/ml saponin for 5 minutes with a 
dose range of Ca2+, 300nM- 100/xM.
3.3.1.3 The effect of a dose range of EGTA on 20/xg/ml saponin permeabilised 
platelets (5 minute incubations).
In order to ascertain the correlation between dense granule release and EGTA, 
[14C]5-HT release, by a dose range of Ca2+, was determined in 20/xg/ml 
saponin permeabilised platelets in the presence of 30/xM or 3/xM EGTA.
In the presence of both EGTA doses, Ca2+ produced a dose dependent increase 
in degranulation, and this was in turn dependent on the amount of EGTA 
present. The lower EGTA dose producing a smaller chelation effect on the Ca2+ 
added, thus producing overall higher amounts of [14C]5-HT release and 30/xM 
EGTA producing a greater chelation effect, with the dose ranges of Ca2+ 
releasing less [14C]5-HT, see figure 45.
3.3.1.4 The effect of a dose of InsP  ^on saponin permeabilised platelets.
In platelets permeabilised with 10/xg/ml and 20/xg/ml saponin for 3, 5 and 10 
minutes, 10/xM InsP3 produced a [14C]5-HT release above vehicle levels and 
greater release occurred with 20/xg/ml saponin compared to 10/xg/ml saponin, 
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Figure 44. The effect o f a dose range o f Ca2+ on [14C]5-HT release in saponin 
permeabilised platelets. Platelets permeabilised with 20/ng/ml saponin, 
challenged with Ca2+ (300nM- 100/zM) (open bars) or vehicle (closed bars) and 
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Figure 45. The effect o f (a) 30/xM and (b) 3/xM EGTA on Ca2+- (open bars) or 
vehicle- (closed bars) induced [14C]5-HT release. Platelets permeabilised with 
saponin 20/xg/ml were treated with EGTA and then challenged with a dose 
range o f Ca2+ (lOOnM- 100/xM). Each point is the mean ±  SE of 3 
determinations.
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the vehicle control and treated preparations to carry out any dose dependent 
studies with InsP3 or analogues and this method was rejected.
3.3.1.5 Saponin permeabilisation of platelets suspended in high K+ buffer.
[14C]5-HT released upon ImM Ca2+ in platelets treated with different saponin 
concentrations (5/xg/ml, 10/xg/ml, 15/xg/ml and 20/xg/ml) was found to be dose 
dependent with 5/xg/ml and 10/xg/ml saponin causing very little dense granule 
release, 20/xg/ml saponin causing extensive degranulation in the presence of 
vehicle only but 15/xg/ml saponin at 5 minutes producing 12% release with 
vehicle and 35% release upon challenging with ImM Ca2+. Thus, 15/xg/ml 
saponin concentration was used for the subsequent studies.
3.3.1.6 The effect of a dose range of EGTA on 15/xg/ml saponin permeabilised 
platelets (3 minute incubations).
Upon treating platelets with a dose range of EGTA in the presence or absence of 
10/xM InsP3 (3 minute incubations), it was observed that at high EGTA 
concentrations, both vehicle and 10/xM InsP3 treated platelets release 
comparable amounts of [14C]5-HT, however as the [EGTA] decreases, and 
reaches 20/xM, a small difference in release appears and this increases with 
decreasing [EGTA], giving rise to a window of 15 % at 3/xM EGTA, see figure 
47.
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Figure 46. The use o f different saponin concentrations, (a) 10/xg/ml and (b) 
20/xg/ml in permeabilising platelets. Platelets were permeabilised with saponin 
for 3, 5 and 10 minutes then treated with vehicle (open bars); ImM Ca2+ 
(closed bars) and 10/xM InsP3 (crosshatch) and [14C]5-HT release was 
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Figure 47. The effect of 3 minute incubations of 10/xM InsP3 on [14C]5-HT 
loaded permeabilised platelets in the presence of a dose range of EGTA. 
Platelets were loaded with [14C]5-HT, permeabilised with 20/xg/ml saponin, 
treated with a dose range of EGTA and vehicle (•), or 10/xM Insp3 (A ), and 
[14C]5-HT release was determined. Each point is the mean +  SE of 3 
determinations.
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3.3.1.7 The effect of a dose range of InsP-< on 15/xg/ml saponin permeabilised
platelets (3 minute incubations  ^ in the presence of 30 or 10/xM EGTA.
Platelets stimulated with a dose range of InsP3 (300nM- 300/xM) for 3 minutes 
in the presence of 30/xM or 10/xM EGTA did not produce a dose dependent 
increase in [14C]5-HT as expected. This could be on account of the [EGTA] 
being too high, and although a separation between InsP3 treated and untreated 
platelets dense granule release was observed above, this may have been missed 
by choosing such a small range of [EGTA].
3.3.1.8 The effect of increasing contact time between platelets and agonist.
The longer incubation times when permeabilised platelets treated with a dose 
range of EGTA (1- 300/xM) in the presence and absence of 10/xM InsP3 (5 and 
7 minutes) had no effect on the magnitude of the window of separation between 
treated and control preparations (see figure 48), in fact it appears to have an 
opposite effect with only 10% separation occurring at 20/xM EGTA.
Thus due to a small window between treated and untreated preparations, dense 
granule release can not be used to assess platelet function.
3.3.1.9 Investigation of electroporation of platelets suspended in ICB.
[14C]5-HT release, upon challenging platelets exposed to 2.2, 2.5, 3.5 and 5 kV 
at 5 and 10 cycle repetitions to varying concentrations of Ca2+ was a measure of 
permeability. At 2.2, 2.5 and 3.5 kV 5 and 10 cycles, [I4C]5-HT release was 
not detected. At 5 kV both with 5 and 10 cycles, Ca2+ caused a dose dependent 
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Figure 48. The effect of 5 minute incubations of 10/xM InsP3 on [14C]5-HT 
loaded permeabilised platelets in the presence of a dose range of EGTA. 
Platelets were loaded with [14C]5-HT, permeabilised with 20/xg/ml saponin, 
treated with a dose range of EGTA and vehicle, (•), or 10/xM InsP3 (A ), and 
[14C]5-HT release was determined. Each point is the mean ±  SE of 3 
determinations.
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Figure 49. Ca2+-induced [14C]5-HT release in electroporated platelets at t= 0  
after poration (closed bars) and t= 6 0  min. after poration (open bars) using (a) 
5; (b) 10 and (c) 15 cycles at 5kV. [l4C]5-HT release. Each point is the mean ±  
SE o f 3 determinations.
3.3.1.10 Investigation of resealing of electroporated platelets suspended in ICB.
Platelets porated with 5, 10 and 15 cycles of 5kV were challenged with Ca2+ 
(300nM- lfxM) immediately after poration (t=0) and after 30 minutes (t=30) 
and one hour incubations at 37°C (t=60).
Platelets were responsive to Ca2+ at t= 0  minutes releasing [14C]5-HT, but not 
after 30 minutes at 37°C, t=30 minutes, nor at t=60 minutes at 37°, see figure 
49, indicating that after poration the platelets were permeable to Ca2+ ions and 
after 30 and 60 minutes at 37 °C they were not, which raises the possibility of 
the platelets having resealed.
3.3.1.11 Investigation of the function of resealed electroporated platelets 
suspended in ICB.
Platelets electroporated with 10 cycles of 5kV did not respond to PAF (lOnM- 
300nM), see figure 50. In addition, after incubations at 37°C for 30 minutes 
and 1 hour these permeabilised platelets also did not respond to PAF and 
[14C]5-HT release could not be detected in the presence or absence of ImM 
Ca2+.
3.3.1.12 Investigation of the function of resealed electroporated platelets 
suspended in high K+ buffer.
Platelets resuspended in high K+ buffer and electroporated with 5, 10 and 15 
cycles of 5kV did not respond to PAF (lOnM- 300nM). In addition, after 
incubations at 37°C for 30 minutes and 1 hour, PAF did not evoke a response 
and [14C]5-HT release could not be detected.
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Figure 50. PAF-induced [14C]5-HT release in (a) intact and (b) electroporated 
platelets. Platelets loaded with [14C]5-HT were stimulated with (a) PAF (10- 
300nM) or (b) electroporated 10 cycles at 5kV and then challenged with PAF 
(10- 300nM), [14C]5-HT release is then determined. Each point is the mean ±  
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Figure 51. To assess permeabilisation and resealing of electroporated cells. 
Platelets loaded with [14C]5-HT and (a) intact platelets challenged with PAF 
(10- 300nM) (open bars) or vehicle (closed bars), (b) electroporated platelets 
(10 cycles at 5kV) challenged with PAF (10- 300nM) at t= 0  after poration and 
(c) electroporated platelets (10 cycles at 5kV) challenged With PAF (10- 
300nM) at t=60 after poration and [14C]5-HT release determined. Each point is 
the mean ±  SE of 3 determinations.
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not responding to millimolar Ca2+ after incubations at 37°C in contrast to the 
responses to Ca2+ observed immediately after permeabilisation. However, the 
preparation is not responsive to PAF after 30- 60 minutes incubations at 37°C, 
indicating a breakdown in the signalling system. Thus with electroporation, 
platelets appear to permeabilise and possibly reseal but with the loss of platelet 
functional responses to extracellular agonists such as PAF, see figure 51.
3.4 Investigating the effects of the Ca2+-influx inhibitor SKF 96365 on platelet 
function.
Ca2+ entry is thought to play an important role in Ca2+ elevation following 
receptor activation. SKF 96365 is an inhibitor of receptor-mediated calcium 
entry and has been used in this study to investigate the role played by 
extracellular Ca2+ in platelet activation.
3.4.1 The effect of SKF 96365 on Ca2± release bv PAF in intact Fura-loaded 
platelets.
Platelets loaded with the fluorescent indicator Fura-2, and challenged with PAF 
(3- 300nM) produced a dose dependent elevation in [Ca2+] with 3nM PAF 
producing a 1/xM rise in [Ca2+]i. This dose was subsequently used to probe the 
effect the influx inhibitor would have on Ca2+ elevation, figure 52.
90 second pre-incubations of the platelets with a dose range of SKF 96365 (1- 
lOOfiM) and then challenged with 3nM PAF, this produced a dose dependent 
inhibition of a 3nM PAF response with an IC50 of 21.1+  1.1/xM (n=3, mean 
±  SE) and a reduction in Ca2+ elevation with 90% inhibition being achieved at 






















Figure 52. Inhibition of PAF-induced elevation of cytosolic calcium 
concentration by SKF 96365. Fura-2 AM loaded platelets were incubated with 
SKF 96365 for 90 seconds prior to stimulation with 3nM PAF. Each point is 
the mean ±  SE of 3 determinations. Inset shows representative traces of the 
dose dependent inhibition of 3nM PAF-induced Ca2+-elevation by a: vehicle, b: 












°  20 +
J± 1 h »h  f ~ l






Figure 53. Inhibition of 3nM PAF-induced [14C]5-HT release by SKF 96365. 
[14C]5-HT loaded intact platelets were incubated with SKF 96365 for 90 
seconds (open bars), or vehicle (closed bars), prior to activation by 3nM PAF. 
Each point is the mean ±  SE of 3 determinations.
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3.4.2 The effect of SKF 96365 on dense granule release.
90 Second pre-incubation of platelets with SKF 96365 (1- 100/xM) produced a 
dose dependent inhibition of dense granule release when platelets loaded with 
[14C]5-HT were challenged with 3nM PAF. Maximal inhibition was achieved 
with 10/xM SKF 96365 with an IC50 of 100nM± 20nM (n=3, mean ±  SE), see 
figure 53.
3.4.3 The effect of SKF 96365 on InsP  ^production.
90 Second pre-incubations of platelets with a dose range of SKF 96365 (1- 
100/xM) produced a dose dependent inhibition of InsP3 production when 
stimulated with 300nM PAF, having an IC50 of 24.3±  3.2/zM (n=3, mean ±  
SE), see figure 54. Levels of InsP3 rise from 4 ±  2.7 pmol basal to 9.1 ±  2.9 
pmol InsP3/109 platelets upon maximal stimulation.
3.4.4 Studies on permeabilised platelets.
3.4.4.1 45Ca release induced by SKF 96365.
SKF 96365 (1- 100/iM) challenged permeabilised platelets (20°C) had no 
capacity to mobilise Ca2+ from InsP3-sensitive stores (see figure 55), in 45Ca- 
loaded permeabilised platelets, in comparison to L1SP3 which releases a 
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Figure 54. Inhibition of 300nM PAF-induced InsP3 production by SKF 96365. 
Platelets were incubated with SKF 96365 for 90 seconds prior to activation by 
300 nM PAF and InsP3 production was determined. Inset shows InsP3 levels at 
basal and maximum stimulation. All values have been obtained by subtracting 
the basal pre-PAF from those obtained after PAF-stimulation. Each point is the 
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Figure 55. Dose response curves to InsP3 (•) and SKF 96365 (£) for their ability 
to release sequestered 45Ca from saponin permeabilised platelets. Permeabilised 
platelets were loaded with 45Ca, stimulated with a dose range of InsP3 or SKF 
96365 for 3 minutes at 20°C and 45Ca release was determined by rapid 
filtration. Each point is the mean ±  SE of 3 determinations.
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3.4.4.2 The effect of SKF 96365 on InsP  ^ and Insfl.3.4.5VP4-stimulated 45Ca
release.
SKF 96365 (1- 100/zM) had no effect of both 3/iM InsP3 and 10/xM 
Ins(l,3,4,5)P4 45Ca-induced mobilisation at 20°C (see figure 56 and 57). 3/*M 
InsP3 releases 68±  2% (n=3, mean ±  SE) of the sequestered 45Ca, whereas 
IOjiM Ins(l,3,4,5)P3 release 28±  3% (n=3, mean ±  SE) of the loaded 45Ca (at 
20°C), figure 58.
3.5 The use of crude platelet membranes for examining InsP^-induced Ca2+ 
release.
3.5.1 45Ca release assay.
3.5.1.1 Optimal cell number and protein concentration for 45Ca.
The amount of 45Ca taken up into the membrane preparation was directly 
proportional to the protein concentration, with the greater protein concentration 
having a greater amount of 45Ca associated with it.
Thus for subsequent experiments platelets were suspended to 109 cell/ml and 
later freeze/thawed for membrane preparation, figure 59.
Protein conc. mg/ml % 4SCa uptake
Platelets /ml
108 0.1 22±  3
2xl08 0.3 31± 1.6
109 0.95 38± 2.1
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Figure 56. The effect of SKF 96365 on 3^M InsP3-induced 45Ca-release. 
Saponin permeabilised platelets were incubated with vehicle (closed bars), or 
SKF 96365 (open bars) for 90 seconds prior to challenge with 3^M InsP3 for 3 
minutes at 20°C. 45Ca release determined by rapid filtration. Each point is the 












Figure 57. The effect of SKF 96365 on 3/xM Ins(l,3,4,5)P4-induced 45Ca- 
release. Saponin permeabilised platelets were incubated with vehicle (closed 
bars), or SKF 96365 (open bars) for 90 seconds prior to challenge with 10/xM 
Ins(l,3,4,5)P4 for 3 minutes at 20°C. 45Ca release determined by rapid 
filtration. Each point is the mean ±  SE of 3 determinations.
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3.5.1.2 Time course of 45Ca uptake into crude platelet membranes.
45Ca uptake was time dependent reaching a plateau after 30 minutes of 
incubation with 45Ca. The plateau was maintained for over one hour which is 
sufficient to carry out a release experiment. The overall percentage of 45Ca 
uptake into these membranes, in comparison to uptake into permeabilised 
platelets, was found to be considerably less, 29% in comparison to 45%, figure 
60.
3.5.1.3 InsP? dose response curve in crude membrane preparations.
Crude platelet membranes prepared on three separate occasions, when 
challenged with InsP3, produced three different dose/response relationships, see 
figure 60. In addition, the dose response curves are nominal in that the EC50 are 
very high indicating little receptor activation or the presence of a low receptor 
concentration. This with the afore mentioned inconsistency in response suggests 
that the platelet membrane preparations on the different days are different with 
respect to InsP3 receptor concentration. The reason for this is not known. Thus, 
crude membrane preparation can not be used to study InsP3- and analogue- 
induced 45Ca release.
3.5.1.4 The effect of heparin on InsP^-induced 4SCa release.
Heparin (300ng/ml- 100/xg/ml) caused a dose dependent inhibition in crude 
rabbit membranes and 100% inhibition was not achieved. However, comparable 
to the inconsistency of InsP3-induced 45Ca experienced above, heparin tested on 








inhibition (see figure 61). Thus, an IC50 value could only be obtained for each 
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Figure 59. Time course of 45Ca uptake into crude platelet membrane 
preparations. Crude platelet membranes were prepared and 45Ca uptake at 
predetermined times was measured over a period of 2 hours. Each point is the 
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Figure 60. Dose response curves to Insp3 of three different crude membrane 
preparations. Crude membranes were prepared on three separate days, loaded 
with 45Ca and challenged with a dose range of InsP3 for 3 minutes. This graph 














Figure 61. Inhibition of 3^M InsP3-induced 45Ca-release in crude platelet 
membranes by heparin. Crude platelet membranes loaded with 45Ca were pre­
incubated with heparin (1/zg/ml- 100/zg/ml) for 3 minutes and then challenged 
with 3/xM InsP3 for 3 minutes at 20°C. Graphs are results of two membrane 




4.1 Structure/activity relationships: The requirements of the InsPi receptor for 
Ca2+ release.
4.1.1 Structural requirements for Ca2+ release.
Intact platelets stimulated with InsP3 did not release Ca2+. This indicates that 
these cells did not become permeable upon incubation with L1SP3 in ICB, and 
that they need to be permeable in order for InsP3 to elicit a response. Upon 
saponin treatment, platelets became sensitive to InsP3.
The ability of L1SP3 to mobilise Ca2+ from intracellular stores was found to be 
stereospecific, as demonstrated by a comparison of D-InsP3 and L-L1SP3 . D- 
InsP3 released 75- 85% of non-mitochondrial Ca2+ with an EC50 of 1.14±  
0.2/iM (at 20°C), whereas L-InsP3 was unable to mobilise Ca2+ (at all 
concentrations examined). This is consistent with previous reports (Strupish et 
al., 1988) in which L-InsP3 was found to be some 2000-fold weaker than D- 
InsP3 and that it exhibited very low affinity for the InsP3-binding site showing 
no partial agonism or antagonism at the InsP3 receptor (Strupish et al., 1988; 
Polokoff et al 1988)
4.1.2 Temperature dependence of InsP^-induced Ca2+ release.
InsP3-induced Ca2+-release was found to be very temperature dependent. The 
EC50 at 4°C, 20°C and 37°C were 0 .18± 0.1/tM, 1.14± 0.2/xM and IOjzM  
respectively. Thus, approximately 50 fold more InsP3 is required to release the 
same amount of 45Ca at 37°C compared to 4°C.
The causes of this marked temperature dependence could include (a), a reduced 
binding affinity of ligand with receptor at 37°C, (b). temperature dependent loss
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of intrinsic Ca2+ mobilisation, (c). a loss in the concentration of InsP3 due to 
increased metabolism, (d). loss in activity of Ca2+-channel at 37°C.
In our system, optimal 45Ca release was observed at 4°C and the rank order for 
Ca2+-release is 4°C > 20°C> >  37°C. This is reflected by the rates of InsP3 
metabolism, see later. The order of efficiency of metabolism is 37° >  >  
20°C > 4°C and greater 45Ca release at the lower temperatures is an indication 
of lower enzyme activity. Thus, at lower temperatures, a higher proportion of 
the exogenously applied InsP3 is conserved. Because InsP3 can reach a higher 
concentration at 4°C in the vicinity of the receptor, due to this reduced 
metabolism, it is capable of releasing a greater proportion of sequestered Ca2+. 
However, L1SP3 remains equally efficacious.
Our data suggests a rapid loss of L1SP3 at 37°C due to metabolism. However, it 
is still possible that other factors such as a. and b. above are contributing to 
these differences in EC50 at 4°C, 20°C and 37°C. In order elucidate the role of 
metabolism in this apparent decrease in potency with increasing temperature, 
studies on metabolic-resistant analogues need to be carried out.
The initial curves for InsP3- and Jcy//o-Ins(l,2,4,5)P4-induced Ca2+ release at 
20°C, indicate that the latter is apparently more potent than InsP3 at mobilising 
Ca2+. However, upon studying the Ca2+ release profiles of scyllo- 
Ins(l,2,4,5)P4 at 4°C, 20°C and 37°C, it was established that scyllo- 
Ins(l,2,4,5)P4-induced Ca2+ release is also temperature dependent. The EC50 at 
4°C, 20°C and 37°C are 0.1 ±  0.05/xM, 0 .1±  0.05/iM and 5 .1 ±  0.2/iM 
respectively. At 4°C, InsP3 and Jcy//o-Ins(l,2,4,5)P4 were equally potent in 
their release ability. At 20°C, InsP3 appears to be 10 fold less potent than 
$cy//0-Ins(l,2,4,5)P4 and at 37°C, L1SP3 appears to be only 2-fold less potent.
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Of interest is the finding that the EC50 for jcy//0-Ins(l,2,4,5)P4 at 4°C and 
20°C are identical (0 .1± 0.05jtM). This may be due to metabolism, and scyllo- 
Ins(l,2,4,5)P4 may be metabolised slowly at these two temperatures.
In addition, we can probably attribute the greater potency of scyllo- 
Ins(l,2,4,5)P4 at 20°C, in comparison to InsP3, to a metabolism effect, L1SP3 
being metabolised at a faster rate than scy//oTns(l,2,4,5)P4 at 20°C. This, 
presumably implies that Jcy//o-Ins(l,2,4,5)P4 is a weaker substrate for the 
metabolic enzymes than InsP3, or that it is even an inhibitor of these enzymes. 
The use of stable analogues of Jcy//o-Ins(l,2,4,5)P4 may help elucidate the role 
of metabolism in this case. However, jcy//<?-Ins(l,2,4,5)PS4, a stable 
phosphorothioate analogue of scyllo-lns(l ,2,4,5)PS4, has been examined but 
found to be a partial agonist in this system and hence unable to define the role 
of metabolism here.
4.1.3 Phosphorothioate modification.
Phosphorothioate analogues are of considerable interest due to their resistance to 
intracellular phosphatases (Willcocks et al. , 1988) and their potential use in 
investigating metabolism. A number of analogues of InsP3 were synthesized in 
order to design a phosphatase resistant analogue. Three InsP3 phosphorothioate 
analogues were examined, Ins(l,4,5)PS3, Ins(l)P(4,5)PS2 and D/L-
Ins(l)PS(4,5)P2 all of which were found to be full agonists, releasing Ca2+ with 
similar potencies to InsP3 with EC50 of 0 .8 ±  0.1/xM, 0 .85±  O.ljtM and 0.65±  
O.lfiM respectively, at 20°C. All three compounds were thus as potent as L1SP3 
in mobilising 45Ca at 20°C. Further, it appears that complete substitution of all 
the phosphates with phosphorothioates, as with Ins(l,4,5)PS3, does not affect 
potency when comparing with selective substitution at the vicinal 4,5-
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bisphosphate, as in Ins(l)P(4,5)PS2 and D/L-Ins(l)PS(4,5)P2. Thus, the 
substitution of phosphates with phosphorothioates causes only a slight loss in 
potency at the platelet receptor. Various studies have reported that Ins(l,4,5)PS3 
is a persistent activator of InsP3-receptor, being resistant to metabolism by the 
InsP3 5-phosphatase (Taylor et al., 1989; Wojcikiewicz et al., 1990; Safrany et 
al., 1991a). The enantiomer of Ins(l,4,5)PS3, L-Ins(l,4,5)PS3, was found to be 
inactive. This is consistent with the stereoselectivity displayed by the L1SP3- 
receptor, as previously discussed, where L-InsP3 was found to be inactive in 
comparison to D-InsP3. In addition, this compound did not display any 
inhibitory effect on InsP3-induced mobilisation. This is not a surprise, since L- 
Ins(l,4,5)PS3 was designed as a non-Ca2+ mobilising 5-phosphatase inhibitor.
Inositol phosphorothioates are finding considerable applications in studies of the 
polyphosphoinositide signalling pathway, (Potter, 1990Z?c; Potter, 1993). 
Luckhoff and Clapham (1992) in their recent work give a direct demonstration 
of activation by Ins(l,3,4,5)P4 of a Ca2+-channel in endothelial cells using 
phosphorothioate analogues.
In all cases where the phosphorothioate analogue, Ins(l,4,5)PS3 has been used, 
its metabolic stability was crucial for these experiments. These compounds are 
proving to be valuable pharmacological and biochemical tools and will continue 
to help solve some of the problems encountered in PI signalling. For review of 
phosphorothioate analogues see (Potter, 1990ac; Potter, 1991; Potter, 1993).
4.1.4 Positional modifications.
The role of the three phosphates (-1, -4 and -5) and the three hydroxyls (2-, 3- 
and 6-) in Ca2+ mobilisation has been investigated in rabbit platelets. This was
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achieved by the availability of various ring modified and phosphate modified 
analogues in order to understand the contribution and significance of these 
phosphates and hydroxyl groups to Ca2+ mobilisation.
4.1.4.1 Modification at the 1-position.
The introduction of a phosphorothioate at the 1-position is tolerated as depicted 
in D/L-Ins(l)PS(4,5)P2. This compound is a potent agonist with an EC50 of 
0.65±  0.1/xM at 20°C. It appears, then, that small changes in the nature of the 
group on the 1-position have little effect on Ca2+-mobilising ability.
In addition, from the literature, a number of semisynthetic derivatives of InsP3 
substituted at the 1-position have been investigated (Henne et al. , 1988) and it 
was shown that the introduction of glyco- and glycero-based large groups at this 
position does not produce a major loss in activity.
4.1.4.2 Modification at the 2-position.
Ins(2,2)F2(l,4,5)P3 has two fluorine atoms replacing its axial 2-OH and the 
equatorial 2-hydrogen. The axial 2-fluorine is expected to mimic the axial 2-OH 
group, both sterically and electronically. This analogue was found to be as 
potent as L1SP3 in mobilising Ca2+ in permeabilised platelets, with an EC50 of 
0.63±  0.09/xM at 20°C, indicating that a major change to the 2-position in 
terms of functional group and ionic environment has little effect on receptor 
binding and mobilisation of Ca2+. Thus, this reveals that the 2-position plays a 
very minor role in InsP3*s action. These results are consistent with studies in 
SH-SY5Y neuroblastoma cells (Saffany et al.t 1990; Safrany et al.t 1992a) and 
the work of Hirata et al (1990; 1993).
1 7 0
Ins(l,2,4,5)p4, a synthetic InsP3 analogue, possesses an additional phosphate on 
the 2-position, as well as the phosphates on the 1-position and vicinal 4,5- 
position of InsP3. This analogue was found to be a full agonist in permeabilised 
platelets with an EC50 of 0.53+ 0.04/xM at 20°C and is as potent as InsP3. This 
supports the idea that the requirements for InsP3 receptor binding are fulfilled 
by this analogue and represents the first observation that a charged anionic 
group at the 2-position does not affect activity to any great extent.
D-myoinositol 1,4,5-trisphosphate A 3
D-lns(1 A5)P3 Sq’/Zo-Tns(l ,2.4)P3
Figure 62. The structures of InsP3 and the possible two binding modes of 
Scyllo-Ins(l,2,4)P3.
InsP-t________,scv//fl-Ins(1.2.41P'i comparison of-OH
2 axial 5 equatorial Different
3 equatorial 6 equatorial Same
6 equatorial 5 equatorial Same
Table 4. Comparison of the position and orientation of the hydroxyls of InsP3 
and 5,cy//o-Ins(l,2,4)P3
1 7 1
It is not apparent immediately how this molecule may interact with the InsP3 
receptor. However, it is possible to envisage two modes of scyllo-Ins(l,2,4)P3 
binding to the InsP3 receptor, see figure 62.
5cy//o-Ins(l,2,4)P3 and InsP3 are the same in terms of the regiochemistry of 
their phosphates, see figure 63, but InsP3 possesses an axial 2-OH which is 
replaced by an equatorial 5-OH in scyllo-lns(1,2,4)P3, see table 4. However, 
the equatorial 3-OH of InsP3 is matched by the equatorial 6-OH of scyllo- 
Ins(l,2,4)P3 and the equatorial 6-OH of InsP3 is mimicked by the equatorial 3- 
OH of scyllo-Ins(l,2,4)P3. 5'cy//o-Ins(l,2,4)P3 is a full agonist as potent as 
InsP3 in releasing Ca2+ with an EC50 of 0 .58+ 0.07/zM. This maintained 
activity despite 2-OH modification, from axial to equatorial, indicates that the 
2-OH is not essential for Ca2+ mobilisation and receptor occupation.
The introduction of large groups at the axial 2-position is tolerated, leading to a 
slight loss in activity (Hirata et al., 1990). The above data all indicate that the 
2-position is relatively unimportant for receptor recognition and Ca2+ 
mobilisation in this study using permeabilised platelets.
4.1.4.3 Modification at the 3-position.
The role of the 3-OH of InsP3 is of particular interest as it is the site of 
phosphorylation by InsP3 3-kinase, and its deletion would be of interest. 
However, 3-deoxy analogues were not available for evaluation in this study.
L-c/z/ro-Ins(2,3,5)P3 is modified at the 3-position, see figure 63, where the 
equatorial 3-OH of InsP3 is replaced by an axial 1-OH of L-chiro-Ins(2,3,5)P3 










Figure 63. The structures of InsP3 and L-c/wro-Ins(2 ,3 ,5 )P3
InsP^________L-cfa>o-Insf2.3.51P't comparison of -OH
2  axial 6  axial same
3 equatorial 1 axial Different
6  equatorial 4 equatorial Same
Table 5. Comparison of the position and orientation of the hydroxyls of InsP3 
and L-c/z/ro-Ins(2 ,3 ,5 )P3
This analogue relative to InsP3, has the same pseudo D-1,4,5- phosphates as 
InsP3 and the orientation of the 2- and 6 -OH groups of L1SP3 are the same as 
those of L-dz/r0 -Ins(2 ,3 ,5 )P3, see table 5. The 2- and 6 -OH groups of Insp3 are 
the same as the 6 - and 4-OH groups of L-c/z/ra-Ins(2 ,3 ,5 )P3 respectively. L- 
c/wro-Ins(2 ,3 ,5 )p3 shows full agonist properties with an EC50 of 1.9± 0.1/zM at 
20°C, and is only 1.7 -fold less potent than InsP3 at 20°C. This indicates that 
the 3-OH, surprisingly plays a minor role in InsP3 binding and Ca2+ release, 
especially when we consider that the action of the 3-kinase is at this position. 
Safrany et al (1992b) and Liu et al., (1992) used SH-SY5Y neuroblastoma cells 
to evaluate this analogue and it was found to be a full agonist with an EC50 of
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1.4± 0.3/xM whereas InsP3 has an EC50 of 0.09/xM, and this is in agreement 
with our findings.
The natural metabolite Ins(l,3,4,5)P4 was found to be weak in mobilising Ca2+ 
in permeabilised platelets, having an EC50 of ^  10/xM at 20°C, thus being »  
10-fold less potent than InsP3. A phosphorothioate analogue of Ins(l,3,4,5)P4, 
Ins(3)PS(l,4,5)P3, designed as an Ins(l,3,4,5)P4 3-phosphatase inhibitor, was 
slightly less potent than the parent phosphate in mobilising Ca2+, as seen in the 
dose response curves, with an EC50 of ^  10/xM. Ins(3)PS(l,4,5)P3 has the same 
phosphates as Ins(l,3,4,5)P4 at the 1-, 4- and 5-positions and, although it 
possess a phosphorothioate at 3-position, it might be expected to be as potent as 
Ins(l,3,4,5)P4. Ins(3)PS(l,4,5)P3 was shown to be slightly less potent than 
Ins(l,3,4,5)P4 at mobilising Ca2+ from the platelet InsP3 receptor. This suggests 
that substitution of a phosphate with a phosphorothioate at the 3-position of 
Ins(l,3,4,5)P4 does not have a significant effect on Ca2+ mobilisation activity.
Ins(l,3,4,5)P4 was found to mobilise Ca2+ in other cell systems. In SH-SY5Y 
neuroblastoma cells Ins(l,3,4,5)P4 induced Ca2+ release with an EC50 of 2/xM 
(Gawler et al., 1990) and although the mechanism of Ins(l,3,4,5)P4-induced 
Ca2+-release is still a matter of controversy, Wilcox et al (1993), in studies 
using SH-SY5Y neuroblastoma cells have recently suggested that 
Ins(l,3,4,5)P4-induced Ca2+-mobilisation is mediated through the InsP3 
receptor.
Seewald et al (1990) found that 3-deoxy-Ins(l,4,5)P3 was a full agonist in NIH 
3T3 cells (no reported E C 5 0 ) ,  and Kozikowski et al (1993ab), synthesized a  
series of deoxygenated analogues including 3-deoxy-Ins(l,4,5)P3 which showed 
full agonism with an E C 5 0  of 1.56± 0.02/xM in SH-SY5Y neuroblastoma cells.
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These results show that the 3-OH plays a relatively unimportant role in receptor 
binding and Ca2+-mobilisation. However, the addition of a phosphate group at 
the 3-position [as in Ins(l,3,4,5)P4] reduces the compounds ability to mobilise 
Ca2+. Replacement with a phosphorothioate group, as in Ins(3)PS(l,4,5)P3, 
further, but marginally reduces the ability for Ca2+ release.
4.1.4.4 Modification at the 4-position.
InsP3 analogues modified exclusively at the 4-position were not available for 
this study. However, several analogues having multiple modifications have been 
modified at the 4-position , see later.
Ins(l,3,5)PS3 does not posses a 4-phosphate moiety, but possesses 1-, 3- and 5- 
phosphorothioate groups. This analogue has no Ca2+-mobilising activity, in 
permeabilised platelets, even at lOjtM, having an EC50 of ^  100pM  at 20°C. 
Although this is a phosphorothioate analogue, the lack of activity indicates to 
the possible importance of this 4-phosphate for activity. Polokoff et al (1988) 
found that the parent compound, Ins(l,3,5)P3 had low potency with an EC50 of 
630/xM in smooth muscle cells. It may be that phosphorothioate substitution of 
Ins(l,3,5)P3, as in Ins(l,3,5)PS3, will further reduce Ins(l,3,5)P3 potency. 
However, it is known that the vicinal 4,5-bisphosphate or a pseudo D-4,5- 
bisphosphate is necessary for activity in other cell systems and the lack of 
activity of this compound is most likely due to this.
4.1.4.5 Modification at the 5-position.
L1SP3 analogues selectively modified at the 5-position were not available for this 
study, however, several analogues having multiple modifications have been 
modified at the 5-position, see later.
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The natural product of dephosphorylation of InsP3 by the 5-phosphatase 
enzyme, Ins(l,4)P2, has been shown to be substantially weaker than InsP3 in 
mobilising Ca2+. This would suggest that it plays a minor role in Ca2+- 
mobilisation in vivo (Potter, 1990£c)
D/L-myo-inositol 1,4-bisphosphate-5-phosphorothioate [Ins(l ,4)P2(5)PS] 
(Potter, 1990b; Safrany et al., 1991a) was found to be a full agonist at the InsP3 
receptor and a potent mobiliser of Ca2+ from permeabilised SH-SY5Y 
neuroblastoma cells, being only 7 fold less potent than InsP3 at mobilising Ca2+, 
where the EC50 of InsP3 is 0.11/uM and for Ins(l,4)P2(5)PS is 0.8/zM.
4.1.4.6 Modification at the 6-position.
The role of the 6-OH, adjacent to the crucial vicinal 4,5-bisphosphate, was 
probed using 6-deoxy-Ins(l,4,5)P3 and 6-deoxy-Ins(l,4,5)PS3, where the 6-OH 
has been deleted in the first case and in addition, the phosphates replaced by 
phosphorothioates in the second case. Both of these analogues were weak as 
Ca2+ mobilizers, showing substantial loss in activity, 6-deoxy-Ins(l,4,5)P3 
releasing a maximum of 40% 45Ca, with an EC50 of ^30/iM  at 20°C, being at 
least 30-fold less potent than InsP3. Any activity expressed by 6-deoxy- 
Ins(l,4,5)P3 is lost upon phosphorothioate replacement, for 6-deoxy- 
Ins(l,4,5)PS3 releases maximally 8% Ca2+ at lOO^M.
6-deoxy-Ins(l,4,5)P3 was found to be a full agonist in permeabilised SH-SY5Y 
neuroblastoma cells (Safrany et al., 1991 b; Potter and Nahorski, 1992; Potter, 
1993) some 70-fold less potent (EC50 6.4/xM) than InsP3 with an EC50 of 6.4/xM 
(InsP3 EC50 0.1/zM). However, in this study using permeabilised platelets 6- 
deoxy-Ins(l,4,5)P3 was found to be a weak mobiliser of Ca2+ with an EC50 of
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^30/iM . In contrast to our data, 6-deoxy-Ins(l,4,5)PS3 was shown to be a 
partial agonist in SH-SY5Y cells (Safrany et al., 1993), mobilising «  50% of 
the Ca2+ pool mobilised by InsP3.
Thus, modification at the 6-position appears to be important in Ca2+-release, 
leading to substantial loss of activity.
4.1.4.7 Multiple modifications.
Ins(4)CO(3,5)P2 is modified at the 1-, 3- and 4—position. Ins(4)CO(3,5)P2 does 
not possess a 1-phosphate group of InsP3, the 3-hydroxyl is occupied by a 
phosphate and its 4,5-positions are occupied by a methylene carboxylate and a 
phosphate group respectively. This compound shows no ability to mobilise Ca2+ 
in rabbit platelets. This is possibly due to the absence of the 1-phosphate. In 
addition, it does not antagonise InsP3-induced Ca2+ release.
Figure 64. The structures of InsP3 and Ins(l)P(4,5)pyrophosphate
Ins(l)P(4,5)pyrophosphate, in figure 64, is modified selectively at the vicinal 
4,5-phosphates which are replaced by a pyrophosphate moiety. This analogue 
does not release Ca2+, even at high micromolar concentrations. In addition, it 




D-lns(1,4,5)P3 D-myo-inositol -1 -phosphate 4,5-pyrophosphate 
hsO )P(4,5)pyrophosphate
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interact or bind to the InsP3 receptor. The 4,5-pyrophosphate group is a rigid 
structure with a similar size to the two phosphate groups it has replaced.
However, the inability of this analogue to activate the receptor may be 
attributed to the rigid structure of the former, where the pyrophosphate group is 
held tightly in its position and is unable to rotate or move to achieve a desirable 
conformation for binding to the InsP3 receptor. It was thought that InsP3 may 
adopt a conformation, when bound to its receptor or in solution, where the 
vicinal 4,5-bisphosphate system chelates a metal ion. Ins(l)P(4,5)pyrophosphate 
was synthesized to mimic this conformation in order to validate this idea. 
However, because this compound is inactive, it provides tentatitive evidence for 
a different conformation of InsP3 when bound to the receptor. This is likely to 
be a conformation where the 4 and 5 phosphates are diametrically opposed as a 
result of ionic repulsion.
Inositol-1-phosphate, which does not possess the vicinal 4,5-phosphates, is 
unable to mobilise Ca2+ in permeabilised platelets, or to interfere with L1SP3- 
induced Ca2+-mobilisation. This lack of activity can be attributed to the absence 
of the 4,5-phosphates.
Thus, our experimental data with inositol phosphate analogues in which the 
vicinal 4,5-bisphosphate are absent, or modified, support previous findings with 
other cell systems. Similar attributes have been assigned to the 4,5-bisphosphate 
and the critical importance of the vicinal groups (Gawler et ah, 1991) and the 
enhancing effects of the 1-phosphate group of InsP3 in receptor binding are now 
well established and appreciated (Potter, 1991; Nahorski and Potter, 1992; 
Potter, 1993).
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The synthetic precursor of 6 -deoxy-Ins(l,4 ,5 )P3, 6-deoxy-2,3-cyclohex- 
Ins(l,4 ,5 )P3 has a bulky cyclohexylidene group on the 2- and 3-OH groups and 
shows no activity in terms of Ca2+ release. The phosphorothioate derivative, 6 - 
deoxy-2 ,3 -cyclohex-Ins(l,4 ,5 )PS3, also has no activity. These synthetic 
precursors show complete loss of activity, in comparison to their parent 
compounds, 6 -deoxy-Ins(l,4 ,5 )P3 and 6 -deoxy-Ins(l,4 ,5 )PS3. This is possibly 
due to steric hindrance caused by the bulky cyclohexylidene group which may 
lead to ring distortion that may disrupt the correct conformation necessary for 
receptor binding. This is surprising, since modifications at the 2- and 3- 
positions do not effect potency and that these positions do not play a significant 
role in Ca2+-mobilisation. Alternatively, and most likely, the size of the 2,3- 
cyclohexylidene group may just be too large to be tolerated by the receptor.
Ins(l,3 ,4 ,6 )P4 was originally identified as a natural metabolite of L1SP3 
produced from the actions of a 6 -kinase on Ins(l,3 ,4 )P3 (Shears et al., 1987; 
Stephens et a l ,  1990). In platelets, Ins(l,3 ,4 ,6 )P4 was found to be a full 
agonist, and to mobilise Ca2+ with an EC50 of 9 .67± 0.5/tM, this is some 8 - 
fold less potent than InsP3. On this basis it seems unlikely than it will have any 
significant role in cellular signalling and Ca2+ release. However, this 
polyphosphate was shown to be a partial agonist of high efficacy in SH-SY5Y 
neuroblastoma cells, mobilising 80- 90% of the Ca2+ pool mobilised by InsP3, 
see Safrany et al (1993). The phosphorothioate analogue, Ins(l,3,4,6)PS4, was 
also investigated in rabbit platelets, and was found to be a weak full agonist, 
mobilising Ca2+ with an EC50 of ^  30/xM. This is consistent with our previous 
findings that substitution of a phosphate for a phosphorothioate reduces the 
compounds activity for Ca2+-release.
When examining the chemical structure of Ins(l,3,4,6)P4, it is not immediately 
apparent why it should be active at all. Ins(l,3,4,6)P4 does not nominally
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possess the essential vicinal 4,5-bisphosphate structure, nor does it possess a 











lns(1 >4,5)P3 recep to r
Ins(l,3,4,6)P4
Figure 65. Alternative binding conformations for Ins(l,3 ,4 ,6)P4
However, it is possible to envisage two potential binding conformations for 
Ins(l,3 ,4 ,6 )P4 at the InsP3 receptor, A and B in figure 65. Both conformations 
mimic a number of important recognition features, namely, the 4,5- 
bisphosphate, the 1-phosphate group and the 6 -hydroxyl group.
In conformation A, the 1- and 6 -phosphates of Ins(l,3 ,4 ,6)P4 resemble the 
vicinal 4,5-bisphosphate of InsP3, and the 4-phosphate is in the position of the
1-phosphate of L1SP3. In conformation B, again, the 6 - and 1-phosphates of 
Ins(l,3 ,4 ,6 )P4 resemble the vicinal 4,5-bisphosphate of InsP3. However, in this
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case, it is the 3-phosphate that is in the position of the 1-phosphate of InsP3, see 
figure 65.
Both conformations contain an extra phosphate at the 2-position of InsP3 is 
apparent from figure 65. However, modifications at the 2-position do not have a 
significant effect on Ca2+-mobilisation, as discussed earlier and we know that 
$cy//0 -Ins(l,2 ,4 ,5)P3 is highly potent. In addition, the conformation of the 3- 
hydroxyl (in the first binding conformation A) and the conformation of the 6 - 
hydroxyl (in the second binding conformation B) are altered, both being axial, 
rather than equatorial as in the case of L1SP3. Thus, this compound can mimic 
the essential features necessary for InsP3 receptor binding, namely the D -l,4 ,5- 
phosphates and the 6 -OH.
On the basis that Ins(l,3 ,4 ,6)P4 was found to be a partial agonist in 
neuroblastoma cells, with high intrinsic activity, it was thought that deletion of 
either of the 3- or 4-phosphates of Ins( 1,3,4,6 )P4, and the further substitution of 
the phosphates with phosphorothioates may give rise to a partial agonist with 
lower intrinsic activity (see section on partial agonists).
Deletion of the 3-phosphate gives rise to D-Ins(l,4 ,6)P3 and deletion of the 4- 
phosphate gives rise to L-Ins(l,3 ,4 )P3. According to this rationale, two such 
analogues (as their racemic mixtures) were synthesised, along with their 
phosphorothioate anlogues (Mills et al., 1993).
D/L-Ins(l,3 ,4 )P3 was a full agonist with an EC50 of ^30/xM at 4°C. This is in 
agreement with Irvine et al., (1986) who report an EC50 of 9/xM for the D- 
isomer, but in marked contrast to studies by Strupish et al.t (1988), where D- 
Ins(l,3 ,4 )P3 is found to be virtually inactive in Swiss 3T3 cells.
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D-myo-inositol 1 .4.5-Wsphosphate L-myo-inositol 1,3.4-Msphosphate
D - l n s (1 ,4,5)P3 L-lns(1,3,4)P3
Figure 66. The structures of I11SP3 and L-Ins(l,3,4)P3
InsP?________L -In sn .3 .4^  comparison of-OH
2 axial 4 equatorial Different
3 equatorial 5 equatorial Same
6 equatorial 2 axial Different
Table 6. Comparison of the position and orientation of the hydroxyls of InsP3 
and L-Ins(l,3,4)P3
Polokoff et al (1990) also found D/L-Ins(l,3,4)P3 to be some 400-fold less 
potent than InsP3 (DiPersio et al., 1988; Gawler et al., 1990). Hirata et al 
(1993) have recently evaluated the Ca2 ■'■-release ability of the resolved 
enantiomers of Ins(l,3,4)p3 and Ins(l,4,6)P3. They conclude that the activities 
exhibited by these two compounds are due to L-Ins(l,3,4)P3 and D-Ins(l,4,6)P3 
respectively. Furthermore, upon examination of the structure of L-Ins(l,3,4)P3, 
it is possible to see a way of arranging the phosphates in a pseudo D -l,4 ,5- 
orientation as explained previously. The same is not evident for the D- 
enantiomer. Thus, it seems most likely that the activity exhibited by D/L-
Ins(l,3 ,4 )P3 in our cell system is due to the L-enantiomer, see figure 6 6 . Table 
6  shows the orientation of the ring hydroxyls in comparison to InsP3.
We have shown the racemic mixture of Ins(l,3 ,4 )P3 to be a weak agonist. 
However, it is possible that upon phosphorothioate substitution, partial agonist 
activity may become apparent, see Ins(l,4 ,6 )P3 and Jns(l,4 ,6 )PS3.
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Figure 67. The structures of InsP3 and D-Ins(l,4 ,6 )p3
Irvine et al (1986) report an EC50 of 9/iM for the D-isomer of Ins(l,3 ,4 )P3. 
This is not in agreement with other reports on the activity of this analogue, 
discussed above, along with our data. It is possible, because the source of this 
analogue was not synthetic, that D-Ins(l,3 ,4 )P3 was contaminated with InsP3, 
Ins(l,3 ,4 ,5 )P4 and/or L-Ins(l,3 ,4)P3. Under these circumstances, the activity 
observed by this analogue could be due to any of these contaminating 
compounds.
Ins(l,4 ,6 )P3 (Mills et al., 1993), see figure 67, was found to be a full agonist 
with an EC50 of 2.07+ 0.08/xM at 4°C, and is 11-fold weaker than E1SP3 (InsP3 
EC50 of 0.18/xM at 4°C). Therefore, despite the differences in the orientation of 
the pseudo 2- and 3-OH of Ins(l,4 ,6 )P3, see table 7, the compound is still able 
to mobilise Ca2+ indicating that these two hydroxyls play a minor role in E1SP3
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binding and activation. It was also found that substitution of the phosphates with 
phosphorothioates rendered this analogue a partial agonist, see section on partial 
agonists.
InsP-i ______ Insfl.4.6TPi comparison of-OH
2 axial 3 equatorial Different
3 equatorial 2 axial Different
6 equatorial 5 equatorial Same
Table 7. Comparison of the position and orientation of the hydroxyls of InsP3 
and Ins(l,4,6)P3
Both L-Ins(l,3,4)P3 and D-Ins(l,4,6)P3 possess a pseudo D -l,4,5-orientation. 
But, are modified at the pseudo 2- and 6-OH for L-Ins(l,3,4)P3 (table 6), and 
pseudo 2- and 3-OH for Ins(l,4,6)P3 (table 7). Both these compounds were full 
agonists. This suggests that the modifications at the 2-, 3- and 6-hydroxyls do 
not significantly effect Ca2+-mobilisation. Indeed, this is in agreement with the 
data of Wilcox et al (1992) and Hirata, et al (1933) where it was found that 
both 3- and 6-OH are important in receptor binding, the 6-OH appears to be 
more important in Ca2+-mobilisation. Kozikowski et al (1993ab) also provide 
evidence for the crucial role for 6-OH.
In conclusion, then, we can see that in our system both L-Ins(l,3,4)P3 and 
Ins(l,4,6)P3 were found to be full agonists. However, phosphorothioate 
substitution of Ins(l,4,6)P3 has provided the best example of a partial agonist 
with low intrinsic activity, see section on partial agonists. This is in accordance 
with the original rationale involved in the synthesis of these analogues.
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The synthetic precursor of Ins(l,2,4,5)P4, Ins(3,6)Bz2(l,2,4,5)P4 does not 
mobilise Ca2+. This may be due to the presence of two bulky benzoyl protecting 
groups on the 3- and 6-positions. It is possible that these protecting groups are 
too large for the receptor to tolerate them. Alternatively, these groups may 
produce ring distortion, preventing receptor binding.
Relatively unimportant for receptor recognition: 
L-chirD-ins(2,3,5)P3 and 
lns(3)deox(1,4,5)P3 are ful agonists.
Essentia] for recognition: 
minor modifications as
lns(1,4)P2(5)PS does not 
effect activity.
Is not important in receptor recognition: 
lns(2,2)F2 shows Sttle loss In activity.
The vidnal 4,5-bisphosphate 
is essential for activity, InsP, 
is inactive as is lns(1 )P(4,5)pyrophosphate
Essential for recognition by the receptor. 
lns(1,4)P2 does not mobilise calcium 
and it does not bind the receptor. Plays a significant role in receptor binding 
and calcium mobftsation.
Deletion as in lns(6)deox(1,4,5}P3 causes 
a substantial loss in activity.
Plays a minor insignificant role 
where bully substitution does not 
cause major bss in activity.
Plays a major role in efficacy 
determination.
Figure 68. Summary of the structural requirements for activity at the platelet 
InsP3 receptor
Analogue Platelets Cell system
D-InsP3 0 .18± 0. IfiM 0 .12/xM in SH-SY5Y (Safrany et a l , 1992; Wilcox et a l , 1993)











0 .8±  O.l c^M 
0 .6 ±  0.09/iM 
1.9± O.lfiU  
2> 10/xM




inactive in SH-SY5Y (Strupish et a l ,  1988);: 
inactive in swiss 3T3 cells (Giese and Kirchner, 1988)
2.5^Min SH-SY5Y (Safrany et a l ,  1991)
0.41jtM in SH-SY5Y (Safrany et a l ,  1990; Safrany et a l ,  1992)
1.4± 0.3/tM in SH-SY5Y (Safrany et a l ,  1992)
2^M (Gawler et a l ,  1990; Ghiggeri et a l ,  1984; Kaiser et a l ,  1981) 
in SH-SY5Y; ^  30/xM in swiss 3T3 cells (Irvine et a l ,  1986)
6.4/xM in SH-SY5Y (Safrany et a l , 1991) 
inactive in SH-SY5Y (Noble et a l ,  1992)
120/zM in smooth muscle cells (Polokoff et a l ,  1988)
^  30/xM in RBL cells (Hirata et a l , 1993)
^30/kM in RBL cells (Hirata et a l ,  1993)
Table 8. Comparison of analogues studied in permeabilised platelets with other cells.











Partial agonist in SH-SY5Y (Gawler et al., 1991) 
partial agonist in SH-SY5Y (Safrany et al., 1993) 
partial agonist in SH-SY5Y (Safrany et al., 1993) 
not known 
not known
Table 8. Comparison of the activities of the partial agonists found in platelets with different cell systems.
4.1.5 Partial agonists.
Partial agonism was displayed by several of the compounds studied, these being 
5cy//o-Ins(l,2,4,5)PS4, L-c/nVo-Ins(2,3,5)PS3 and D/L-Ins(l,4,6)PS3.
Interestingly, Jcy//o-Ins(l,2,4,5)P4, L-dw>0-Ins(2,3,5)P3 and Ins(l,4,6)P3, the 
parent polyphosphates of each phosphorothioate analogue were all full agonists. 
Of the three phosphorothioates, only Ins(l,4,6)PS3 caused a dose dependent 
inhibition of InsP3-induced Ca2+ release with lOO^M Ins(l,4,6)PS3 producing 
50% inhibition.
In SH-SY5Y cells, receptor binding has been characterised, and it appears that 
the introduction of phosphorothioate groups causes a substantial reduction in 
agonist efficacy with only a small reduction in the receptor affinity, and because 
P5S]Ins(l,4,5)PS3 labels two populations of sites with similar affinity one of 
which is the InsP3 receptor and the second is a site that displays low affinity for 
L1SP3 (Safrany et al., 1993). It is conceivable that InsP3 receptors in platelets 
also possess these two affinity sites. As a result, it is tentatively suggested that 
the two partial agonists that show no antagonistic activities i.e  scyllo- 
Ins(l,2,4,5)PS4 and L-c/z/ro-Ins(2,3,5)PS3, are acting through this second low 
affinity site mobilising Ca2+ and having no effect on the high affinity InsP3 
receptor. Thus, upon investigation of the effect of scy//0 -Ins(l ,2,4,5)PS4 and L- 
chiro-Ins(2,3,5)PS3 on Insp3-induced Ca2+-release, inhibition is not observed.
It is known that phosphorothioate substitution leads to changes in molecular 
size, hydrophobicity and charge distribution, any or all of which may contribute 
to producing a less than maximal response. Thus, we suggest that 
phosphorothioate substitution coupled with another perturbation are required for 
a compound to exhibit partial agonism. Partial agonist activity may be generated
188
by a suboptimal binding interaction produced by a D-l,4,5-trisphosphorothioate 
motif, in combination with another structural perturbation, such the presence of 
an additional equatorial 2-phosphorothioate group in Jcy//o-Ins(l,2,4,5)PS4, or 
the presence of an 3-axial hydroxyl of L-c/zz>o-Ins(2,3 ,5)PS3, or the equatorial
2-OH and axial 3-OH of Ins(l,4,6)PS3, see figure 68.
It should be noted that for the second messenger cAMP phosphorothioate 
substitution has generated competitive cAMP antagonists, see Safrany et al 
(1993). These antagonists are Rp-cAMPS and CAMPS2 (Parker Bothelo et al., 
1988,ab) reviewed in Potter (1992).
Upon examining the structures of the three inositol phosphate partial agonists, it 
appears that they share a high degree of similarity between each other and with 
InsP3, see figure 69. 5cy//0-Ins(l,2,4>5)PS4 does have 1-, 4-, and 5- 
phosphorothioates. However, L-c/w>o-Ins(2,3,5)PS3 and Ins(l,4,6)PS3 doe not 
nominally possess phosphates at the 1-, 4- and 5- positions, analogues to InsP3 , 
it is nevertheless possible to envisage binding conformations of these two 
compounds in which do they have phosphorothioates at these positions, see 
figure 69. Of the three partial agonists, jcy//0-Ins(l,2,4,5)PS4 possessed the 
highest intrinsic activity, releasing 61.7 ±  11% 45Ca. This was followed by L- 
c/zz>0-Ins(2,3,5)PS3, which possessed a lower intrinsic activity, releasing 42.3±  
6% 45Ca, and D/L-Ins(l,4,6)PS3 being the partial agonist with the lowest 
intrinsic activity, releasing 21.1+4%  45Ca.
Ins(l,4,6)PS3 (3- 100/xM) produces 50% inhibition at 100/xM, and it appears 
that inhibition of the InsP3 response is only occurring at concentrations of 10/zM 
and above. This is consistent with the dose response curve of Ins(l,4,6)PS3
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where the curve appears to be in two phases. A low level of release is observed 
at concentrations up to 10/zM. At concentrations above 10/xM,
OH
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Figure 69. The chemical structures and numbering of Jcy//o-Ins(l,2,4,5)P4 (8); 
jcy//0-Ins(l,2,4,5)PS4 (18); L-c/»>0-Ins(2,3,5)p3 (9); L-c7w>0-Ins(2,3,5)PS3 
(19); Ins(l,4,6)P3 (10) and Ins(l,4,6)PS3 (20).
a second phase of higher release is observed plateauing out at 100/zM and it is at 
these concentrations that an inhibitory effect is observed. Alternatively, an 
inhibitory response may be occurring at the lower concentrations of 0.03- 3/zM, 
but is at such a weak level, that its effects are with the limits of error.
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Thus, in order to synthesize further analogues that are partial agonists with even 
lower intrinsic activity, or even antagonists, it appears that all D-1,4-5-positions 
of L1SP3 need to be occupied by phosphorothioates, see figure 70. In addition, 
as mentioned above, it is possible the further modifications at the pseudo 2 - and
3- positions of InsP3, as seen in all three of the partial agonists, confer low 
intrinsic activity.
In this study 6 -deoxy-Ins(l,4 ,5 )PS3 did not show partial agonism or affect 
InsP3-induced 45Ca release. However, the EC50 for this analogue was too high 
and this may mask any partial agonist activity present. This is in contrast with 
reports using SH-SY5Y neuroblastoma cells (Safrany et a l ,  1993).
Further, Ins(l,3 ,4 ,6)P4 which was also found to be a patrial agonist in SH- 
SY5Y neuroblastoma cells (Potter and Nahorski, 1993; Gawler et a l ,  1991) 
was found to be a full agonist in permeabilised platelets (this thesis). An 
interpretation of the differences between the activities observed in platelets and 
neuroblastoma cells is the existence of tissue specific receptor popoulations (see 
summary of discussion).
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X= S or any other group at the 1-, 4- or 5- positions
 hydroxyls at these positions can have either orientation, axial or equatorial
Figure 70. The proposed structural requirements for partial agonist activity.
4.1.6 InsP-i-receptor antagonists and Inhibitors of InsPi-induced Ca2+-release.
4.1.6.1 Heparin.
Heparin is a polysulphated polysaccharide with a molecular weight between 
6000 and 20,000, depending on its origin and preparation. It is a competitive 
reversible antagonist of InsP3 binding at the InsP3-receptor (Ghosh et al., 1986). 
In saponin permeabilised platelets, heparin up to 100/xg/ml had no effect on 
InsP3-induced Ca2+-release. In this study two heparins, one with high molecular 
weight and the second with 3000 molecular weight were used and both were 
ineffective in inhibiting InsP3-induced Ca2+ release in permeabilised platelets.
This can be explained by the fact that stimulated platelets secrete antiheparin 
proteins. As early as 1955 Deutsch introduced the term platelet factor 4 (PF4) 
to describe a platelet protein with antiheparin activity (Rucinski et al., 1979). In 
addition, two further proteins secreted by platelets were found to possess weak 
antiheparin activity, these being B-thromboglobulin (BTG) and low-affinity 
platelet factor 4 (LA-PF4) (Rucinski et al., 1979). These antiheparin proteins 
act to inactivate heparin activity, and it can be envisaged that upon heparin 
incubations, these proteins will act to neutralise heparin and upon subsequent 
InsP3-stimulation Ca2+ release will occur as usual.
The only study on the effect of heparin on InsP3-induced calcium mobilisation 
in permeabilised platelets was that of Rao and colleagues (Rao et al., 1991), and 
they found that high molecular weight (2- 15 kDa) heparins have no inhibitory 
effects and only one of six low molecular weight heparins (4- 6 kDa, sigma 
H5640) caused a significant inhibition of InsP3-induced Ca2+-mobilisation. They 
attribute this lack of inhibition to the way permeabilisation was achieved, using
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low saponin concentration. However, other studies have used saponin to 
permeabilise cells (Ghosh et al., 1986) and this appears not to interfere with the 
inhibitory effects of heparin reported as having an IC50 of 5/ig/ml. However, 
they do report that sensitivity to heparin increases with decreasing the molecular 
size.
In addition to inhibiting InsP3 binding, heparin also inhibits InsP3 3-kinase 
activity, but it has no effect on InsP3 5-phosphatase activity or Ins(l,3,4,5)P4 5- 
phosphatase activity. In addition, it inhibits Ins(l,3,4,5)P4 binding and its 
ability to mobilise Ca2+ (Taylor and Richardson, 1991) and these effects 
severely limit the use of heparin as an InsP3 receptor antagonist.
4.1.6.2 Decavanadate.
Decavanadate, a decameric vanadate cluster, inhibits InsP3-induced Ca2+- 
mobilisation (Fohr et a l ,  1989). In permeabilised rabbit platelets, decavanadate 
caused a dose dependent inhibition of InsP3-induced 45Ca-release with an IC50 of 
7.82±  0.4/xM.
It has been found to inhibit competitively InsP3-binding and to inhibit InsP3- 
induced Ca2+-release (IC50 of 5/xM) (Strupish et al., 1991 ab; Fohr et al., 
1991). However, decavanadate was found to be non-specific in its inhibitory 
activity of InsP3-binding (Strupish et al., 1991 ab). Decavanadate was also found 
to inhibit L1SP3 3-kinase and Ins(l,3,4,5)P4 5-phosphatase (Strupish et al., 
1991) in permeabilised SH-SY5Y neuroblastoma cells as well as inhibiting the 
specific binding of Ins(l,3,4,5)P4 to cerebellar membranes and its ability to 
mobilise Ca2+ from cerebellar microsomes, (Challis et al., 1991; Strupish et 
a l ,  1991 ab).
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Although decavanadate and heparin are potent and competitive antagonists at the 
&1SP3 receptor, they possess an array of other actions which limits their use as 
tools in investigating the InsP3 signalling pathway and clearly small-molecule 
antagonists are required.
4.1.6.3 Benzene 1.2.4-trisphosphate,
Recently, a very loose structural analogue of InsP3, benzene 1,2,4-trisphosphate 
(BZP3) was shown to interact with the InsP3 receptor where it inhibited L1SP3- 
binding to adrenal cortex microsomes with an IC50 of 428/iM and an 80% 
inhibition at 500/nM (Poitras et al., 1993). In permeabilised rabbit platelets, we 
found that BZP3 had no inhibitory effect on InsP3-induced Ca2+-mobilisation at 
concentrations up to 500/zM. This lack of activity, on the InsP3 response, could 
be due to our different source of this compound, or that tissue specific receptors 
are present.
4.1.7 The InsPi receptor.
Limited information is available at present concerning the conformation(s) 
adopted by InsP3 in solution, and there is no information relating to the 
conformation of this molecule in the bound state. An early study on pH effects 
on the conformation of InsP6 in solution demonstrated that at neutral and 
alkaline pH, InsP6 adopts the expected conformation of five equatorial and one 
axial phosphate groups, whereas at acidic pH the cyclohexane ring "flips" to 
give reverse conformation with one equatorial and five axial phosphate 
substituents stabilised by intramolecular hydrogen-bonding interactions (Challiss 
et al., 1991). This unusual conformation may also be adopted at acidic pH by 
other highly charged phosphorylated inositol derivatives, and the likelihood of
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this occurrence will presumably increase with increasing the degree of 
phosphorylation. However, it is unlikely that this will be the case with InsP3, 
due to the small number of phosphate groups in comparison to InsP6. A more 
recent study of pH effects on the solution conformation of InsP3 did not support 
this idea (Lindon et al., 1987). Thus, the distinct pH-dependence of InsP3- 
receptor binding can not be explained by the predicted physical properties of the 
ligands. Furthermore, the difference may reside in the protein conformation and 
ionisation of titratable groups within the ligand-binding site of the receptor 
(Challiss et al., 1991).
The initial cloning of the cDNA for the L1SP3 receptor from mouse cerebellum 
has provided a substantial image of the receptor structure (Furuichi et al., 
1989), and subsequent studies from other tissues has shown that the sequence of 
the receptor is highly conserved (Mikoshiba, 1993). Subsequent transfection of 
cDNA (Furuichi et al., 1989) and reconstitution (Ferris et al., 1989; Maeda et 
al., 1991; Kamata et al., 1992) experiments suggested that the cDNA actually 
encodes for a protein containing both the ligand binding site and Ca2+-channel 
activity. From these data it was concluded that the receptor is a Ca2+ channel 
(Nakade et al., 1991). The primary sequence of the receptor shares no 
homology with the voltage-operated Ca2+ channels on the plasma membrane 
(Furuichi et al., 1989), but shares a significant homology with the ryanodine 
receptor, for review see (Mikoshiba et a l ,  1993; Mikoshiba, 1993).
Patterns of Ca2+ release by InsP3 suggested an intracellular localisation of the 
InsP3 receptor in non-mitochondrial stores associated with microsomal fractions. 
However, there has been considerable debate over the intracellular localisation 
of this receptor (Mikoshiba, 1993; Mikoshiba et al., 1993). The InsP3 receptor 
has been found to be present in multiple subcellular areas (Sharp et al., 1992)
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and one study suggests that the receptor associates with the plasma membrane, 
suggesting the presence of receptor subtypes (Sharp et al., 1992). In addition, 
neuronal and non-neuronal receptors have been shown to exist (Danoff et al., 
1991). Further, biochemical data demonstrated that InsP3 binding has different 
characteristics in different tissues (Guillemette et al., 1988; Rossier and Putney, 
1991; Sudhof et al., 1991), and that different receptors may be expressed in 
different subcompartments (Sudhof et al., 1991).
Three subtypes of the InsP3 receptor from different genes have been identified 
(Sudhof et a l ,  1991; Blondel et al., 1993; Mikoshiba et al., 1993; Mikoshiba, 
1993) all having different affinities for InsP3. Therefore it is possible that InsP3- 
mediated Ca2+ release is directed by various forms of InsP3 receptor (from the 
different genes) and these may possibly have different functional properties in 
Ca2+ release. There is then the possibility that intracellular Ca2+ signalling may 
be regulated in different ways dependent on different InsP3 receptor transduction 
pathways, thus giving rise to multiple pathways for Ca2+-release.
4.1.7.1 Receptor regulation.
The InsP3 receptor is regulated by pH, ATP, calcium and magnesium (Taylor 
and Richardson, 1991; Van Delden et al., 1993), and phosphorylation by PKA 
(Hajnoczky et al., 1993), PKC and Ca2+/calmodulin-dependent protein kinase 
II (Taylor and Richardson, 1991; Mikoshiba, 1993). Further, the membrane 
associated cytoskeletal protein, ankyrin, is also thought to play a role in receptor 
regulation where it was found to inhibit InsP3 binding and InsP3-mediated Ca2+ 
release (Bourguignon et al., 1993). ATP enhances InsP3-dependent Ca2+ release 
(Mikoshiba et al., 1993), and ATP binding sites are located near the receptor 
phosphorylation sites (Ferris et al., 1992; Mikoshiba, 1993). Ca2+ is known to
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play a pivotal role in L1SP3 binding, and InsP3-induced Ca2+ flux shows a bell 
shaped curve depending on the Ca2+ concentration (Danoff et al., 1988; Varney 
et al., 1990). A recent report suggest that receptor activation which causes 
elevations in [Ca2+]i might result in the degradation of the N-terminal, InsP3- 
binding part of the receptor mediated through an enzyme belonging to the 
calpain family (Magnusson et al., 1993).
PKA, PKC and CaM Kinase II phosphorylate the receptor, the former being the 
most efficient (Ferris et al., 1991). These enzymes phosphorylate three distinct 
serines (Ferris et al., 1991). PKA phosphorylation is associated with an 
alteration in the potency of InsP3 in releasing Ca2+ and may increase the 
sensitivity of the calcium stores to InsPa (Ferris et al., 1992; Hajnoczky et al., 
1993). Furthermore, a recent report suggests that the purified and reconstituted 
receptor autophosphorylates on serine and displays protein kinase-like activity 
(Ferris et al., 1992) and the physiological role for autophosphorylation is 
thought to be in modifying the response of the receptor to L1SP3, Ca2+ and ATP 
(Ferris et al., 1992). The InsP3 receptor is the first ion channel protein complex 
to display serine autophosphorylation activity and it may be the first receptor of 
any sort for which serine kinase activity on other substrates and on the receptor 
itself to be recognised. Although the L1SP3 receptor does not appear to have a 
full protein kinase domain (Ferris et al., 1992), it does bind ATP with high 
affinity making it an ideal candidate for autophosphorylation.
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4.1.8 Additional compounds investigated.
4.1.8.1 cyclic ADP-ribose (cADPRL
cADPR was first shown to mobilise Ca2+ in sea urchin eggs (Lee et al., 1989). 
Subsequently, cADPR has been found to be the endogenous activator of the 
non-skeletal ryanodine receptor (Galione, 1992; Meszaros et al., 1993) and in 
addition the ryanodine receptor has been cloned (Otsu et al., 1990) and like the 
InsP3-receptor has been found to possess an intrinsic Ca2+ channel (Llach, 
1985; Chen e t a l ,  1993).
In this study cADPR and its precursor ADPR were both inactive in releasing 
Ca2+ in permeabilised platelets. This could be due to the possibility that 
platelets do not possess ryanodine receptors, as to date no evidence is available 
that suggests the presence of ryanodine receptor in platelets. Alternatively, 
cADPR may be rapidly hydrolysed in platelets, or that the receptors are present 
only in low numbers. Indeed, cADPR is very rapidly hydrolysed in cells as 
might be expected of a molecule with such potent Ca2+-mobilising activity 
(Galione, 1992). In addition, a cADPR-hydrolysis enzyme activity has been 
found in rabbit brain extract (Rusinko and Lee, 1989).
4.1.8.2 Phorbol esters fPMA) and diacvlgycerol (DAGL
It has been reported that phorbol esters, which are direct activators of isozymes 
of PKC, except PKC zeta, attenuate InsP3-induced Ca2+-release in 
electroporated rat pancreatic acinar cells (Arita et al., 1992). King and 
Rittenhouse suggest this is due to the enhancement of InsP3 hydrolysis in 
thrombin stimulated platelets (King and Rittenhouse, 1989). However, in human
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and rabbit platelets, activation of PKC inhibits receptor induced InsP3 formation 
and Ca2+ elevation. Furthermore, inhibitors of PKC markedly stimulate 
receptor induced formation of InsP3 and prolong the elevation of cytosolic Ca2+ 
(Poll and Westwick 1986; Murphy et al, 1991; Murphy et al, 1992).
Yoshida and Nachmias (Suzuki et al., 1990) report that pretreatment of platelets 
with PMA before saponin treatment increases ATP-dependent 45Ca-uptake and 
that most of the sequestered 45Ca is released by InsP3 or ionomycin.
In permeabilised rabbit platelets pretreatment with PMA or DAG had no effect 
on InsP3-induced Ca2+-mobilisation at concentrations up to 100/xM and lOOnM 
respectively, and they had no capacity to mobilise 45Ca alone. Activation of 
endogenous PKC by DAG is thought to regulate InsP3 levels (Lin et al., 1990; 
Taylor, 1992; Thomas et al., 1992; Cobbold et al., 1993). Many authors have 
proposed that oscillations in InsP3 levels are controlled at the level of the 
receptor/signal transduction apparatus through a cyclical activation o f DAG- 
dependent PKC leading to feedback inhibition of InsP3 formation by the 
inactivation of PLC which also results in lowering DAG levels. In addition, 
Brass and Laposata (Brass and Laposata, 1987) have found that OAG, a 
synthetic analogue of DAG, caused 45Ca-release from the dense tubular system. 
However, they found that the phorbol esters TPA did not duplicate this effect 
and they conclude that it is unlikely that the effects they observed from OAG 
were mediated through PKC.
It appears from the conflicting data available that the role of DAG in InsP3- 
induced Ca2+-release is still in contention, attenuating release in some cells 
whilst enhancing it in others. However, in our system, PMA and DAG did not 
mobilise Ca2+ or influence InsP3-induced Ca2+-mobilisation.
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4.2 Metabolism of PHlInsP  ^and the effect of some enzyme inhibitors.
pH]InsP3 metabolism was examined at 4°C, 20°C and 37°C. Dramatically 
different metabolic profiles were observed at these three temperatures. At 4°C, 
pH]InsP3 is conserved to such a great extent, that it is still present at 10 
minutes. In addition, at 4°C, very little Ins(l,3,4,5)P4 and Ins(l,3,4)P3 are 
formed throughout the 10 minute period. In marked contrast, at 20°C, 
substantial amounts of Ins(l,3,4,5)P4 are formed after 1 minute, and 
Ins(l,3,4)P3 being formed after 3 minutes. However, at 37°C, pH]InsP3 
metabolism is completed by 3 minutes. Furthermore, at 37°C, Ins(l,3,4,5)P4 is 
not detected at all, Ins(l,3,4)p3 is formed, but only as a small proportion and by 
10 minutes, only Ins(4)Pi is left.
The temperature dependence of InsP3 metabolism is a reflection of enzyme 
activity. At 4°C, enzyme activity is minimal thus maintaining higher levels of 
pH]InsP3 over a longer time scale. Whereas, enzyme activity is greater at 37°, 
thus reducing pH]Insp3 levels rapidly. Furthermore, it is interesting to note that 
at 4°C and 37°C smaller amounts of Ins(l,3,4,5)P4 and Ins(l,3,4)P3 are 
formed. Whereas at 20°C, substantial amounts of Ins(l,3,4,5)P4 and 
Ins(l,3,4)P3 are formed during metabolism.
At 4°C, the reduction in these two metabolites may be attributed to the 
reduction in enzyme activities. However, at 37°C, this effect could be due to 
(a), the presence of greater Ins(l,3,4,5)P4 5-phosphatase activity at 37°C 
compared to 20°C. Thus, metabolising any Ins(l,3,4,5)P4 formed at a greater 
rate, reducing the amounts of Ins(l,3,4,5)P4 present, (b). It could be due to an 
increased InsP3 5-phosphatase activity, thus, directing the route of metabolism 
via Ins(l,4)P2 and not Ins(l,3,4,5)p4. (c). Alternatively, this could be a possible
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indication of a reduced activity of InsP3 3-kinase, thus, reducing the amount of 
Ins(l,3,4,5)P formed or (d). an overall increase in 3-kinase activity such that 
Ins(l,3,4,5)P is not detected after just 1 minute. All these would result in 
smaller amounts of Ins(l,3,4,5)P4 being formed from InsP3, at 37°C. One 
approach we could adopt to establish if any of these enzymes are involved is by 
the use of selective enzyme inhibitors. In addition, the use of metabolic resistant 
analogues of inositol phosphates would reveal a temperature dependent 
metabolic effect.
The metabolic profile at 37°C is of considerable consequence, since the body 
operates at 37°C. If metabolism does occur with this profile in vivo, then 
metabolites such as Ins(l,3,4,5)P4 and Ins(l,3,4)P3 will play an insignificant 
role in signalling and Ca2+-mobilisation. This then invokes the possible roles 
Ins(l,3,4,5)p4 and Ins(l,3,4)p3 may have in vivo. It is possible that under 
normal conditions, these metabolites do not play a role in cellular signalling, 
and are only of any significance in disease states where an overproduction of 
these metabolites occurs, see later.
For any subsequent experiment to investigate metabolism, platelets were 
maintained at 20° C as this shows the widest range of metabolites over the 10 
minute period.
Pretreatment of permeabilised platelets with two inositol phosphate analogues, 
L-Ins(l,4,5)PS3 and Ins(l,3,5)PS3, produced a dose dependent inhibition of 
pH]InsP3 metabolism with a concomitant potentiation of InsP3-induced 45Ca- 
release.
Preincubation with L-Ins(l,4,5)PS3 (3- 30/zM) produced a high degree of 
conservation of InsP3, a reduction in the amount of InsP2 formed, an increase in
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the amount of Ins(l,3 ,4 ,5 )P4 formed and a reduction in Ins(l,3,4)P3 
accumulation. In contrast, Ins(l,3 ,5 )PS3 (3- 30/xM) did not affect InsP3 levels, 
however, a reduction in InsP2 accumulation, an increase in Ins(l,3 ,4 ,5 )P4 
formation and reduction in Ins(l,3 ,4 )P3 production was observed.
It is apparent from these studies that the two analogues, L-Ins(l,4 ,5 )PS3 and 
Ins(l,3 ,5 )PS3, are inhibitors of InsP3 5-phosphatase, as indicated by the 
reduction in InsP2 formation with both analogues. In addition, it appears that L- 
Ins(l,4 ,5 )PS3 also inhibits Ins(l,3 ,4 )P3 formation (acting on and inhibiting 
Ins(l,3 ,4 ,5)4  5-phosphatase) whereas Ins(l,3 ,5 )PS3 does not. This would 
confirm the findings of Majerus et al, (Connolly et al., 1985; Connolly et al 
1986; Majerus et al.f 1991; Majerus, 1992), that in platelets two 5-phosphatase 
enzymes are present. One responsible for the dephosphorylation of InsP3 and the 
second for Ins(l,3 ,4 ,5 )p3 dephosphorylation.
L-Ins(l,4 ,5 )PS3 also appears to inhibit 3-kinase. As a result of the inhibition of 
InsP3 5-phosphatase, metabolism will be enhanced via the InsP3 3-kinase route 
and an increased formation of Ins(l,3 ,4 ,5 )P4 is expected. However, with L- 
Ins(l,4 ,5 )PS3, 30/zM preincubation gives the same amount of Ins(l,3 ,4 ,5 )P4 as 
control indicating that metabolism via this route is minimal and inhibited. In 
addition, levels of InsP3 are maintained higher than control suggesting that 
metabolism of L1SP3 by both InsP3 5-phosphatase and 3-kinase is inhibited.
In the presence of Ins(l,3 ,5 )PS3, increased formation of Ins(l,3 ,4 ,5 )P4 suggests 
that InsP3 3-kinase is functional and not affected. Ins(l,3 ,5 )PS3 is not a 
substrate for 3-kinase, probably due to the presence of a phosphorothioate group 
on the 3-position. Making it a selective, non-Ca2+ mobilising inhibitor of InsP3 
5-phosphatase.
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The phosphorothioate analogue of InsP3, Ins(l,4,5)PS3, was found to be a 
potent inhibitor of InsP3 5-phosphatase. Because it is known that the D-isomers 
of L1SP3 analogues are substrates for 5-phosphatase, and that L-InsP is a week 
inhibitor of 5-phosphatase, it was thought that the phosphorothioate analogue of 
L-Ins(l,4,5)P3 would prove to be a more potent inhibitor than the parent 
compound. Thus, L-Ins(l,4,5)PS3 was originally synthesized as 5-phosphatase 
inhibitor. A clear picture has emerged from our work to confirm this 
hypothesis, and L-Ins(l,4,5)PS3 was found to inhibit both InsP3 5-phosphatase 
and Ins(l,3,4,5)P4 5-phosphatase.
The novel analogues investigated in this study thus provide new tools with 
which InsP3 metabolism and function can be modulated, as they are potent InsP3
5-phosphatase inhibitors. Due to the lack of specific L1SP3 receptor antagonists, 
specific enzyme inhibitors may help elucidate the functional significance of 
InsP3 metabolism in signalling. Recently, reports indicate that disulfiram and its 
analogues inhibit InsP3 5-phosphatase at micromolar concentrations (Fowler et 
al., 1993). However, these compounds were found toxic to the cell and reduced 
cell proliferation significantly, and so can not be used to in vivo. In addition, a 
calmodulin inhibitor calmidazolium chloride appeared to inhibit the 5- 
phosphatase with an IC50 of 100/xM, however its actions were thought not to be 
through calmodulin inhibition (Fowler and Eriksson, 1993). Furthermore, Li+ 
which is widely used in the treatment of affective disorders is thought to exert 
its actions through inhibiting the two enzymes, inositol 1-phosphatase and 
inositol monophosphatase thus disrupting the signalling mechanism.
A potentially important recent development is the recognition of a second 
dephosphorylation pathway of InsP3 to myoinositol 4,5-bisphosphate 
[Ins(4,5)P2] in the presence of Li+ in neural tissue (Hughes and Michell, 1993)
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and receptor-stimulated accumulation of Ins(4,5)P2 in the presence of Li+ was 
demonstrated. The significance of formation of Ins(4,5)P2 is not yet known. 
Ins(4,5)P2 can release Ca2+ from intracellular stores with 100 fold less potency 
than InsP3. In addition, Ins(4,5)P2 was shown to inhibit the calmodulin- 
dependent Ca2+-ATPase pump of erythrocytes (Hughes and Michell, 1993). A 
recent finding suggests that beryllium ions competitively inhibit inositol 
monophosphatase, being three times more potent than Li+ (Faraci et al., 1993). 
All these agents will help develop a clearer understanding of PI signalling.
The significance of defects in inositol phosphate metabolism at the 5- 
phosphatase enzyme is depicted in diseases such as Lowe's occulocerebrorenal 
syndrome (OCRL) where an inborn error in inositol phosphate metabolism has 
been implicated (Attree et al., 1992). Furthermore, HIV-infected 
lymphoblastoid cells show abnormal metabolism with chronically elevated levels 
of Ins(l,3,4,5)P4 (Nye et al., 1992) and there is evidence that inositol 
monophophatase activity is elevated in schizophrenic patients (Hughes and 
Michell, 1993). It is clear that selective 5-phosphatase inhibitors are required to 
investigate inositol phosphate metabolism and the putative role of Ins(l,3,4,5)p4 
and so far the two analogues investigated provide the best leads for further 
syntheses of more selective and potent enzyme inhibitors. A crucial need, 
however, is to make these inhibitors membrane permeable.
Purified platelet InsP3 3-kinase was shown to contain two polypeptides (53 and 
36 kDa) both of which expressed activity (Lin et al., 1993) and the catalytic site 
was shown to be located at the C-terminal end of the protein. However, other 
data indicate that the two polypeptides are indeed two isozymes of InsP3 3- 
kinase (Lin et al., 1993). While the analogues investigated in this study did not 
suggest the presence of isozymes, nevertheless the
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good substrates
analogues modified at the 
5-position like h s (1 f4,5)P3-5S and
the 1 -phosphate group appears 
to enhance recognition but not 
to be an essential feature:
lns(4.5)P2 is a weak substrate
5-methylenephosphonate-lns(1,4.5)P3 mechanistic hydroxyl group:
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Figure 71. Summary of the requirements of the 5-phosphatase
analogues may be nonspecific 3-kinase inhibitors thus showing no selectivity for 
the different isozymes. Still, considering that the purified InsP3 3-kinase has a 
higher affinity for InsPs (Km 0.76/iM) than that of the platelet InsP3 5- 
phosphatase (Km 25/xM) (Mitchell et al., 1989), the purification of this enzyme 
should facilitate further investigations concerning the possible role this enzyme 
plays in platelet function. The functional significance of InsP3 3-kinase has been 
studied and suggestions that InsP3 3-kinase may act as a regulator of the Ca2+- 
phosphoinositide signal transduction mechanism (Balia et al., 1991) have been 
proposed. It was found that in fibroblasts transfected with rat brain 3-kinase, the 
conversion of L1SP3 to Ins(l,3 ,4 ,5 )P4 is greatly increased, with a concomitant 
reduction in InsP3 levels and the attenuation of the Ca2+ response (mobilisation 
and influx).
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Figure 72. I11SP3 and its metabolites. An up to date version of InsP3 metabolism 
and the various metabolites formed along the way taken from Hughes and 
Michell (1993).
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4.3 Ca2+ entry and the effect of SKF 96365 in platelet signalling.
Cytosolic calcium elevation can occur by one of three ways; (i) the release from 
intracellular stores upon PIP2 breakdown and InsP3 and DAG production 
(Berridge, 1993); (ii) through voltage operated Ca2+ channels in which the 
developments of drugs that act as antagonists such as dihydropyridines and 
phenylalkylamines at the receptor site has greatly contributed to understanding 
this area ; (iii) through receptor mediated Ca2+ entry (RMCE) of which little 
was understood until the recent development of two imidazol derivatives [(+ )-l-  
2,3-bis(4-methoxyphenyl)-methoxy)propyl]l-H-imidazol (SC 38249) and its 4- 
methoxyphentyl derivative SKF 96365, which have provided tools for the study 
of RMCE. SKF 96365 has been shown to inhibit Ca2+ influx having no effect 
on mobilisation in a variety of cells including platelets, neutrophils and 
endothelial cells (Merritt et al. , 1990aZ>; Ciardo and Meldolesi, 1990; Chan and 
Greenberg, 1991).
In this study, using fura-loaded platelets, racemic SKF 96365, whose structure 
can be seen in figure 73, was found to dose-dependently inhibit PAF-induced 
Ca2+ release. In order to establish if  inhibition is at the receptor or post-receptor 
level, the effect of SKF 96365 on InsP3-production upon PAF stimulation was 
measured and SKF 96365 was found to dose dependently inhibit InsP3- 
formation with a similar EC50 to the inhibition of PAF-induced Ca2+ release in 
fura-loaded platelets. This suggests, contrary to the literature, that SKF 96365 is 
inhibiting Ca2+ release through the inhibition of InsP3 formation. However, the 
contributions of Ca2+-influx and Ca2+-mobilisation to the Ca2+-release detected 
were not determined and it may be that InsP3-induced Ca2+-mobilisation plays a 
minor insignificant role in the Ca2+-response observed here. Thus, InsP3 having 
a minor role, and that SKF 96365 is still exerting its effect through a major
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inhibition of Ca2+ influx. This situation is further complicated by the finding 
that SKF 96365 causes a dose dependent inhibition of dense granule release at 
concentrations an order of magnitude lower than that observed with the 
inhibition of Ca2+-release and InsP3 formation. It is possible that dense granule 
release is more sensitive to the other product of PIP2 hydrolysis, namely DAG, 
and inhibiting DAG formation may inhibit the platelet release reaction. Further, 
it is conceivable that SKF 96365 may have an intrinsic effect on some aspect of 
platelet function, by inhibiting adhesion, shape change or aggregation. Thus, 
preventing dense granule release.
Figure 73. The structure of SKF 96365
SKF 96365 did not mobilise Ca2+ from permeabilised platelets. In addition it 
did not effect InsP3- or Ins(l,3,4,5)P4-induced Ca2+ release indicating that SKF 
96365 does not possess the structural requirements for receptor binding.
These findings are consistent with our previous results where SKF 96365 was 
found to inhibit Ca2+ release through inhibiting InsP3-production, possibly 
through inhibiting PIP2 hydrolysis. Merritt et al (1990ab) suggest in their initial 
studies that SKF 96365 can interfere with mobilisation of Ca2+ from 
intracellular stores, and Chan & Greenberg (1991) find that elevations in [Ca2+]i
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are also inhibited with SKF 96365. However both of these groups report that 
this is a negligible effect not mediated through InsP3.
The Ca2+-influx inhibitor in our system was not found to be selective in 
blocking Ca2+-release through RMCC, rather it was found to inhibit Ca2+ 
release induced by PAF and further investigations indicate that this effect is 
through inhibiting L1SP3 formation.
The indirect control InsP3 has on Ca2+ entry is illustrated in the capacitative 
Ca2+ entry hypothesis. This is based on the finding that emptying intracellular 
Ca2+ stores is itself sufficient to activate Ca2+ entry (Irvine, 1992) based on the 
results using thapsigargin, an inhibitor of Ca2+-ATPase (Takemura et al., 
1991). However, as a result of this hypothesis, a major question is left 
unanswered, and this is : How does the Ca2+ content of the intracellular stores 
communicate with the plasma membrane so as to control Ca2+ entry ?.
Principally three mechanisms have been proposed;
(i) The low luminal Ca2+ levels may stimulate the generation of a soluble 
second messenger that acts upon a receptor in the plasma membrane. Recent 
reports have isolated such a molecule which caused Ca2+ influx when applied to 
cells and was named CIF (Ca2+-influx factor) (Randriamampita and Tsien, 
1993), further, Parekh et al., (1993) have also found the presence of a small 
diffusable messenger and they suggest that the molecule is not an inositol 
phosphate.
(ii) Low luminal Ca2+ may result in low free Ca2+ near the plasma membrane 
(Putney, 1986), and evidence shows that decreasing cytosolic Ca2+ can affect 
Ca2+ entry (Irvine, 1992). However, in experiments where [Ca2+]i is raised by
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agonists such as thapsigargin, Ca2+ entry is still initiated despite the free Ca2+ 
near the plasma membrane being high (Irvine, 1992).
(iii) Communication could occur via a protein (or proteins) anchored in the ER 
such that its structure is modulated by luminal Ca2+ levels (Irvine, 1992). Other 
reports have proposed that InsP3 may be directly involved in the control of Ca2+ 
entry. Intracellular applications of InsP3 to sea urchin eggs, lacrimal gland cells 
and mast cells produce a response indicative of activation of both Ca2+ 
mobilisation and Ca2+ entry from the extracellular space (Putney, 1992). In 
addition Heparin, an InsPs receptor antagonist, blocks both phases of the [Ca2+]» 
signal. However, in some cases it appears that the presence of Ins(l,3 ,4 ,5 )P4 is 
necessary for the second Ca2+ entry phase. In most studies, InsP3 applied 
directly to the plasma membrane does not increase their Ca2+ permeability. 
Furthermore, InsP3 receptors have not been revealed on the plasma membrane 
of Purkinje cells. (Putney, 1992).
Ins(l,3 ,4 ,5 )P4 is rapidly formed whenever InsP3 is produced in a cell, and 
whether or not it can control Ca2+ entry by interacting with specific receptors 
(see figure 74) is still controversial (Irvine, 1992). Irvine and colleagues were 
the first to propose a role for Ins(l,3 ,4 ,5 )P4 in the control of Ca2+ entry (Irvine 
et al., 1985; Irvine, 1988; Irvine, 1991). However, Bird et al., (1991) opposed 
this idea where they found that in mouse lacrimal cells InsP3 without the 
presence of Ins(l,3 ,4 ,5)P4 caused Ca2+ entry, and they argued that in previous 
experiments sufficient InsP3 was not added to see this effect and in those cases 
Ins(l,3 ,4 ,5 )P4 was acting to protect L1SP3 from metabolism (Berridge and 
Irvine, 1989) and itself was being converted back to InsP3 via a 3-phosphatase 
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Figure 74. The involvement o f Ins(l,3,4,5)P4 in Ca2+ entry. The interaction 
between the InsP3 receptor and the Ins(l,3,4,5)P4 receptor, a. resting cell; b. 
InsP3 production and binding to its receptor causes Ca2+-mobilisation and leads 
to a conformational change in the Ins(l,3,4,5)P4 receptor; c. Ins(l,3,4,5)P4 or 
InsP3 binding to the Ins(l,3,4,5)P4 receptor leads to; d. Ca2+-entry.
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Further studies by Smith et al., (1992) showed that although very high levels of 
InsP3 do cause Ca2+ entry, Ins(l,3,4,5)P4 additions could further enhance Ca2+ 
entry.
Luckhoff and Clapham in their work give a direct demonstration of activation 
by Ins(l,3,4,5)P4 of a Ca2+-channel in endothelial cells (Luckhoff and 
Clapham, 1992). This effect is reversible and not mimicked by InsP3 , except at 
high doses and InsP3 does not enhance this effect. However, Luckhoff and 
Clapham (1992) used a relatively high free Ca2+ (0.5^M) in order to see their 
channel, and at these concentrations, the Ca2+-channel is already partially 
activated, and this activation was further increased by increasing [Ca2+] up to 
ImM,
Thus, although there is considerable evidence for the role of inositol phosphates 
in Ca2+ entry, the nature of this role and the specific inositol phosphates 
involved is much less clear. This is likely due, at least in part, to difficulties in 
assaying the effects of inositol phosphates on Ca2+ entry. Investigations into the 
effects of inositol phosphates on Ca2+ entry require methods for introducing 
these highly polar hydrophilic compound into the cells, while maintaining 
sufficient support of the plasma membrane to permit measurements of its 
permeability to Ca2+. The techniques most used are patch-clamp, both in whole 
cell and excised patch configurations and microinjection. Much of the confusion 
in the field of receptor-regulated Ca2+ entry is generated by reports of  
conflicting findings derived from studies with these different approaches, which 
may be in part attributable to the difficulties and problems inherent to each 
approach.
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It is beyond any doubt that Ins(l,3,4,5)P4 can do something. It binds to a 
receptor protein (Donid and Reiser, 1991; Cullen and Irvine, 1992), synergizes 
with InsP3 to mobilise Ca2+ (Joseph et a l ,  1987; Irvine and Moor, 1987), can 
effect Ca2+ reuptake (Boynton et a l ,  1990) or cause Ca2+ entry (Guse et a l ,  
1991) for review see (Irvine, 1992; Irvine, 1991). However, experimental 
artifacts are being generated which hamper our understanding of the role of this 
molecule and the advent of inositol phosphate analogues that are capable of 
crossing cell membranes, such as lipophilic analogues, will no doubt help 
overcome the problems associated with accessibility of the compounds to the 
intracellular compartment without having to disrupt the plasma membrane. The 
variation in results regarding Ins(l,3,4,5)P4 studies can also be overcome with 
the use of phosphorothioate analogue of Ins(l,3,4,5)P4, namely Ins(l,3,4,5)PS4 
and Ins(3)PS(l,4,5)P3. Ins(l,3,4,5)PS4 is predicted to be resistant to 5- 
phosphatase metabolism and would help elucidate the ambiguous role played by 
Ins(l,3,4,5)P4 in Ca2+ entry.
4.4 The effects of InsP  ^ and analogues on Ca2+ release and the functional 
responses: dense granule release and aggregation.
4.4.1 Fluorescent studies on permeabilised platelets.
Since the advent of fluorescent dyes such as quin-2, fura-2 and fluo-3, they 
have been used extensively to measure Ca2+-release induced by InsP3 in a wide 
variety of cell membrane and permeabilised cell preparations (Guillemette and 
Segui, 1988; Debs et a l ,  1988; Champeil et a l ,  1989; Mohr et a l ,  1993). 
However, to date studies using fluorescent dyes and permeabilised platelets or 
platelet preparation have not been used to assess InsP3-induced release o f Ca2+.
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In this study we set out to develop a method for the use of fluorescent dyes for 
the detection of Ca2+ release in permeabilised platelets and two platelet 
membrane preparations, a crude and pure preparation, and both the 
acetoxymethyl ester and the free acid of fura-2 have been used in this study. In 
all cases, regardless of buffer, permeabilisation technique (electrical, saponin, 
streptolysin-O), the use of permeabilised platelets or membranes, the use of 
different Ca2+ chelators (EGTA, EDTA, BAPTA) or simply passing the buffer 
or source of water over a Ca2+-chelating agent such as chelex or Ca2+-sponge, 
InsP3-induced Ca2+-release was not detected (data not shown). Due to the low 
intracellular [Ca2+] » lOOnM and the high extracellular [Ca2+] » ImM it is 
essential to reduce the Ca2+ content of the platelet suspension buffer to avoid 
platelet activation upon permeabilisation. Further buffering is necessary in order 
to detect small [Ca2+]i elevations above basal upon agonist stimulation, where if  
basal [Ca2+]i was ljtM, a lOOnM rise in [Ca2+] would not be easily detected.
In this study an appropriate buffering system could not be established on 
account of the sensitivity of the system to [Ca2+]. Overbuffering with agents 
like EGTA and EDTA leads to the quenching of any signal produced upon InsP3 
activation. On the other hand underbuffering leads to high [Ca2+] present upon 
permeabilisation, which will mask any elevation in [Ca2+] upon InsP3 addition. 
Thus an alternative method for reducing [Ca2+] was investigated. Here the 
platelet buffer was passed over a Ca2+ chelators such as chelex or a Ca2+- 
sponge in order to reduce the Ca2+ content. This was not found to have any 
additional benefits over the previous Ca2+-chelators used, and Ca2+ release 
upon InsP3-addition could not be detected (data not shown).
Various reports suggest leaving [Ca2+] unbuffered, and after permeabilisation 
the buffer is supplemented with ATP which will initiate Ca2+-uptake via the
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Ca2+-ATPase pump (Renard et al., 1992; Combettes et al., 1993; Hofer and 
Machen, 1993). However, in this study ATP did not initiate Ca2+ uptake, and 
the platelets became fully activated upon permeabilisation. In addition, in most 
cases ATP added to the cuvette was found to quench the fluorescence signal. 
Other reports do not modify [Ca2+] (Mohr et al., 1993; Hershey et a l ,  1993). 
In addition, ATP and Mg2+ are excluded from the buffer as a result of the 
concern that ATP will inhibit InsP3 binding to its receptor.
Furthermore, a recent report (Richardson and Taylor, 1993) suggests that Ca2+ 
chelators such as EGTA, EDTA and BAPTA act to inhibit InsP3-stimulated 
Ca2+ release because they will act as competitive antagonists of InsP3 binding to 
its receptor. These Ca2+ chelators are often used to buffer the free [Ca2+] of the 
various buffers in which the cells are suspended. Thus, these chelators will 
interfere with InsP3 binding to its receptor and any subsequent Ca2+ release or 
functional effect to be studied.
To date, there are little data available using fluorescent Ca2+ studies in 
permeabilised platelets and in the light of this work, we will not be able to 
contribute to this deficiency.
4.4.2 Functional studies: aggregation and dense granule release.
It is widely accepted that in most cells InsP3 mobilises Ca2+ which leads to 
various functional responses and the same is true of platelets. L1SP3 has been 
shown to induce aggregation (Knezevic et a l ,  1992) and dense granule 
secretion (Brass and Joseph, 1985) from permeabilised platelets and our aim in 
this study was to set up such methods in order to assess the effect o f L1SP3
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analogues on platelet function and to establish if a  correlation between L1SP3- 
induced Ca2+ release and platelet functional responses exists.
Upon saponin permeabilisation of platelets, an aggregatory response was 
observed (data not shown). Although a previous report by Knezevic et al., 
(1992) suggest that there exists a narrow saponin concentration range which 
facilitates InsP3-mediated responses, without leading to platelet activation, as 
shown in permeabilised platelets supplemented with 100/xg/ml fibrinogen, this 
was not apparent in our study. An all or nothing effect was observed with 
saponin in our system where saponin either produced aggregation and 
permeabilisation at 5.25/tg/ml or not at concentrations of 5/xg/ml, where 
permeabilisation was not achieved as indicated by the lack of aggregation upon 
ImM Ca2+ addition. Modifications to the suspension buffer in terms of Ca2+ 
buffering, salt constituents and a different permeabilising chemical did not cause 
permeabilisation without aggregation (data not shown).
Thus, aggregation could not be used to investigate the functional effects of 
inositol phosphate analogues due to the inherent aggregation produced upon 
permeabilisation.
InsP3-induced dense granule release was also investigated using permeabilised 
platelets. Brass & Joseph (1985) use an EGTA buffered system to demonstrate 
that Ca2+ alone causes [14C]5-HT release and addition of InsP3 shifted this curve 
to the left where InsP3 causes an additional [14C]5-HT release, in our system, 
this separation between Ca2+ and InsP3 induced dense granule release was also 
present (»10-15%  of total [14C]5-HT release). However, this window was too 
small for any further studies such as dose response curves to InsP3 and 
analogues.
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InsP3 being hydrophilic requires permeabilised cell systems, in order to gain 
access to the intracellular compartment and although permeabilised cells are 
more physiological than membrane preparation, it is desirable to study these 
compounds in an intact cell system. Knight & Scrutton (1987) have used a high 
electric discharge to render platelets permeable. Furthermore, incubating cells at 
37°C for 60 minutes reseals electroporated cells (Hughes and Crawford, 1990). 
This technique was used to encapsulate hydrophilic L1SP3 or analogues for the 
later investigation on Ca2+ release, aggregation and dense granule release. Due 
to the small size of the platelet, a high electric field of 10- 20kV is necessary 
(Knight and Scrutton, 1987; Hughes and Crawford, 1990; Daniel et al., 1992) 
with 10 cycles. This high voltage however could not be achieved by the 
electroporater available for this study, 5kV being the maximum attainable. 
Hence, the number of cycles was increased to compensate for this shortcoming. 
It was observed that upon electroporation, platelets did become permeable (as 
indicated by dense granule release due to Ca2+ addition). However, upon 
incubating at 37°C for 60 minutes, all responsiveness of the platelets is lost.
A further complication is that platelet functional responses are optimal at 37°C. 
However, as demonstrated by the metabolism data in this thesis, InsP3 is very 
rapidly metabolised at this temperature and this may hamper those studies where 
the local InsP3 concentration at the receptor may be greatly reduced due to 
metabolism.
We attempted to set up a functional assay in platelets in order to assess the 
effects o f InsP3 and its analogues, especially the partial agonists and the 5- 
phosphatase enzyme inhibitors, on platelet function and to further elucidate the 
roles of InsP3 in platelet activation and responses. Of interest would have been 
the effect of the partial agonists on function to see whether partial activation of
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the platelets would occur, whether a smaller percentage of the dense granules 
would be released or if aggregation would be attenuated. However, when we 
consider the mechanisms of platelet activation, involving the many positive 
feedback mechanisms involved in activation and dense granule release it would 
appear that partial activation would not be possible. In addition, the significance 
of one metabolite over another in platelet activation and function could have 
been addressed by investigating the effect of the metabolic enzyme inhibitors, 
L-Ins(l,4 ,5 )PS3 and Ins(l,3 ,5 )PS3, on platelet function.
Research into PI signalling would substantially benefit from the synthesis of 
lipophilic analogues of InsP3. These analogues would be capable of crossing cell 
membranes and the need for cell poration or membrane preparations would not 
be required. This would provide a more physiological environment for the study 
of these compounds. In addition, the cells would not be exposed to such harsh 
treatments such as a high electric field or detergents for poration which affect 
the cell's integrity and function.
4.5 Summary of the discussion.
We have been able to demonstrate stereospecific InsP3-induced Ca2+-release 
from permeabilised platelets. D-L1SP3 is a potent full agonist with an EC50 of  
0 .18±  0 .01/xM at 4°C (1. 14/xM at 20°C) and L-L1SP3 is completely inactive. In 
addition, InsP3-induced Ca2+-release was shown to be temperature dependent, 
4°C being the optimum temperature for release reactions probably due to the 
slow rate of metabolism at this temperature.
From this thesis, a structure/activity relationship has become apparent and it is 
possible to predict, to a limited extent, the activity of novel analogues in
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permeabilised platelets from this relationship. The three phosphates at the 1-, 4- 
and 5-positions are essential for activity, and removal of any of these, especially 
the vicinal 4,5-bisphosphate, causes a substantial loss in activity. Of the 
hydroxyl groups, the 2- and 3-OH's do not appear to be important. However, 
deletion o f the 6 -OH causes a significant loss in activity indicating that this may 
be essential for receptor recognition or Ca2+-mobilisation.
It appears that phosphate substitution with phosphorothioates decreases in 
intrinsic activity, although this is not always the case as in Ins(l,3 ,4 ,6 )PS4 and 
Ins(l,4 ,5 )PS3. In this study, three such analogues have been investigated, and 
these are important because it appears from their structures the requirements for 
InSP3-binding are met in that they all possess pseudo 1-, 4- and 5- phosphates. 
They also possess an equatorial pseudo 6 -OH of L1SP3 . The partial agonist with 
the highest intrinsic activity, jcy//o-Ins(l,2 ,4 ,5 )PS4 possesses a 
phosphorothioate group at the 2-position. Ins(l,4 ,6 )PS3 is a partial agonist 
possessing the lowest intrinsic activity. It mobilised a maximum of 20% of the 
sequestered 45Ca, and was able to antagonise the effect of InsP3.
To date, a specific selective antagonist at the InsP3 receptor is still not available. 
The two antagonists available, heparin and decavanadate, are large molecules, 
non-specific in their activity and possess other activities such as enzyme 
inhibition. Thus, our aim is to uncover small molecule antagonists, based on the 
structure of InsP3. From the data obtained with studies using partial agonists, 
we now have a better idea of the requirements for potency and intrinsic activity. 
We may be able to develop these to make partial agonists with even lower 
intrinsic activity, with the aim to develop an antagonist.
Studies using partial agonists indicate the possibility of tissue-specific InsP3 
receptors. Ins(l,3 ,4 ,6 )P4 and 6 -deoxy-Ins(l,4 ,5 )P3 were found to be partial
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agonists in SH-SY5Y neuroblastoma cells (Gawler et al., 1991; Safrany et al 
1993) but were found to be full agonists in permeabilised platelets (this thesis). 
In addition, some analogues appear to be full agonists with low potency in 
permeabilised platelets, e.g. D/L-Ins(l,3,4)P3 has an EC50 of ^  30/zM in 
permeabilised platelets. The Ca2+-release profile by D/L-Ins(l,3,4)P3 is 
probably due to the presence of the L-isomer, the D-isomer being completely 
inactive. Strupish et a l ,  (1988) found that D-Ins(l,3,4)P3 was presumably 
inactive in Swiss 3T3 cells and in permeabilised smooth muscle cells with an 
EC50 of 120/xM (Polokoff et al., 1988). The findings that the same analogues 
possess different activities in different tissues points towards the possibility of 
tissue specific receptors.
The calcium influx inhibitor, SKF 96365, was used to probe the role of Ca2+ 
entry in L1SP3 signalling and to probe the contentious issue of the synergistic 
actions of L1SP3 and Ins(l,3,4,5)P4 acting to elevate intracellular Ca2+ with 
InsP3 mobilising intracellular Ca2+ and Ins(l,3,4,5)p4 facilitating Ca2+ entry. 
However, in our hands SKF 96365 was found not to be a pure Ca2+-influx 
inhibitor, but it appeared to have an effect on PI signalling. It was capable of 
inhibiting PAF-induced InsP3-production, Ca2+-release and [14C]5-HT release 
which is a result of InsP3-production and the subsequent Ca2+-elevation. 
Consequently, we were unable to make as effective a use of this compound as 
we had initially hoped.
Platelets and platelet activation play an important role in coronary disease and 
thrombosis. Thus, modulating platelet function may have a role in controlling 
these diseases. Blocking platelet activation could be achieved by blocking 
receptor activation by the use of specific receptor antagonists. However, this is 
not feasible when considering the number of intrinsic molecules and agents
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released by platelets and other immune cells that act to activate platelets and a 
large number of specific platelet antagonists would be required.
Alternatively, activation can be prevented by blocking the signalling 
mechanisms involved in platelet activation. Since most platelet agonists signal 
through PI, elevating InsP3 levels and subsequently Ca2+, modulating this 
aspect of platelet activation is a more viable proposition. Data from this thesis 
indicates the possibility of tissue specific receptors. Thus, uncovering a specific 
InsP3 receptor antagonist for platelets would present a real possibility of 
modulating platelet activation and may have long term implications in diseases 
such as thrombosis. This in conjunction with the subsequent synthesis of 
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